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Abstract 
Through the Finding of Rare Disease Genes in Canada (FORGE Canada) initiative, 
individuals affected with rare Mendelian diseases were clinically ascertained with a goal of 
identifying the genetic origin of their disease. Herein, I describe the methods for identifying 
the genetic basis of four Mendelian diseases. The application of next generation sequencing 
led to the discovery of non-synonymous variation in the DNA of individuals affected by rare 
diseases. The effects of the candidate variants were assessed using a series of functional 
experiments to complement the human genetics data. The variants observed in patients’ cells 
are extremely rare, were consistently predicted to be pathogenic by multiple in silico 
predictive programs, segregated with disease status in the family, and affected the biological 
properties of their respective gene products, as measured by functional assays. 
Having successfully identified genetic variants underlying the Mendelian diseases, we 
sought to use the same approach to extract the genetic variation that may predispose 
individuals to complex diseases, primarily neurodegenerative disorders. We designed a 
neurodegeneration specific gene panel that utilizes next generation sequencing chemistry. 
We sequenced patients diagnosed with one of five neurodegenerative diseases: 1) 
Alzheimer’s disease; 2) amyotrophic lateral sclerosis (ALS); 3) frontotemporal dementia 
(FTD); 4) Parkinson’s disease; or 5) vascular cognitive impairment, as part of the Ontario 
Neurodegenerative Disease Research Initiative (ONDRI). We were successful in detecting 
rare variants in a large fraction of cases that may be related to the neurodegenerative 
phenotypes. 
We also independently ascertained three large, unique families affected with familial 
ALS and FTD across multiple generations. The three families are diagnosed with ALS and/or 
FTD and in which the same hexanucleotide repeat expansion in the C9orf72 gene has been 
observed in all three pedigrees, but their phenotypes vary significantly. We sequenced 
affected individuals and observed several, distinct variants in these families that may explain 
the additional neurodegenerative phenotypes observed. In summary, the application of next 
generation sequencing has successfully identified novel genetic loci in both Mendelian and 
complex diseases. 
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Chapter 1 - Introduction 
1 Overview 
Materials from the following texts with appropriate modifications, were incorporated in 
Chapter 1: 
(1) Farhan, SMK., and Hegele, RA. “Genetics 101 for cardiologists: Rare genetic 
variants and monogenic cardiovascular disease”. Canadian Journal of Cardiology. 2013; 
29(1): 18-22 (PMID: 23200093). 
 
(2) Farhan, SMK., and Hegele, RA. “Exome sequencing: new insights into lipoprotein 
disorders”. Current Cardiology Reports. 2014; 16(7): 507-517 (PMID: 24893940). 
 
(3) Farhan, SMK., and Prasad, AN. “Exploring the Epilepsiome I: Genetics of Age 
dependent Epileptic Encephalopathies”. Pediatric Epilepsy, 4th edition, Chapter 7. 
 
(4) Prasad, AN., and Farhan, SMK. “Exploring the Epilepsiome II: Approaching the 
Complex Epilepsies”. Pediatric Epilepsy, 4th edition, Chapter 8. 
 
(5) Farhan, SMK., ONDRI Investigators, Strong, MJ. “The Ontario Neurodegenerative 
Disease Research Initiative (ONDRI)”. Canadian Journal of Neurological Sciences. 
2016; Accepted. 
 
1.1 Variation in the human genome 
Variation in the human genome, which is composed of approximately three billion base 
pairs, can lead to benign or pathogenic biological effects. These DNA variations often 
classified as neutral, adaptive, or deleterious, can be under positive selection (Darwinian 
selection) or negative selection (purifying selection) based on their effect on an 
individual’s fitness (Fay et al., 2001). DNA variations that increase an individual’s fitness 
are under positive selection; conversely, deleterious variants, which decrease an 
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individual’s fitness, are under negative selection. Importantly, some pathogenic variants 
can escape natural selection by exerting their effects post sexual reproduction. In this 
section, I will introduce the various classes of genetic variation observed in the human 
genome and provide examples of diseases caused by each class of variation. 
 
1.1.1 Inherited and de novo variation 
Inherited variations are DNA changes transmitted through the germline from parent to 
offspring. Conversely, de novo or sporadic variants spontaneously arise in the offspring’s 
germ cells and are absent from the parents’ germ cells. Importantly, if de novo variations 
are not deleterious, they can be transmitted to the progeny and are reclassified as 
inherited variation. De novo variations are the most rare class of genetic variation and 
have recently been of great interest in neurodevelopmental diseases, primarily autism 
spectrum disorders (Ku et al., 2012; Neale et al., 2012; Yuen et al., 2015). 
 
1.1.2 Germline and somatic variation 
Errors during DNA replication that escape polymerase proofreading can occur within 
germ or somatic cells. Unlike somatic variation, germline variation can be transmitted to 
the progeny. Familial diseases, which reappear in multiple generations in pedigrees, are 
often linked to germline variation. An example of a familial disease is Marfan syndrome 
(OMIM 154700), an autosomal dominant disorder characterized by defective connective 
tissue leading to increased height, disproportionate limbs, and multiple cardiovascular 
anomalies; and often caused by heterozygous variation in the FBN1 gene (Dietz et al., 
1991). Conversely, pathogenic somatic variation can give rise to sporadic phenotypes like 
non-familial cancer (Greenman et al., 2007). 
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1.1.3 Structural variation 
1.1.3.1 Chromosomal abnormalities: numerical and structural chromosomal 
aberrations 
Chromosomal abnormalities can be either numerical or structural aberrations, which can 
be easily visualized using cytogenetic techniques. Numerical chromosomal aberrations 
also termed chromosomal aneuploidy, are any cases when the karyotype is not 46, XY or 
46, XX for males and females, respectively. Therefore, they are caused by the absence 
(monosomy) or addition (trisomy, triploidy) of chromosomes in cells. An example of a 
numerical chromosomal aberration is Down syndrome (Trisomy 21, OMIM 190685), a 
neurodevelopmental disorder characterized by distinct facial features and intellectual 
disability in addition to multiple systemic anomalies, due to three copies of chromosome 
21 (or chromosome 21q) (Wiseman et al., 2009). Chromosomal abnormalities are usually 
the result of nondisjunction at the first or second meiotic division (Ioannou and Tempest, 
2015). 
 Individuals with structural chromosomal aberrations may still have a normal 
karyotype however, sizable portions of chromosomes have been deleted, duplicated, or 
inverted. Additionally, portions of DNA may have merged and translocated with other 
chromosomes (Weckselblatt and Rudd, 2015). An example of a disease caused by 
structural chromosomal abnormalities is DiGeorge syndrome (22q11.2 deletion 
syndrome, OMIM 188400), a characteristic dysmorphic facial syndrome with congenital 
heart defects (Michaelovsky et al., 2012). 
 
1.1.3.2 Copy number variation 
Copy number variation (CNV) were originally classified as structural DNA segments that 
are >10 Kb in the genome and are variations that are more frequently observed than 
chromosomal aberrations (Redon et al., 2006; Sebat et al., 2004). Importantly, CNV can 
differ in size: <1 Kb - <1Mb (Park et al., 2010). CNVs can be benign variation among 
unrelated individuals or can contribute to disease based on their proximity to genetic 
elements. Their imbalance can alter gene dosage leading to gene amplification or deletion 
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if encompassing the entire gene or localized within regulatory elements (Stranger et al., 
2007). CNV can also influence select regions within genes such as exons, and can 
sometimes encode an abnormal protein. Among a multitude of examples, CNVs within 
chromosome 16p13.1 have been associated with schizophrenia (Ingason et al., 2011), 
autism spectrum disorders, and intellectual disability (Ullmann et al., 2007). 
 
1.1.3.3 Variable number of tandem repeats 
One third of the human genome is comprised of repetitive DNA sequences, which are in 
the form of large segmental duplications (low CNVs) or long and short interspersed 
transposon derived elements (LINEs and SINEs) (Kozlowski et al., 2010). In addition, 
variable number of tandem repeats (VNTR) are a class of genetic variation that are due to 
multiple nucleotides repeating consecutively within genes. There are two main types: 
minisatellites and microsatellites, which typically occur outside of coding regions, in 
non-coding sequences that often flank genes. Minisatellites are sometimes referred to as 
VNTR and range in size from 10-60 nucleotides and have been observed in thousands of 
locations in the human genome (Kozlowski et al., 2010). Similarly, microsatellites, often 
referred to as short tandem repeats (STR), are typically composed of 2-10 nucleotides and 
are hypermutable sites across the genome (Kozlowski et al., 2010). Interestingly, these 
common repeat regions served as markers for genome-wide linkage studies prior to the 
emergence of the International HapMap Project (International HapMap, 2005).  
Importantly, when these repeats are located in regulatory or coding regions and 
exceed the normal, stable range, they can result in aberrant gene products, eventually 
causing disease (Lopez Castel et al., 2010). Examples of diseases due to multinucleotide 
expansions include Fragile X syndrome (OMIM 300624), an intellectual disability caused 
by CGG repeats within the 5’-untranslated region of the FMR1 gene (Bagni et al., 2012). 
In addition, Huntington’s disease (OMIM 143100) is a neurodegenerative disease caused 
by CAG repeats within the coding region of the HTT gene producing a polyglutamine 
tract (Mahalingam and Levy, 2014). 
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1.1.3.4 Insertions and deletions 
Insertions or deletions (indels) of nucleotides in the DNA sequence may have an impact 
on gene expression or protein function. Indels can range from 1-50 base pairs with the 
majority consisting of <10 base pair changes. Depending on their location, indels can 
cause inframe or frameshift variants, or splicing variants. For example, the most common 
variant in cystic fibrosis (OMIM 219700), an autosomal recessive respiratory disease 
characterized by defective mucociliary clearance, is a three-nucleotide deletion in the 
CFTR gene, causing the loss of phenylalanine at amino acid position 508, within the 
ABC transporter domain (Flume and Van Devanter, 2012). While >90% of intron-
containing genes undergo alternative splicing to regulate gene expression and protein 
synthesis, indels within or near the exon-intron junctions alternating the 5’, 3’ splice sites 
or the branch point, can cause disease (Singh and Cooper, 2012). These DNA changes 
can potentially prevent the spliceosomes, the splicing machinery, from recognizing these 
elements ultimately inducing inadvertent exon skipping or intron retention (Singh and 
Cooper, 2012) 
 
1.1.4 Single nucleotide variation 
Single nucleotide variation (SNV), which is also referred to as point mutation or 
substitution, is the most common class of variation. They can be either transitions where 
the SNV is an interchange between purines (adenine, C <-> guanine, G) or pyrimidines 
(cytosine, C <-> thymine, T); or transversions, which interchanges purine and 
pyrimidines (A<->C, A<->T, G<->C, or G<->T). If an SNV is within the codon frame, it 
can result in synonymous or non-synonymous changes. The degeneracy of the genetic 
code allows for multiple unique codons to generate the same amino acid. Therefore, 
SNVs within codons, especially in the third nucleotide position may not alter the amino 
acid as proposed in ‘the wobble hypothesis’ (Crick, 1966). These synonymous changes 
are often referred to as silent or neutral variants as they typically do not modify the 
phenotype. Conversely, SNVs can exert non-synonymous changes in which the codon 
codes for an alternate amino acid or results in a stop codon. These classes of variation are 
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termed missense or nonsense variants, respectively. SNVs can also cause splicing defects 
if located within or near the exon/intron boundaries and can alter the splice donor or 
acceptor recognition sequence, rendering them unrecognizable by splicing machinery 
(Cartegni et al., 2002). An example among many SNV-mediated human diseases is 
Duchenne muscular dystrophy (OMIM 310200), an X-linked muscle disorder, most often 
caused by nonsense variation within the DMD gene leading to protein truncation 
(Hoffman et al., 1987). 
 
1.2 Genetic diseases in humans 
1.2.1 Monogenic (Mendelian) diseases 
Mendelian traits, first characterized by Austrian monk Gregor Mendel in the mid-1800s, 
explain simple and apparent parent to child transmission patterns (Henig, 2000; van der 
Waerden, 1968). Mendel first studied these traits in plants by observing height and colour 
differences in subsequent generations (Henig, 2000; van der Waerden, 1968). In doing so, 
the laws of Mendel emerged, which attempt to explain these noticeable differences. The 
first law, known as ‘the law of independent assortment’, states that during gamete 
formation, different pairs of alleles segregate independently of each other (Castle, 1903; 
Monaghan and Corcos, 1984). The second law, ‘the law of segregation’, suggests that the 
two alleles for each trait separate (segregate) during gamete formation, and then unite at 
random (Castle, 1903; Monaghan and Corcos, 1984). The third law, ‘the law of 
dominance’, states that recessive alleles are always masked by dominant alleles that 
determine the phenotype (Castle, 1903; Monaghan and Corcos, 1984).  
Although additional complexities and exceptions have been recognized since they 
were originally proposed, these principles are still in use and are applied today in 
research and more importantly, in clinical genetic testing (Farhan and Hegele, 2013). 
Mendelian diseases are considered simple genetic diseases as they are typically caused by 
variants in a single gene (monogenic). Mendelian diseases are also recognized by their 
distinct inheritance patterns including: autosomal dominant, co-dominant, or recessive 
and X-linked (sex-linked) dominant or recessive (Farhan and Hegele, 2013). In dominant 
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disorders, one variant is sufficient to cause disease; this is in contrast to recessive 
disorders, where two defective alleles are necessary.  
Mendelian diseases are typically not affected by exogenous factors such as the 
patient’s environment, gene by environment interactions, or epigenetic modifications 
however; these factors can exacerbate or alleviate the phenotype. For example, 
individuals diagnosed with phenylketonuria (PKU, OMIM 261600), an autosomal 
recessive, metabolic disease commonly caused by variations in the PAH gene, can 
exacerbate or alleviate the intellectual disability phenotype caused by an accumulation of 
tyrosine, if an affected individual maintains a high or low protein diet, respectively 
(Demirkol et al., 2011). Mendelian diseases are mostly rare in the general population as 
they are the result of a highly penetrant variant in a highly conserved and physiologically 
essential protein (Farhan and Hegele, 2013). Individuals affected by severe Mendelian 
diseases such as Tay-Sachs disease (OMIM 272800), a severe early-onset neurological 
disorder caused by variants in the HEXA gene, do not reach the age of sexual maturity; 
and if they do, are unable to reproduce due to many biological and social factors 
(Fernandes Filho and Shapiro, 2004). 
 
1.2.2 Digenic diseases 
Digenic inheritance, considered the simplest form of oligogenic inheritance, is 
characterized by the presence of two independent variants that jointly modify the 
phenotype. Digenic inheritance is a relatively unrecognized type of disease inheritance, 
as its definition has not been clearly defined and often mistaken with epistasis, the 
interaction of genes. In 2013, Alejandro Schäffer suggested a universal definition of 
digenic inheritance in medical genetics: ‘inheritance is digenic when the variant 
genotypes at two loci explain the phenotypes of some patients and their unaffected (or 
more mildly affected) relatives more clearly than the genotypes at one locus alone’ 
(Schaffer, 2013). In recognition of the importance of digenic inheritance in human 
diseases, the ‘digenic disease database’ was created with the intent of aggregating 
comprehensive information on reports of digenic inheritance in various diseases (Gazzo 
et al., 2016). 
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An example of a disease with digenic inheritance is long QT syndrome (OMIM  
192500), a congenital heart disease characterized by a prolonged QT interval as detected 
by electrocardiography (Millat et al., 2006). While variants in either KCNQ1 or KCNH2 
can cause long QT syndrome, the condition can also result from co-occurrence of variants 
in both genes (Berthet et al., 1999). Furthermore, the digenic inheritance observed in long 
QT syndrome, has been replicated in other studies (Millat et al., 2006; Tester et al., 
2005). Importantly, digenic traits can also be considered complex diseases as they can be 
modulated by non-genetic factors, as described in the subsequent section. 
 
1.2.3 Polygenic (complex) diseases 
Complex diseases are affected by various factors including a burden of genetic variation, 
the environment, gene-environment interactions, or epigenetic modifications (Cordell, 
2009; Iyengar and Elston, 2007; Petrovski and Kwan, 2013). Complex diseases are more 
prevalent in the population therefore, they often follow a ‘common variant, common 
disease’ genetic principle. Traditionally, common variants are primarily studied in 
complex diseases however, they only marginally contribute to disease susceptibility. 
Potentially, the presence of multiple genetic variants with modest but cumulatively, 
significant effects can confer risk to disease (Do et al., 2012; Petrovski and Kwan, 2013). 
Despite these biological consequences, low effect variants are able to persist in the 
population, as they are individually not large enough to be targeted by natural selection. 
Based on these observations, conventional genome-wide association studies 
(GWAS) used single nucleotide polymorphism (SNP) arrays, which did not capture any 
rare variation and were based on a priori knowledge of common susceptibility SNPs 
(Koboldt et al., 2013). However, there has been growing interest in assessing the effects 
of rare variants in complex diseases to identify the missing heritability (discussed in 
subsequent sections). The availability of next generation sequencing technologies 
(discussed in upcoming sections) allows for unbiased detection of both common and 
novel rare variation. Likewise, exome-wide genotyping arrays are commercially available 
at significantly lower costs and permit large scale rare and common variant association 
testing (Koboldt et al., 2013). 
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As initially observed by Francis Galton and Karl Pearson in the 1900s, 
quantitative traits typically follow a Gaussian (normal) distribution (Galton and Galton, 
1997). Individuals residing at the tail ends of the distribution are often studied to identify 
any genetic variation contributing to the trait of interest. This approach, referred to as 
extreme phenotype sampling, is robust in detecting rare variation enriched in cases 
(extreme phenotypes), than controls (individuals within the normal range) (Auer and 
Lettre, 2015). Moreover, in the absence of large effect variants, which can underlie 
Mendelian diseases as previously discussed, individuals with extreme phenotypes may 
carry a burden of multiple small effect variants that collectively increase risk for disease. 
The burden of genetic risk is often quantified by summation of risk alleles to produce a 
‘polygenic risk score’ (Dudbridge, 2013). Finally, in addition to genetic predisposition, 
age, sex, puberty, pregnancy, or diet can influence disease manifestation. 
 
1.3 Phenotypic variation 
As discussed in the preceding section, complex disorders are influenced by multiple 
factors and therefore, can have multiple etiologies. The phenotypic variation in an 
individual with a complex trait can be attributed to genetic variation, environmental 
conditions, or an interplay of both potential influences (Zuk et al., 2012). Simply, the 
phenotypic value (P) is equal to the sum of the genotypic value (G) and the 
environmental deviation (E). Therefore, changes in G and/or E influence the variability in 
P: 
P = G + E 
 
 Importantly, G is comprised of three components: 1) the additive genetic value 
(A); 2) the dominance component (D); and 3) the epistasis (I, interaction of genes). 
G = A + D + I  
 
These genetic influences make up the heritability of a quantitative trait, which I will 
discuss next. 
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1.3.1 Heritability 
To determine the effect of genetic variation on phenotypic variation (VP), we often rely 
on the heritability of the phenotype of interest. Heritability is the variation in an 
individual’s phenotype that is attributed to the genetic variation transmitted through the 
parents’ germ cells (Zuk et al., 2012). Specifically, heritability is the ratio of genetic 
variance (VG) to phenotypic variance (VP). There are two main types of heritability: 
broad sense and narrow sense. Broad sense heritability (H2) is all the genetic variance:  
H2 = VG/VP = (VA + VD + VI)/VP. 
 
Alternatively, narrow sense heritability (h2) is only the additive genetic variance: 
h2 = VA/VP 
 
1.4 Epigenetics and human diseases 
In addition to genetic variations that contribute to benign human diversity or disease, the 
expression of genes can be modulated by epigenetic modification machinery. In general, 
epigenetics is the study of mechanisms that control gene expression without altering the 
DNA sequence. These potentially heritable processes are stable and are particularly 
important during development. There are multiple types of epigenetic modifications 
grouped into three main categories: 1) DNA methylation; 2) histone modification; 3) and 
nucleosome positioning (Handy et al., 2011; Portela and Esteller, 2010). 
DNA methylation is the process of adding a methyl group to a CpG site, yielding 
a transcriptionally inactive gene. Therefore, methylation and demethylation respectively 
silence or activate gene expression ultimately affecting protein synthesis (Handy et al., 
2011). Similarly, histone modifications can modulate gene expression and protein 
synthesis. Specifically, the tail ends of histones can under go post-translational 
modifications including acetylation, methylation, phosphorylation, ubiquitination, 
SUMOylation, or ADPribosylation (Portela and Esteller, 2010). Finally, positioning of 
nucleosomes can regulate gene expression by blocking transcription start sites, ultimately 
preventing transcription (Portela and Esteller, 2010). 
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An example of a disease with epigenetic modification is ATR-X syndrome 
(OMIM 301040), an X-linked dominant disease characterized by intellectual disability 
and alpha-thalassemia (Badens et al., 2006). ATR-X syndrome is caused by heterozygous 
(hemizygous) variants in the ATRX gene and males are predominantly affected however, 
carrier females may have skewed X-inactivation (Badens et al., 2006). ATRX binds 
DAXX to form a chromatin-remodeling complex, and pathogenic variants in either 
protein can lead to telomere dysfunction, genomic instability, or altered gene expression 
(Leung et al., 2013; Watson et al., 2013). 
 
1.5 Approaches to studying genetic diseases 
The relationship between disease penetrance and allele frequencies can help in 
prioritizing which approach to pursue when studying genetic diseases. As previously 
discussed, highly penetrant phenotypes are more likely to be caused by very rare genetic 
variation. While low-to-intermediate penetrant phenotypes can also be attributed to very 
rare genetic variation, these phenotypes are typically not severe enough to be clinically 
ascertained (McCarthy et al., 2008). In contrast, common variants typically result in low 
penetrant phenotypes, and are often the targets of GWAS (McCarthy et al., 2008). 
 In this section, I will introduce conventional approaches to study genetic diseases 
in related individuals (family studies applying forms of linkage analysis) and in unrelated 
individuals (population studies applying forms of association analysis). While linkage 
studies, candidate gene approaches, and GWAS have been successful in identifying loci 
that are causal or confer risk to disease, massively parallel sequencing is able to rapidly 
and economically identify causal variants, which I will discuss in subsequent sections. 
 
1.5.1 Family studies 
1.5.1.1 Linkage studies 
Genetic linkage, first postulated by three British geneticists namely, William Bateson, 
Edith Rebecca Saunders, and Reginald Punnett, is when two loci are transmitted together 
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from parent to offspring, more often than expected (Dawn Teare and Barrett, 2005; 
Edwards, 2012). Across a population, when alleles at separate loci are associated with 
each other at a significantly higher frequency than would be expected by chance, they are 
in linkage disequilibrium and therefore, can be evidence of common ancestry (Dawn 
Teare and Barrett, 2005). Using linkage maps, which were initially developed by Thomas 
Hunt Morgan and his student, Alfred Sturtevant, helped us further refine linkage studies. 
Morgan and Sturtevant hypothesized that recombination of genes was dependent on the 
physical distance between them, measured in centimorgans (cM; 1 cM is approximately 1 
million base pairs) (Sturtevant et al., 1919). This proposition allowed for linkage studies 
to be applied in humans to identify regions of the genome containing disease-associated 
genes. Furthermore, a specific subtype of linkage analysis known as the parametric of 
inheritance model-based analysis, determines co-segregation of genetic markers in 
families (Dawn Teare and Barrett, 2005). As the proximity of loci on a chromosome 
reduces the probability that they will separate by recombination, it is likely that a closely 
related disease cohort would co-inherit an entire section within the chromosome. As 
aforementioned, this phenomenon known as ‘linkage disequilibrium’ defies Mendel’s law 
of segregation. Using this approach, a genetic region unique to affected individuals and 
absent from healthy controls, can be identified. This approach also assigns a logarithm of 
the odds (LOD) score for each linkage event with significantly large LOD scores 
indicative of linkage; and low or negative values are evidence of genetic recombination. 
LOD scores of ≥3 are equivalent to P-values of ≤0.001, and are traditionally considered 
statistically significant. 
 
1.5.1.2 Candidate gene approaches 
Prior knowledge of genes implicated in a disease has a central advantage over traditional 
linkage studies and GWAS. Candidate gene approaches are hypothesis driven and are 
based on a well-established relationship of a gene with a disease, prior knowledge from 
genetic analysis (genetic variant present in affected individuals); or a high likelihood 
region identified via linkage analysis (Jorgensen et al., 2009). Targeting candidate genes 
by sequencing or genotyping individuals for variation in genes implicated in the disease, 
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can significantly expedite genetic discoveries. However, candidate gene approaches are 
generally not suited for novel diseases or diseases exhibiting locus heterogeneity. 
 
1.5.2 Population studies 
1.5.2.1 Association studies 
Association approaches are more useful for elucidating susceptibility alleles underlying 
complex diseases in multiple unrelated individuals. This unbiased approach facilitated the 
era of GWAS, which used genotyping arrays to screen a large number of cases and 
controls, for thousands of common variants across the genome (Auer and Lettre, 2015). 
To identify genuine disease-associated variants, the variant frequency in cases must be 
significantly higher than in controls, which at first glance, likely favours linkage 
disequilibrium (Auer and Lettre, 2015). The International HapMap Project assessed 
common variation in a global, ethnically diverse cohort, and determined that when 
considering linkage disequilibrium, there are approximately one million unique loci in the 
human genome (International HapMap, 2005). Following a Bonferonni correction for the 
million unique loci, which are treated as independent tests, a genome-wide significant P-
value = <5×10-8, became the standard threshold. In addition to observing genome-wide 
significance of an association between an allele and a phenotype, it is important to 
replicate the association in an unbiased population sample to eliminate possible 
confounding variables such as population stratification, which may occur when 
subpopulations within the study cohort carry the allele due to differences in ancestral 
origin, rather than disease state (McCarthy et al., 2008). Furthermore, association of the 
variant and disease should be followed by ensuring the signal is replicable and harboured 
in or near a gene biologically relevant to the disease mechanism. 
 
1.6 Tools to study genetic variation in disease 
In this section, I will introduce tools available to study genetic variation with an emphasis 
on sequencing technology. 
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1.6.1 Sequencing versus genotyping: benefits and pitfalls 
To identify the genetic basis of human diseases, we often use sequencing or genotyping-
based assays. In sequencing approaches, we indiscriminately identify the full nucleotide 
sequence of genes. In genotyping approaches, we use a known set of genetic markers to 
determine their presence or absence in individuals. Each approach is selected based on 
the study hypothesis and objectives. Traditionally, GWAS used arrays to rapidly 
genotype cases and controls, as previously discussed. Knowledge of the entire genetic 
sequence is preferred however, genotyping approaches are often selected to reduce costs. 
In my PhD thesis, I used sequencing approaches to discover novel disease loci and 
genotyping approaches to screen for the newly discovered loci in cases and controls. 
 
1.6.2 Massively parallel sequencing 
Today, we are in the era of massively parallel DNA sequencing often referred to as next 
generation sequencing. Next generation sequencing technologies is a broad umbrella term 
for technologies that facilitate rapid, efficient sequencing of multiple genomes by 
performing millions of reactions simultaneously leading to high throughput of data 
(Farhan and Hegele, 2014). This is in contrast to Sanger sequencing, now considered first 
generation sequencing, which has been widely and successfully used in genetic studies 
most notably in elucidating the code of the first human genome (Lander et al., 2001). 
However, Sanger sequencing is labour intensive and can be prohibitively expensive for 
studies with a large sample size. The advent of next generation sequencing technologies 
has accelerated gene discoveries in virtually all diseases. There are three main types of 
next generation sequencing applications for sequencing DNA variants: 1) whole genome 
sequencing; 2) exome sequencing; and 3) targeted gene panels. 
Whole genome sequencing is an indiscriminate approach that decodes the genetic 
information in an individual’s genome. In contrast, exome sequencing targets only the 
protein-coding regions or the “exome” of the genome by designing probes that are unique 
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to the exons. Targeting only the protein-coding regions of the genome originates from the 
observation that a large fraction of human genetic diseases are caused by non-
synonymous variants in evolutionarily considered protein-coding genes (Chong et al., 
2015; Ng et al., 2009). Moreover, the difference in cost between the two methods; and 
the computational power necessary to reassemble the human exome (1-2% of the human 
genome), is significantly less resource intensive (Farhan and Hegele, 2014).  
Notably, while next generation sequencing has led to the discovery of genes not 
previously implicated in human diseases, in general, the majority of findings are novel 
variants in known disease-causing genes. These trends have consequently led to the 
development of custom designed next generation sequencing gene panels where disease-
specific genes are preselected and are screened without sequencing other regions of the 
genome. This allows for a prioritized, economical, and rapid genetic diagnostic approach 
without the burden of incidental and secondary findings in known disease-causing genes 
not relevant to the disease of interest. I describe the approach of developing a targeted 
neurodegeneration gene panel in Chapter 6. 
 
1.6.3 Molecular studies and model organisms 
The use of molecular approaches and model systems allows us to recapitulate genetic 
variation found in human diseases and provides a clearer understanding of the biological 
consequence exerted by the variants (Nabbout and Dulac, 2011). There are multiple 
molecular biology approaches to investigate the effect of variants beginning primarily 
with the patients’ tissue (ex vivo experiments). Gene expression and protein interaction 
assays are examples of experimental approaches to investigate the pathogenicity of 
candidate genetic variants within patient derived cells. However, ex vivo experiments are 
not always possible especially when studying neurological diseases as many neurological 
disease-causing genes are predominantly expressed in the central nervous system and 
require invasive extraction procedures (Ottman et al., 2010; Prasad and Hoffmann, 2010). 
To overcome this limitation, in vitro assays can be performed to assess whether the gene 
product or its equivalent, is defective and disrupts any downstream pathways. In in vitro 
assays, the variant is genetically engineered into DNA and introduced into an artificial 
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system using established cell lines. Using this approach, we can determine whether the 
variant exerts a loss or a gain of protein function and the resulting effect on the 
connecting pathways. 
Finally, in vivo models, where the candidate gene is disrupted or the variant is 
genetically engineered and implanted into embryos that develop into model organisms, 
have led to the advancement of human genetics research. Specifically, various non-
mammalian organisms including Amoeba proteus (amoeba), Caenorhabditis elegans 
(worms), Drosophila melanogaster (fruit flies), and Danio rerio (zebrafish) have been 
routinely used as model organisms in research given their relatively simple development 
and short lifespan. The absence of these characteristics in transgenic non-human animal 
models makes them significantly more challenging to study (Cunliffe et al., 2014). 
However, despite the long generation times of non-human animal model organisms such 
as Mus musculus (mice), Sus scrofa (pigs), or Pan troglodytes (chimpanzee), they are 
more related genetically and physiologically, to humans and therefore, these animals are 
more likely to generate a phenotype consistent with the human disease (Kullmann et al., 
2014). The application of both types of model organisms has greatly advanced our 
knowledge of human diseases and has ushered the successful development of drugs used 
to treat the patients. 
 
1.7 Variant causality criteria 
Naturally, a single human genome contains numerous rare and common variations. 
Therefore, prioritization criteria are needed to distinguish a potentially causative variant 
from merely common benign genetic variation. Being able to ascribe causality to a 
particular DNA variant with a high degree of likelihood is essential for genetically 
diagnosing patients with inherited diseases. In this PhD thesis, I have applied the 
following conservative criteria, which includes multiple lines of evidence, to increase the 
likelihood that the genetic variants observed in patients in Chapters 2-5, are disease 
causing. Importantly, given the complexity in the diseases described in Chapters 6 and 7, 
I did not apply all steps of the variant causality criteria. 
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(1) The genetic variant is rare in the population 
Allele frequency is an important metric of variant deleteriousness. Intuitively, rare 
diseases are more likely to be caused by rare variants, as they are relatively depleted in 
the population, as previously discussed. Upon obtaining next generation sequencing data, 
I prioritized rare variants, which often have a minor allele frequency (MAF) <<1% or 
may not have a MAF, in ascertained samples in population databases. To determine the 
allele frequency, I surveyed multiple population databases containing thousands of 
healthy controls (Table 1.6.1.1) as well as disease specific databases (Table 1.6.1.2). It is 
important to mention that some of the databases listed here were not initially available 
during the duration of my PhD studies. Furthermore, in addition to incorporating 
thousands of individuals, it is important to ensure the reference databases used are 
ethnically diverse and accurately catalogue human diversity. Population ascertainment 
bias can occur and can lead to misinterpretation of the allele frequency. For example, 
European populations are enriched in currently available reference sources. Therefore, 
the absence of a variant in European populations should be interpreted with caution, as 
the same variant can be more frequent in African or Middle Eastern populations, which 
are currently not adequately represented. 
 
Table 1.7.1 Population databases of healthy controls. 
 
Databases Sample # Type of sequence Reference 
ExAC 60,706 Exome Lek et al., 2015 
NHLBI ESP 6,500 Exome Fu et al., 2013 
1000 Genomes 2,500 (originally 1092) Genome Abecasis et al., 2012 
dbSNP  Multiple Sherry et al., 2001 
 
ExAC, Exome Aggregation Database; NHLBI ESP, National Heart, Lung, and Blood Institute Exome 
Sequencing Project; dbSNP, database of single nucleotide polymorphisms. Empty cells depict unknown 
information. 
 
Table 1.7.2 Disease databases. 
 
Databases Type of disease Type of sequences Reference 
ClinVar Mendelian and complex Multiple Landrum et al., 2014 
OMIM Mendelian Multiple Hamosh et al., 2002  
HGMD Mendelian and complex Multiple Cooper et al., 1998 
DECIPHER Mendelian and complex Multiple Bragin et al., 2013 
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OMIM, Online Mendelian Inheritance in Man; HGMD, Human Gene Mutation Database; DECIPHER, 
Database of genomic variation and phenotype in humans using Ensembl resources. 
 
(2) The genetic variant is predicted to affect the protein function using in silico 
predictive programs 
Conservation is another important metric of variant deleteriousness. The conservation of 
the wild type allele throughout evolution illustrates its importance in gene function. 
Accordingly, I used multiple in silico predictive software (Table 1.6.1.3) to assess the 
conservation of the wild type residues and also the potential biological effect of the 
amino acid change. Intuitively, a drastic change in amino acid properties is more likely to 
affect protein function potentially by disrupting folding, ultimately altering or abolishing 
ligand-binding sites. Ultimately, the results of these programs are merely prediction and 
were always interpreted with caution, as their algorithm basis is the same across all 
genes, independent of gene function or expression. 
 
Table 1.7.3 Examples of in silico predictive tools. 
 
Tool Category Algorithm basis Reference 
PolyPhen-2 Missense Protein structure and conservation Adzhubei et al., 2013 
SIFT Missense Conservation Ng et al., 2003 
MutationTaster Missense Protein structure and conservation Schwarz et al., 2010 
CADD Missense Simulated variants and fixed alleles Kircher et al., 2014 
Condel Missense Implements PolyPhen-2, SIFT, and 
MutationAssessor 
González-Pérez et al., 2011 
MutationAssessor Missense Conservation Reva et al., 2011 
PANTHER Missense Conservation Mi et al., 2016 
 
Asseda Splicing Combined gene information content Mucaki et al., 2013 
Human Splicing Finder Splicing Proximity to exon/intro Desmet et al., 2009 
MaxEntScan Splicing Entropy Yeo et al., 2004 
 
GERP Conservation Genomic conservation rates Cooper et al., 2005 
phyloP Conservation Alignment and phylogenetic trees Pollard et al., 2010 
ClustalW* Conservation Alignment and phylogenetic trees  Larkin et al., 2007 
 
*Not predictive software, through alignment, researchers can observe the conservation of wild type 
residues. 
 
(3) The genetic variant segregates with disease status 
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Association of the genetic variant with disease status is important in establishing 
causality. Herein, I prioritized variants that were significantly overrepresented in cases 
than controls. I screened all available family members to determine whether the variants 
observed segregate with the disease status in the pedigrees, in the predetermined mode of 
inheritance. 
 
(4) Functional validation of the genetic variant 
Appropriate assays should be used to experimentally validate the pathogenicity of the 
candidate variants. These experiments can demonstrate whether the variant exerts a gain 
or loss of protein function and how this is related to the biology of disease. Experiments 
using patient-derived tissue (ex vivo), genetically engineered cell lines expressing the 
mutants (in vitro), or model organisms (in vivo) that clearly recapitulate the human 
disorder, are useful in assessing variant pathogenicity. This is often the rate-limiting step 
in implicating DNA variation in human disease. In Chapters 2, 3, and 5, I used multiple 
experimental approaches to objectively evaluate the effect of the candidate variants. 
 
1.8 Thesis outline 
In this section, I will introduce the projects and opportunities to study monogenic 
diseases and complex diseases (familial and sporadic). More details are provided in 
Chapters 2-7. 
 
1.8.1 Finding of Rare Disease Genes (FORGE) Canada 
1.8.1.1 Project rationale 
Rare genetic diseases affect the lives of approximately 500, 000 children in Canada 
(Mackenzie and Boycott, 2012). While individually rare, collectively they account for a 
significant proportion of hospitalizations (Farhan and Hegele, 2013). Their 
disproportionate prevalence in certain communities is often the result of years of 
isolation, which eventually leads to low genetic variation. In these cases, we can infer the 
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disease-causing variant is harbored within a highly homozygous region in affected 
individuals and is transmitted through asymptomatic carriers (Broman and Weber, 1999; 
Lander and Botstein, 1987; Puffenberger et al., 2012). Previously, the use of standard 
genetic techniques such as homozygosity genetic mapping and candidate gene 
sequencing have been successful although costly and laborious, in identifying the genetic 
basis of monogenic disorders (Lahiry et al., 2009; Puffenberger et al., 2004). The 
application of next generation sequencing has identified hundreds of disease-causing 
genes and has greatly advanced the study of rare inherited disorders. 
 
1.8.1.2 Project overview 
The FORGE Canada Consortium was a nationwide initiative to ascertain and study the 
genetic basis of multiple inherited pediatric onset rare genetic disorders (Beaulieu et al., 
2014). The Children’s Hospital of Eastern Ontario Research Institute at the University of 
Ottawa was established as the lead institution. Gene discovery was an overall objective of 
the consortium. Accordingly, there were five categories in which to group the multiple 
disorders submitted by Canadian clinicians. These include: 1) multiple unrelated 
individuals affected by the same rare disorder; 2a) consanguineous families; 2b) 
autosomal dominant families; 3) non-consanguineous families with two or more affected 
individuals; and 4) single affected individuals with no family history. Overall, 264 
projects were funded to study their genetic basis. The 264 disorders were distinct clinical 
phenotypes affecting multiple systems and observed in either single or multiple 
pedigrees. 
 
1.8.1.3 Project aims 
The overall aims of FORGE, which are recapitulated here, are to: 
1) Assist clinicians and researchers in recruiting patients with rare genetic diseases. 
2) Use next generation sequencing technologies and strategic functional tests to identify 
the genetic basis of disease in patients. 
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3) Organize and facilitate a national data coordination centre to accelerate and improve 
the interpretation of large-scale sequence data. 
4) Establish ethical guidelines for analyzing and interpreting sequence data for the 
purposes of genetic counseling. 
 
1.8.1.4 Project significance 
Identifying disease genes is important for several reasons. First, it can help us understand 
the dynamic function and mechanism of the gene product in the normal state. Second, we 
can implement presymptomatic testing and carrier screening for high-risk populations. 
Third, depending on the biochemical pathway, the gene may be druggable. While these 
disorders are each clinically distinct, the process used to identify the causative gene is the 
same in each case. Publishing causative genes and variations for which the confidence in 
their causality is high will allow research groups locally and globally to move the 
discovery process forward using different lines of experimentation in which they are 
expert. These efforts can eventually lead to targeted therapeutic interventions. 
 
1.8.1.5 My role in the project 
Members of the Hegele lab worked with clinicians and scientists who have ascertained 
multiple, distinct rare disorders that became approved by the FORGE Canada 
Consortium. Four disorders: 1) infantile mitochondrial complex II/III deficiency 
(IMC23D); 2) seizures scoliosis macrocephaly (SSM) syndrome; 3) progressive 
myoclonus epilepsy with ataxia; and 4) nocturnal seizures with developmental delay 
became independent research chapters within my PhD thesis. All four phenotypes are 
described in great detail in subsequent chapters. 
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1.8.2 The Ontario Neurodegenerative Disease Research Initiative 
(ONDRI) 
1.8.2.1 Project rationale 
Dementia is the single greatest cause of neurological disability in our senior population 
with a global incidence of 47.5 million cases (2008; 2015). The annual cost of caring for 
individuals affected with dementia in Canada is $15 billion – a figure expected to grow to 
nearly $153 billion by 2038 - including a tenfold increase in demand for long-term care 
(Herrmann et al., 2015). The cumulative global cost of Alzheimer's disease and dementia 
is currently estimated to be $605 billion, which is equivalent to 1% of the entire world's 
gross domestic product. This figure will continue to grow unless disease-modifying 
interventions are found to alter these alarming trends (2008; Herrmann et al., 2015). Key 
to any such initiative will be the ability to identify early and accurately those individuals 
who are at risk for developing a dementia, either as an independent disease process or as 
a co-morbidity of a related neurodegenerative or neurovascular disorder. 
 
1.8.2.2 Project overview 
ONDRI is a prospective cohort study that will use a multimodal approach to predicting 
the occurrence or progression of cognitive or neuropsychological impairment in a defined 
patient population. Disease progression will be monitored in 600 patients from across 
Ontario, Canada, for up to three years using rigorous evaluations across multiple 
assessment platforms, including neuroimaging, detailed neuropsychological evaluations 
(including comprehensive speech and language assessments), genomics, evaluations of 
cognitive control of eye movements and retinal layer thickness and morphology, gait 
performance, and neuropathology. 
Patients will be enrolled in the study with either 1) Alzheimer’s disease (AD) or 
amnestic single or multidomain mild cognitive impairment (aMCI), 2) amyotrophic 
lateral sclerosis (ALS), 3) frontotemporal dementia (FTD), 4) Parkinson’s disease (PD) 
or 5) vascular cognitive impairment (VCI). These disorders were selected based on their 
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prevalence within the aging population and the frequent occurrence of 
neuropsychological dysfunction in each at various stages over their course. Amongst 
these, AD pathology is the most common, underlying approximately 63% of all dementia 
cases (Herrmann et al., 2015; Sperling et al., 2011). While objective memory loss 
characterizes aMCI, unlike AD, the cognitive impairment does not significantly disrupt 
daily functioning (Gomersall et al., 2015). Although traditionally considered to be a 
disorder of upper and lower motor neurons, over 50% of ALS patients will exhibit 
neuropsychological deficits that range from subtle syndromes of cognitive or behavioural 
dysfunction, including impairments in social cognition, to FTD (Strong et al., 2009). 
When present, frontotemporal dysfunction in ALS is associated with a reduction in 
survival by approximately a year (Woolley and Strong, 2015). Parkinson’s disease affects 
approximately 1 in 1,000 in the general population and 1 in 100 individuals over age 65 
years (Dorsey et al., 2007). The prevalence of PD is expected to double by the year 2030 
(Dorsey et al., 2007). Similar to ALS, a significant proportion of PD patients present with 
or will develop neuropsychological dysfunction (Aarsland et al., 2005) and, over time, 
dementia (Parkinson’s Disease Dementia; PDD) develops in over 80% (Hely et al., 
2008). FTD, including subtypes of primary progressive aphasia, progressive non-fluent 
aphasia, semantic dementia and behavioural variant FTD (bvFTD), accounts for 20% of 
early-onset dementia cases with symptom onset commencing at 45-65 years of age 
(Kertesz, 2004). Finally, VCI is the second most common form of dementia with 30% of 
stroke patients developing dementia (Pendlebury et al., 2012; Saposnik et al., 2009; 
Saposnik et al., 2011). The risk of stroke and dementia rises exponentially with each 
decade over 65, with a third of our population expected to have a stroke, dementia, or 
both in their lifetime (Hachinski et al., 2006). 
 
1.8.2.3 Project aims 
The multimodal approach will rapidly detect meaningful neuropsychological change over 
a short time interval, allowing for the early and accurate prediction of the presence of, or 
progression of, dementia. Furthermore, we may identify different forms or profiles of 
dementia that will map onto specific neural circuits, some shared and some differing 
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across disorders depending on the hubs primarily affected. ONDRI will also examine the 
contribution of small vessel pathology to each of these disorders given the increasing 
recognition of the prevalence and potential synergistic effects of this important co-
morbidity. 
 
1.8.2.4 Project significance 
ONDRI is a unique, prospective multimodality study undertaken to improve 
understanding of the pathogenesis of neuropsychological deficits across a broad range of 
neurodegenerative disorders. Beyond this, ONDRI has already facilitated the 
development of standardized assessment protocols, which will allow for direct 
comparisons to be made across a range of neurodegenerative and neurovascular 
disorders. These tools will allow for a systems-based approach to identify not only unique 
clinical, imaging, ocular, genetic, and other biological markers associated with each of 
these disorders, but also to define where there are significant biological overlaps. While 
the numbers of patients being studied is small (600) relative to larger prospective studies, 
patients enrolled in ODNRI will be a unique resource as they will be deeply 
endophenotyped and their de-identified data publically available by request through the 
ONDRI publications and data analysis committee. 
Furthermore, current therapeutic approaches in neurodegenerative diseases, where 
available, tend to be directed towards single biological mechanisms that may be 
inadequate given the complexity of these multifaceted diseases in addition to the 
spectrum of mechanisms by which neurodegeneration is expressed (Iadecola and 
Anrather, 2011). Through this integrated discovery approach, we have the unique 
opportunity to identify multiple markers of brain health that will contribute to the 
development of: 1) biomarkers for neurodegenerative diseases that may ultimately be 
used in the identification of pre-symptomatic individuals; 2) improved identification of 
overlap syndromes amongst neurodegenerative diseases for both clinical and research 
purposes; and, 3) personalized treatments, which may require a “cocktail” similar to the 
approach that has been applied in cancer, and are likely to be more efficacious in halting 
disease progression than current drug regimens (Lang, 2010). These may vary depending 
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on the stage of the disorder being treated, the genetic predispositions discovered to be 
contributing to an individual’s disease, and the possible role of mixed pathologies. 
Hence, this longitudinal exploratory study has the potential to contribute to significant 
impacts on health care in the rapidly growing area of neurodegenerative and 
neurovascular diseases. 
 
1.8.2.5 My role in the project 
Within ONDRI, ONDRI Genomics focuses on identifying genetic variants that may 
contribute to disease onset and progression. The ONDRI Genomics team, which is led by 
Dr. Hegele, developed the ONDRISeq panel, which is a custom designed 
neurodegeneration gene panel specific to the ONDRI diseases. I played a major role in 
the development, optimization, and integration of ONDRISeq in the ONDRI study, which 
I describe in depth in Chapter 6. 
 
1.8.3 Familial ALS and FTD study: defining the role of oligogenic 
inheritance in neurodegenerative disease 
1.8.3.1 Project rationale 
While the exact cause of ALS is unknown, there is substantial evidence that a significant 
proportion has a genetic basis, including ALS cases without a family history of the 
disease (sporadic ALS). Increasingly, some of these affected individuals are observed to 
have more than one genetic abnormality – a phenomenon known as oligogenic 
inheritance as previously discussed. While many of these genes are thought to be 
causative of ALS, many are considered to be disease modifiers. However, even within 
individual families carrying at least one genetic variant, the disease manifestations can 
vary dramatically from a relatively pure ALS phenotype with only motor neuron deficits, 
to dementia with minimal motor involvement, or phenotypically unaffected carriers. This 
raises the possibility that while a single gene may be dominant in inducing the disease, its 
effect will be profoundly modified by the presence of additional genetic variation. 
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1.8.3.2 Project overview 
We have access to three previously unreported ALS families with widely differing 
disease manifestations, each of which carries a pathological expansion of C9orf72. These 
families provide a unique opportunity to understand the role of multiple gene inheritance 
in ALS, how the genes interact with each other, and how this interaction may lead to a 
degenerative disease state. 
Although a significant number of genetic variations are known to be associated 
with ALS, either as causative or disease modifying, it is not clear that the wide 
phenotypic variability that has become a hallmark of the disease, can be fully explained 
by individual genes acting independently of one another. The most glaring example of 
this is the wide phenotypic variability observed with pathological hexanucleotide 
expansions of C9orf72, in which affected individuals may develop ALS, FTD, or some 
combination thereof. While oligogenic inheritance is held forth as an explanation, the 
biological mechanism(s) underlying such interactions has yet to be defined. Our 
hypothesis is that the clinical disease state accompanying oligogenic inheritance is the net 
effect of the interactions of multiple genes in a hierarchical manner such that while one 
gene defect will be dominant, its effect will be modified by the presence of additional 
genetic aberrations. 
 
1.8.3.3 Project aims 
Using these pedigrees, we will address the following specific aims: 
1. Determine the phenotypic effect(s) of patient specific variations individually and 
describe the cumulative effects of variations. This can be established by correlating 
patient clinical data with the presence of variant(s) and post-mortem tissue pathology. 
2. Examine the role of each of the proteins encoded by the mutated genes and the changes 
in binding partners between the mutant protein and the wild type protein in ALS affected 
spinal cord tissue. 
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3. As a long-term goal, determine the effect of these variations in an in vivo model system 
using Drosophila melanogaster, to assess neuron-specific effects. 
 
1.8.3.4 Project significance 
While the concept of oligogenic inheritance in ALS is not novel, these experiments 
represent a unique opportunity to determine the biological effect of oligogenic 
inheritance in a clinically relevant scenario and describe how this can lead to disease 
variability among related and unrelated individuals. Upon completion of all long-term 
goals, we will have investigated: 1) the effect of each variant in neuronal cells; 2) the 
hierarchy of neurotoxicity for each combination of genes when they are expressed 
simultaneously; and 3) how many of these are expressed simultaneously to produce a 
neurodegenerative phenotype. 
 
1.8.3.5 My role in the project 
I performed the experiments and analysis with assistance by other personnel, as outlined 
in Chapter 7. I also assisted Dr. Strong and Mrs. Anne Row in collecting blood samples 
from the families, in preparing the ethics documentation for the study, and overall project 
management. 
 
1.9 Thesis hypotheses 
The research aims presented in this PhD thesis seek to assess the following hypotheses: 
1) The four Mendelian diseases, IMC23D, SSM syndrome, progressive myoclonus 
epilepsy with ataxia, and nocturnal seizures with developmental delay (Chapters 2-5) are 
caused by highly penetrant genetic variants inherited in an autosomal recessive manner. 
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2) Conversely, the neurodegenerative disorders (Chapters 7) are complex genetic diseases 
partly caused by single, rare, highly penetrant variants or multiple, low-to-modest effect 
variants acting synergistically to mediate disease expression. 
 
1.10 Thesis aims 
1) I propose to apply next generation sequencing (exome sequencing) to identify genetic 
variants that may be underlying the Mendelian diseases in Chapters 2-5. 
 
2) I propose to design a neurodegeneration specific gene panel to identify genetic variants 
underlying familial and sporadic neurodegenerative disorders, ascertained through the 
ONDRI project and the familial ALS and FTD study. 
 
3) I plan to apply conservative variant causality criteria on any candidate variants 
observed in the sequencing experiments. 
 
1.11 Conclusion 
In this PhD thesis, I studied the genetic basis of Mendelian and complex diseases. In the 
subsequent chapters, I describe the application of next generation sequencing in 
identifying highly penetrant variants in patients affected by rare Mendelian diseases 
ascertained through the FORGE Canada Consortium. In addition, I also describe the 
development of a custom designed gene panel specific to neurodegenerative diseases, 
which is currently used to sequence all patients within the ONDRI study as well as 
patients in the familial ALS and FTD study. The collective research experiments 
presented here have successfully identified novel genetic loci in multiple human diseases. 
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Chapter 2 - Novel phenotype, novel gene: NFS1 deficiency 
in a novel Fe-S cluster disease, infantile mitochondrial 
complex II/III deficiency. 
 
2 Study rationale 
As part of the FORGE Canada Consortium, we have ascertained a presumed novel 
disorder classified here as ‘infantile mitochondrial complex II/III deficiency’ (IMC23D). 
Testing of mitochondrial and nuclear genes associated with the biochemical phenotype 
observed in the affected children did not yield any candidate mutations. Multiple clinical 
and biochemical geneticists could not diagnose the patients with any known disease. The 
pedigree as presented in addition to the known history of endogamy observed in the Old 
Order Mennonite community, led us to postulate that IMC23D is an autosomal recessive 
disease. Accordingly, we applied autozygosity mapping to generate a highly significant 
homozygous region. Using whole exome sequencing, we identified two genetic variants 
and we treated both as candidate variants until functional evidence led us to isolate NFS1 
as the probable disease-causing gene. 
 Chapter 2 was published as an independent study: “Exome sequencing identifies 
NFS1 deficiency in a novel Fe-S cluster disease, infantile mitochondrial complex II/III 
deficiency” in Molecular Genetics and Genomic Medicine in 2014 (Farhan et al., 2014, 
PMID: 24498631). 
 
2.1 Overview 
Iron-sulfur (Fe-S) clusters are a class of highly conserved and ubiquitous prosthetic 
groups with unique chemical properties that allow the proteins that contain them, Fe-S 
proteins, to assist in various key biochemical pathways. Mutations in Fe-S proteins often 
disrupt Fe-S cluster assembly leading to a spectrum of severe disorders such as 
Friedreich’s ataxia or ISCU myopathy. Herein, we describe infantile mitochondrial 
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complex II/III deficiency, a novel autosomal recessive mitochondrial disease 
characterized by lactic acidemia, hypotonia, respiratory chain complex II and III 
deficiency, multisystem organ failure, and abnormal mitochondria. Through autozygosity 
mapping, exome sequencing, in silico analyses, population studies, and functional tests, 
we identified c.215G>A, p.Arg72Gln in NFS1 as the likely causative mutation. We 
describe the first disease in man caused by deficiency in NFS1, a cysteine desulfurase 
that is implicated in respiratory chain function and iron maintenance by initiating Fe-S 
cluster biosynthesis. Our results further demonstrate the importance of sufficient NFS1 
expression in human physiology. 
 
2.2 Introduction 
Iron-sulfur (Fe-S) clusters are a class of ubiquitous prosthetic groups highly conserved in 
essentially all organisms (Sheftell et al., 2010). Their unique chemical properties allows 
the proteins that contain them to assist in vital and diverse biochemical pathways such as 
iron metabolism and homeostasis as well as DNA damage repair (Kispal et al., 1999; Lill 
et al., 2012; Rudolf et al., 2006). Eukaryotic Fe-S proteins are localized to the 
mitochondria (Lill et al., 2012), cytosol (Tong and Rouault, 2006), endoplasmic 
reticulum (Lill et al., 2006), and nucleus (Naamati et al., 2009). Fe-S proteins initiate 
biogenesis of the Fe-S cluster complex, which can transfer electrons, act as catalysts, 
stabilize protein structures and execute regulatory functions (Kispal et al., 1999; Rudolf 
et al., 2006). Given the central role of Fe-S clusters in many fundamental biochemical 
pathways, deficiency in genes encoding Fe-S proteins are expected to cause human 
disease. Classic examples of Fe-S cluster deficiency related to human disease include: 
Friedreich’s ataxia (FRDA (OMIM 229300), the most common autosomal recessive 
ataxia due to a homozygous expansion of a GAA trinucleotide repeat in intron 1 of the 
FXN gene (Koeppen, 2011) and ISCU myopathy (OMIM 255125), due to a splicing 
defect in the ISCU gene that alters the C-terminus ultimately reducing protein expression 
(Kollberg et al., 2009). Other Fe-S cluster related diseases include those caused by 
mutations in the NFU1 gene or the BOLA3 gene, which ultimately disrupt Fe-S enzyme 
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lipoate synthase activity (Cameron et al., 2011). This leads to a severe infantile 
multisystem disorder known as multiple mitochondrial dysfunctions syndrome, which is 
characterized by hyperglycinemia, lactic acidosis, hypertension, and failure to thrive 
(Cameron et al., 2011). 
In this Chapter, we describe infantile mitochondrial complex II/III deficiency, a 
novel autosomal recessive mitochondrial disease. We used autozygosity mapping, exome 
sequencing, in silico analyses, population studies, and functional assays to isolate 
c.215G>A, p.Arg72Gln in NFS1, as the probable genetic cause of disease. NFS1 is a 
cysteine desulfurase implicated in respiratory chain function and iron homeostasis via 
initiating Fe-S cluster assembly, an essential and highly conserved biochemical process. 
 
2.3 Materials and methods 
2.3.1 Ethics 
Ethics approval was obtained for all FORGE projects in accordance with the Research 
Ethics Board (18152) at Western University, London, Ontario, Canada. Ethics approval 
was obtained from the parents on behalf of all six family members: two parents, three 
affected children, and one unaffected child. Of the three affected children, the first two, 
IV-1 and IV-2, are deceased. We also obtained ethical approval from all DNA samples 
tested in our study. 
 
2.3.2 Patients and biological materials 
Blood and tissue (skin-derived fibroblast cells) samples were collected from all family 
members. An autopsy was conducted on IV-1 and IV-2, and muscle and liver tissue were 
also obtained. 
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2.3.3 DNA isolation 
DNA was isolated from 4 ml of blood or cultured cells collected from every participant 
using the Gentra Puregene Blood kit (Qiagen, Venlo, Netherlands) according to the 
manufacturer’s instructions. DNA quality and concentration were measured using 
NanoDrop-1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). 
 
2.3.4 Enzymology assays 
The following assays were conducted in Dr. Rupar’s laboratory at Children’s Health 
Research Institute in London, Ontario. Mitochondrial electron transport chain enzyme 
activities were measured using muscle and liver autopsy or biopsy samples taken from 
the first two affected individuals. Mitochondrial enzyme activities were measured using a 
previously described protocol with minor modifications (Trounce et al., 1996). 
 
2.3.5 Histology 
Pathologist, Dr. David Ramsay at University Hospital, performed the following 
procedures. First, tissue from the muscle biopsy from affected individual IV-II was 
frozen and fixed in glutaraldehyde. Second, using standard methods, frozen sections were 
treated with the following stains and histochemical methods: Gomori modified trichrome 
(GMT); hematoxylin, phloxin and saffron (HPS); acid phosphatase; ATPase (at pH 4.2 
and 9.6), cytochrome C oxidase (COX); reduced nicotinamide adenine dinucleotide-
tetrazolium reductase (NADH); periodic acid-Schiff (PAS) and succinic dehydrogenase 
(SDH). Finally, the tissues fixed in glutaraldehyde were post-fixed in osmium tetroxide 
and embedded in Epon; thin sections (silver interference) were mounted on standard grids 
and stained with uranyl acetate.  
Routine pediatric autopsies were performed on individuals IV-I and IV-II. 
Representative areas from all organs were examined microscopically. The brains were 
retained and fixed in 20% formalin. Next, a standard neuropathological examination was 
conducted, including widespread sampling of various regions for microscopic 
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examination. All sections were stained with hematoxylin and eosin; in addition, selected 
sections from the liver were stained with oil red O. 
 
2.3.6 SNP genotyping 
Genomic DNA (gDNA) extracted from all family members was genotyped for single 
nucleotide polymorphisms (SNPs) using Affymetrix® (Santa Clara, CA, USA) protocols 
as instructed by the manufacturer. 500 ng of genomic DNA was digested with two 
restriction enzymes, NspI and StyI separately. All DNA fragments were ligated to 
sequence specific adaptors complementary to a PCR primer. Each digest was PCR 
amplified then combined and purified. Finally, PCR products were fragmented, labeled, 
and hybridized to the Affymetrix® Genome-Wide Human SNP Array 6.0. SNP genotypes 
were determined using the Birdseed v2 algorithm employed in the Affymetrix® 
Genotyping Console™ Software 4.1.1 (Korn et al., 2008; Rabbee and Speed, 2006). 
 
2.3.7 Autozygosity mapping 
GeneSpring GT v2.0 (Agilent Technologies, Santa Clara, CA, USA) software was used 
to identify regions of homozygosity that are identical by descent in family members. SNP 
allele frequencies from healthy Caucasian controls were used to estimate logarithm of the 
odds (LOD) scores for each SNP. Location scores were calculated by summation of LOD 
scores of accumulated homozygous regions in the genome (Broman and Weber, 1999; 
Lander and Botstein, 1987). Homozygous regions unique to the affected individuals with 
significantly high location scores were treated as candidate loci. 
 
2.3.8 Exome sequencing 
Exome sequencing was performed using gDNA from two affected individuals (IV-2 and 
IV-3) on the Illumina HiSeq 2000 with 2x100 paired end chemistry in accordance with 
library protocols used at The Centre for Applied Genomics (TCAG) at the Hospital for 
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Sick Children, Toronto, Ontario. The SureSelect Target Enrichment kit v1 (Agilent 
Technologies, Santa Clara, CA, USA) was used to enrich 40 Mb of exome region. 
Briefly, DNA is enzymatically fragmented and adapters are added on to the 
sequence, and placed on a flow cell. The Illumina platform uses sequencing-by-synthesis 
employing reversible dye terminators, which is a DNA polymerase-dependent method 
that allows for real-time sequencing (Metzker, 2010; Voelkerding et al., 2009). 
Specifically, the template encounters bridge amplification, as the adapters are 
complementary to the sequence attached on the flow cell (Metzker, 2010). Extending the 
vacant 3’ OH with a fluorescently labeled primer that is complementary to the adapter 
hybridizes, and light is emitted and detected, revealing the identity of the nucleotide base 
(Metzker, 2010). 
 
2.3.9 Sequence alignment 
Raw sequencing reads in the form of FASTQ files were aligned to the Hg19 reference 
genome using the Burrows-Wheeler Aligner (BWA) algorithm to generate SAM/BAM 
format files, which are sorted by genomic coordinates (Li and Durbin, 2009; Li et al., 
2009; Quinlan and Hall, 2010). A BAM file is a binary form of a SAM file, which holds 
information on all sequencing reads and their respective genomic coordinates. Post-
alignment processing steps included flagging and removing duplicate reads generated by 
PCR amplification bias, using Picard (http://picard.sourceforge.net/). Furthermore, local 
realignment was performed around insertions and deletions as these types of genetic 
variation can produce sequencing artifacts due to misalignment in previous steps. Finally, 
recalibration of base quality score was performed to ensure each base call is adequate as 
downstream variant calling algorithms are score dependent. 
 
2.3.10 Variant calling and annotation 
Genome Analysis Toolkit (GATK) was used to generate the coverage of the whole 
exome in the form of variant calling format (VCF) files (DePristo et al., 2011; McKenna 
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et al., 2010) in accordance with GATK Best Practices 
(https://www.broadinstitute.org/gatk/guide/best-practices). In conjunction, CLC Bio 
Workbench (Aarhus, Denmark) was used to generate VCF files for comparison. Variants 
within VCF files were annotated using ANNOVAR (Wang et al., 2010) and GATK 
Haplotype Caller 
(https://www.broadinstitute.org/gatk/guide/tooldocs/org_broadinstitute_gatk_tools_walke
rs_haplotypecaller_HaplotypeCaller.php), which included context and functional 
annotations. Context annotations provided information regarding the quality of the 
sequence reads. Functional annotations provided information on the biological effect of 
the variants, including: 1) type of variant (synonymous, non-synonymous, splicing, 
insertions, or deletions); 2) coordinates (genomic, transcript, and protein); 3) zygosity in 
patients; 4) and the associated allele frequency based on 1000 Genomes (Genomes 
Project et al., 2012) and dbSNP (Sherry et al., 2001). 
 
2.3.11 Variant discovery 
2.3.11.1 Prioritization of homozygous, non-synonymous, and rare variants 
Given the rarity and severity of disease and the pedigree structure, we used a 
homozygous, non-synonymous, and rare variant (minor allele frequency [MAF] <1%) 
according to NCBI dbSNP and 1000 Genomes, approach to identify any variants. 
Because we identified a highly significant homozygous region on chromosome 20, we 
prioritized variants within 20p11.2-q13.1. 
 
2.3.11.2 In silico analyses 
To determine the predicted biological effect of non-synonymous variants on protein 
function, all non-synonymous variants identified as candidate variants (NFS1 
p.Arg72Gln and CDH22 p.Arg167Cys) were assessed using the following tools: 
Polymorphism Phenotyping version 2 (PolyPhen-2) (Adzhubei et al., 2010), Sorting 
Intolerant From Tolerant (SIFT) (Kumar et al., 2009), MutationTaster2 (Schwarz et al., 
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2014), and PMut (Ferrer-Costa et al., 2005). To determine amino acid conservation, 
human protein sequences were aligned to other protein sequences from a diverged set of 
species using ClustalW2 (Thompson et al., 1994). 
 
2.3.12 Variant validation 
To determine whether p.Arg72Gln in NFS1 and p.Arg167Cys in CDH22 co-segregated 
with disease status in the pedigree, we genotyped family members using standard Sanger 
sequencing methods. 
 
2.3.12.1 PCR 
Forward and reverse primers specific to amplify g.1573G>A in NFS1 were: 5’-
TTGGTGGGTAGTTTTGTGGG-3’ and 5’-CCATTTCTACCTCCATGCAC-3’, 
respectively. Forward and reverse primers specific to amplify g.10682C>T in CDH22 
were: 5’-CAAGTACACCATCTCAGGCGAGG-3’ and 5’-
TCTTTTCTGTCCCTCCCCAGAGG-3’. PCR conditions for NFS1 consisted of: initial 
denaturation at 95˚C for 5 minutes; 30 cycles of denaturation at 95˚C for 30 seconds; 
annealing at 58˚C for 30 seconds; extension 72˚C for 30 seconds, and a final extension at 
72˚C for 7 minutes. PCR conditions for CDH22 consisted of: initial denaturation at 95˚C 
for 7 minutes; 30 cycles of denaturation at 95˚C for 20 seconds; annealing at 60˚C for 20 
seconds; extension 72˚C for 20 seconds and a final extension at 72˚C for 7 minutes. 
 
2.3.12.2 Imaging, purifying, and sequencing of PCR products 
PCR products were loaded on a 1.5% agarose gel with SybrSafe DNA gel stain (Life 
Technologies, Carlsbad, CA, USA) and processed against a 100 bp DNA Ladder 
(Thermo Fisher Scientific, Cambridge, MA, USA). The gel was maintained at 100 V for 
45 minutes using GIBCO BRL Horizontal Gel Electrophoresis Apparatus (Life 
technologies, Carlsbad, CA, USA) and imaged using Variable Intensity UV 
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transilluminator VWR (BioDoc-It Imaging System, Upland, CA, USA). Once PCR 
products aligned to the correct size fragment as determined by the pre-calculated PCR 
product size and the corresponding ladder fragment size, PCR products were purified 
using calf intestinal phosphatase/ExoI (New England BioLabs, Ipswich, MA, USA) 
according to manufacturer’s instruction. 
Purified PCR products were sequenced on an ABI 3730 DNA Sequencer (Applied 
Biosystems, Foster City, CA, USA). Electropherograms produced were analyzed using 
Applied Biosystems SeqScape® Software version 2.6 with the reference sequence of each 
gene obtained from NCBI GenBank database. 
 
2.3.13 Population screening 
Importantly, while we were conducting this study, there were many resources not 
available to us that later became available as next generation sequencing and the 
corresponding annotation pipelines became commonplace. For example, the availability 
of public databases such as the National Heart, Lung, and Blood Institute Exome 
Sequencing Project (NHLBI ESP) (http://evs.gs.washington.edu/EVS/) and Exome 
Aggregation Consortium (ExAC) (http://exac.broadinstitute.org/) were not yet available 
or coalesced. As a result, we conducted our own genotyping to determine the MAF of the 
variants. When we finished our study, the NHLBI ESP database became available and we 
compared the allele frequencies reported to the allele frequencies we obtained. 
Furthermore, to the best of our knowledge, these individuals were free from any 
mitochondrial-like diseases. 
 
2.3.13.1 Genotyping of local population 
To determine the allele frequency in the local Old Order Mennonite community, NFS1 
g.1573G>A and CDH22 g.10682C>T were both screened in 40 healthy Old Order 
Mennonite controls using standard Sanger sequencing as previously described. 
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2.3.13.2 Genotyping of an ethnically diverse cohort 
To determine the allele frequency in a genetically heterogeneous population, we screened 
for NFS1 g.1573G>A and CDH22 g.10682C>T in a large ethnically diverse cohort. DNA 
from individuals with ancestral origins from North America, Europe, Asia, and Africa 
collected by Dr. Hegele and collaborators were used in our study. 
 
2.3.13.2.1 TaqMan genotyping assay 
NFS1 g.1573G>A was genotyped in 3,033 individuals from an ethnically diverse cohort 
using a custom-designed TaqMan genotyping assay (Life Technologies, Carlsbad, CA, 
USA). Primers used during the custom probe assay were 5’-
CGCTCAAGGAAAATGATCTGTTCTG-3’ and 5’-
GGAGTGTGGGTTCCCATAGTAGTT-3’. SNP genotyping was performed using an 
allelic discrimination assay on the 7900HT Fast Real-Time PCR System (Life 
Technologies, Carlsbad, CA, USA) and genotypes were identified using automated 
software (SDS 2.3; Life Technologies). Reactions were processed in 5 µl volumes with 
an amplification protocol of: 95˚C for 10 minutes; 50 cycles for 95˚C for 15 seconds, and 
60˚C for 1.5 minutes. 
 
2.3.13.2.2 Pooling samples 
For technical reasons, we were unable to genotype individuals for CDH22 g.10682C>T 
using the same TaqMan genotyping assay previously described. We were also unable to 
genotype individuals using Sanger sequencing as the cumulative cost of genotyping a 
well powered cohort would have been ~$10,000. Therefore, we pooled 781 DNA 
samples in batches of 8-10 depending on sample availability, quality, or quantity and 
performed restriction enzyme based genotyping. 
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2.3.13.2.2.1 Restriction enzyme digestion 
2-5 ul of ~100 ng/ul DNA was added to an eppendorf tube in batches of 8-10 samples for 
technical reasons. Samples were enzymatically digested using endonuclease AciI to 
detect an abolished cut site, in accordance with the manufacturer’s instructions (New 
England BioLabs®, Ipswich, MA, USA.). Post enzyme digestion, products were loaded 
on a 1.5% agarose gel and maintained at 100 V for 45 mins as previously described. 
 
2.3.13.2.2.2 Visualizing and inferring genotypes 
PCR product size was compared to a neighboring 1 Kb DNA ladder (Thermo Fisher 
Scientific, Cambridge, MA, USA). Genotype of samples was inferred from observing a 
single band (homozygous) or two bands (heterozygous). Any sample that appear ed 
heterozygous was independently reprocessed by enzymatically digesting the DNA to 
determine patient zygosity. Three controls were included in every gel: 1) DNA from a 
CDH22 p.Arg167Cys homozygote; 2) a heterozygote, and 3) a homozygote for the wild 
type allele. 
 
2.3.14 Cell culture 
Skin fibroblasts from patients and healthy controls were cultured in Petri plates with 
Dulbecco’s modified Eagle’s medium (GIBCO, Carlsbad, CA, USA) containing 50 
units/ml penicillin and 50 µg/ml streptomycin, supplemented with 10% fetal bovine 
serum and maintained at 37˚C/5% CO2 until 60-70% confluency. 
 
2.3.15 Immunoblotting 
Protein levels were measured using immunoblotting and quantified by densitometry.  
Proteins isolated from cultured fibroblasts were supplemented with 50 mM Tris-Cl pH 
6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue and 10% glycerol, and heated to 
95˚C for 5 min before resolving on 4-20% SDS-PAGE and transferred onto 
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polyvinylidene difluoride membranes (Invitrogen, Carlsbad, CA, USA). The membranes 
were blocked in TBS containing 0.1% Tween-20 and 5% fat-free dry milk for 1 hr and 
then incubated with their respective primary antibody overnight at 4˚C. The membranes 
were then incubated with peroxidase-conjugates anti-species specific secondary for 1 hr, 
followed by primary antibody visualization with enhanced chemiluminescent detection 
with horseradish peroxidase and luminol reagent according to the manufacturer's 
instructions (Santa Cruz Biotechnology, CA, USA). 
 
2.3.16 Quantitative PCR 
RNA was isolated from fibroblast cells using the RNeasy Mini Kit according to the 
manufacturer’s instructions (Qiagen, Valencia, CA, USA). RNA quality was measured 
using the Agilent 2100 Bioanalyzer (Agilent Genomics, Santa Clara, CA, USA).  RNA 
was reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription 
Kit (Life Technologies, Carlsbad, CA, USA) to subsequently perform quantitative 
reverse-transcription PCR (qRT-PCR) using custom designed probes specific to the 
beginning and end of the NFS1 transcript 5’-AGCGCACTCTTCTATCAGGTTTGGA-3’ 
and 5’-AGCTACAACTCCTCTGGACCCCCGG-3’ and also for the CDH22 transcript 
5’-TGGACCCCAAGACCGGCGTAATCCG-3’ and 5’-
TTGACATCCAAGACAACACCGCTG C-3’ (Life Technologies). Gene expression 
assays were performed on the 7900HT Fast Real-Time PCR System (Life Technologies), 
and gene expression profiles were determined using automated software (SDS 2.3; Life 
Technologies). 
 
2.3.17 Co-immunoprecipitation 
Co-immunopreciptations were preformed to isolate wild type and p.Arg72Gln NFS1 
proteins along with protein interactors from the lysate samples of cells of controls and 
patients, respectively. Experimental procedures were in accordance with the 
manufacturer’s instructions with slight modifications using AminoLink Plus Resin (The 
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Pierce Co-Immunoprecipitation Kit, Thermo Fisher Scientific, Waltham, MA, USA). Co-
immunoprecipitations were performed with anti-NFS1 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) using 10 µg of cell lysate followed by immunoblotting with anti-ISD11 
(Aviva Systems Biology, San Diego, CA, USA).  
 
2.3.18 Antibodies 
Anti-NFS1 (1:200, Santa Cruz Biotechnology); anti-CDH22 (1:200, LifeSpan 
Biosciences, Inc, Seattle, WA, USA); and anti-ISD11 (1:100, Aviva Systems Biology) 
were used. For a positive control, α-tubulin (1:10,000, Sigma-Aldrich, Saint Louis, MO, 
USA) was used. Anti-mouse (1:10,000, Jackson ImmunoResearch Labs, West Grove, 
PA, USA) was used as a secondary antibody. 
 
2.3.19 Statistics 
The Student's t-test was used to determine the significance of the differences between 
case and control. All error bars represent SEM. The data are representative of four 
separate, independent experiments. A P value of less than 0.05 was considered 
significant. 
 
2.4 Results 
2.4.1 Clinical characterization of IMC23D 
The content in this section was compiled and transcribed by me and extensively reviewed 
by Dr. Prasad, Dr. Rupar, Dr. Kronick, Dr. Siu, and Dr. Hegele. 
Three children born to healthy Canadian Old Order Mennonite third cousins have 
been extensively studied for a suspected autosomal recessive inherited mitochondrial 
disease (Figure 2.4.1). All three children were born after an uncomplicated pregnancy at 
full term by spontaneous vaginal delivery. Birth height, weight, and head circumference 
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were in the normal range for the third affected child. There were no dysmorphic features 
in any of the children. Cytogenetic tests did not reveal any structural or numerical 
chromosomal abnormalities (Table 2.4.1). 
 The first child was admitted to London Health Sciences Centre (London, Ontario) 
at seven months of age. She was dehydrated and hypoglycemic after suffering a brief 
episode of pharyngitis. One day prior to admission, she presented with lethargy, anorexia 
and oliguria. She had a generalized seizure followed by metabolic acidosis, respiratory 
decompensation and severe myocardial failure. Her blood lactate, liver enzymes, and 
amylase levels were elevated (Table 2.4.1). She developed persistent hypotension, 
worsening oliguria, and peripheral edema. She died of cardiac failure three days post-
admission.   
 The second child was admitted with respiratory failure and cyanosis at six weeks 
of age. He was normoglycemic but had elevated levels of lactate, aspartate 
aminotransferase (AST) and creatine kinase (CK) (Table 2.4.1).  At 15 weeks, he was 
readmitted with truncal hypotonia, feeding problems, vomiting and acidosis. He 
developed multisystem organ failure including cardiorespiratory failure, which required 
intubation, ventilation and inotropic support. He had focal seizures with cerebral 
infarction documented by computed tomography, renal failure and disseminated 
intravascular coagulation. He was treated with a mitochondrial cofactor therapy 
consisting of riboflavin (50 mg twice daily [BID]), coenzyme Q10 (30 mg BID), 
thiamine (50 mg BID), vitamin C (100 mg BID), vitamin E (400 IU once daily [OD]), 
and vitamin K (2 mg OD), which led to a rapid and substantial clinical and biochemical 
improvement allowing extubation and discharge from hospital. He did continue to have 
mild hypotonia. At seven months, symptoms recurred, he worsened rapidly and died of 
cardiac failure three days post admission, despite intensive treatment. 
A third child was born to the couple and was monitored for the same suspected 
mitochondrial disease. Neonatal neurological examination revealed symmetrical mild 
hypotonia of the upper limbs and to a lesser extent, of the lower limbs. He had symptoms 
in infancy consistent with those observed in his siblings, which included hypotonia, 
lethargy, weight loss and abnormal lactate levels (Table 2.4.1). Similarly, he was treated 
with a mitochondrial cofactor therapy from six months until about 11 years of age. He is 
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generally healthy today. However, his blood lactate, AST and CK levels remain elevated 
(Table 2.4.1). While he has no history of seizures or problems related to his heart, he still 
has some mild developmental and gross motor delay, consisting primarily of a minor 
tremor and overall low energy. The lactic acidemia has persisted albeit fluctuated, for 
approximately eight years but has recently abated. The results of metabolite analyses in 
all three children support the diagnosis of a mitochondrial disease. All three children 
were negative for causative mutations of four known mitochondrial disorders, mainly (1) 
mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS 
[OMIM 540000]); (2) cardiomyopathy with or without skeletal myopathy (OMIM 
590050); (3) myoclonic epilepsy with ragged red fibers (MERF [MIM 545000]) and (4) 
neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP/Leigh syndrome 
[OMIM 551500]) (Table 1). The couple has since conceived a fourth child who does not 
have the mitochondrial disease but has cystinuria (OMIM 220100), for which she is 
currently receiving treatment. 
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Figure 2.4.1 Pedigree of IMC23D family. 
An Old Order Mennonite pedigree showing a union between two healthy third cousins. Three out of four children are 
affected with autosomal recessive infantile mitochondrial complex II/III deficiency. Affected individuals are shown in 
shaded squares (male) and circles (female). Diagonal lines across symbols indicate deceased individuals.  A double line 
between two individuals shows a consanguineous union. Horizontal dashes above symbols indicate individuals who 
underwent DNA analysis. Diamonds indicate unspecified genders. 
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Table 2.4.1 Clinical and biochemical findings of patients with IMC23D.                         
 Affected Individuals (year of birth) 
Clinical Features IV-I (1992) IV-II (1994) IV-III (1999) 
Gestation Full term Full term Full term 
Sex F M M 
Karyotype 46,XX 46,XY 46,XY 
Facial/limb dysmorphology - - - 
Lethargy/anorexia/hypotonia + + + 
Autopsy + + + 
Age at last assessment 7 months, deceased 7 months, deceased 12 years 
Height (cm)   154.9 (50th percentile) 
Weight (kg)   50 (75th-90th percentile) 
Associated diagnoses    
   Respiratory failure + + - 
   Cardiac failure + + - 
   Hemorrhagic pancreatitis + - - 
   Cerebral infarction - +* - 
   Renal failure + + - 
   Disseminated intravascular coagulation + +  
   Seizures 
 
+ +*  
Differential diagnoses    
   Mitochondrial encephalomyopathy, lactic 
acidosis, and stroke-like episodes (MELAS), 
c.3243A>G 
 
- 
 
- 
 
- 
   Myopathy, c.3260A>G - - - 
   Cardiomyopathy, c.3303C>T - - - 
   Myoclonic epilepsy with ragged red fibers 
   (MERF), c.8344A>G 
 
- 
 
- 
 
- 
   Neurogenic muscle weakness, ataxia, 
and retinitis pigmentosa (NARP)/Leigh syndrome, 
c.9883T>G/C 
 
 
 
- 
 
 
- 
 
 
- 
Biochemical findings    
   Hypoglycemia + + - 
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   Increased lactate (normal: 0.5-2.2 mmol/L) + + + (ranged between 4-6 mmol/L) 
   Increased aspartate aminotransferase + + + 
   Increased amylase + -  
   Increased creatine kinase + + + 
   Increased plasma amino acid concentration + (most amino acids) + + (small increase in Alanine) 
   Urine organic acids + N + 
   Amino aciduria - + + 
   Metabolic acidosis 
 
+ + + 
Respiratory chain enzymes    
   Muscle mitochondria (nmol/min/mg)    
     Complex I + III (range: 37-99, mean: 71) 23a 33b, 29a  
     Complex II + III (range: 85-214, mean: 152) 5a 27a, 23b  
     Complex IV (range: 193-354, mean: 264) 156a 181b, 111a  
     Citrate synthase (range: 170-481, mean: 339) 229a 846b, 540a  
   Liver mitochondria (nmol/min/mg)    
     Complex I + III (range: 2-14, mean: 7) 7a 19b  
     Complex II + III (range: 18-70, mean: 45) 133a 13b  
     Complex IV (range: 15-100, mean: 41) 39a 35b  
     Citrate synthase (range: 15-53, mean: 33) 
 
37a 14b  
 
Abbreviations are as follows: N, normal; +, present; -, absent; a, autopsy; b, biopsy; *, at 15 weeks of age. Blank cells indicate 
unavailable information.
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2.4.2 Histopathological evaluation of affected individuals 
No specific findings relevant to the molecular abnormalities were noted from the general 
autopsy materials. However, both cases exhibited hepatic steatosis, a common 
nonspecific finding in various, including metabolic, disorders. Hemorrhagic pancreatitis 
with secondary mesenteric fat necrosis, a nonspecific complication of 'critical illness', 
was present in individual IV-I and there was evidence of acute myocardial ischemic 
injury in individual IV-II, a common agonal finding. No other definite histological 
abnormalities were noted in the myocardium although this does not exclude the presence 
of a significant mitochondrial disorder in the heart. With respect to the brain, no 
significant or specific abnormalities were seen in either case. There was, however, an old 
medial left occipital infarct in individual IV-II whose significance is uncertain. This is an 
uncommon lesion in infants and its cause in this case is unknown; however, the lesion did 
not have the typical superficial location at the crest of the gyri of the infarcts associated 
with MELAS nor did it show any similarities in appearance or location to the areas of 
hemorrhagic vasoproliferation that characterize the central nervous system lesions in 
Leigh's disease. Its localized nature suggests it is not directly related to the primary 
metabolic disorder. 
  Under the light microscope, the majority of the muscle fibers in the biopsy from 
individual IV-II were unusually small and many of them contained small, faintly 
basophilic granules in the section stained with HPS; these granules were magenta in the 
section stained with GMT and exhibited increased enzyme activity in the sections treated 
with NADH and COX histochemistry. The SDH activity was extremely weak in 
comparison to normal controls. Focally prominent subsarcolemmal collections of PAS-
positive glycogen were observed.  The ultrastructural abnormalities are illustrated in 
Figure 2.4.2 and described in the corresponding legend. 
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Figure 2.4.2 Pathological findings in patients with IMC23D.  
These electron micrographs show scattered lipid droplets (black arrows) and abundant 
glycogen (G), which are common nonspecific findings.  Note also the lack of capillaries 
(left) - there should be at least three but only one can be seen (C). The lipid droplets are 
often close to directly or attached to the mitochondria (bottom right). There are a variety 
of mitochondrial abnormalities (white arrows), including concentric cristae (top middle 
and right), a honeycomb arrangement of the cristae (top middle and right, bottom 
middle), vacuolated or ‘blown’ mitochondria reminiscent of artifacts but possibly also 
evidence of ‘metabolic fragility’ (bottom centre), scant cristae (bottom right). Scale bars 
2 μm (left), 1 μm (bottom centre), 500 nm (top centre and right, bottom right). 
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2.4.3 Autozygosity mapping generated 20p11.2-q13.1 as a 
candidate region 
Genome-wide autozygosity mapping generated a locus on chromosome 20p11.2-q13.1, 
approximately 27.7 Mb with a highly significant location score of 1754 (Figure 2.4.3). 
The long segment of homozygosity was unique to the affected individuals, which was 
consistent with an overwhelming likelihood that the causative mutation was harboured 
within (Figure 2.4.3). The autozygous region contained 4,239 SNPs belonging to 453 
genes bordered by SNPs rs4305333:A>C and rs6125184:A>G, which correspond to 
20:18891229 and 20:46576714, respectively (Figure 2.4.3). 
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Figure 2.4.3 Autozygosity mapping of IMC23D family 
A: Genome-wide autozygosity mapping generated a long homozygous segment unique to 
the affected individuals on chromosome 20 with a highly significant location score of 
1754. B: Ideogram depicting the homozygous segment unique to the three affected 
individuals, chromosome 20p11.2-q13.1, spanning 27.7 Mb. 
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2.4.4 Exome sequencing and in silico analyses generate 
candidate variants 
Exome sequencing together with bioinformatic and in silico analyses were applied to 
determine suspected disease-causing variants within the autozygous region. A novel 
homozygous variant was identified within the 27.7 Mb homozygous segment: c.215G>A, 
p.Arg72Gln in NFS1 (Figure 2.4.4). It was not reported in NCBI dbSNP, 1000 Genomes, 
or HGMD. However, we surveyed the NHLBI ESP when it became available and the 
variant was reported to have a MAF of 0.015%. NFS1 p.Arg72Gln is located within the 
aminotransferase class V domain and PMUT, PolyPhen-2 and SIFT predicted the variant 
to be ‘pathogenic’. Interestingly, the wild type residue in NFS1 is conserved across all 
phylogeny including prokaryotes (Figure 2.4.4). It also co-segregated with disease status 
in the family (Figure 2.4.4). All three patients were homozygous for p.Arg72Gln in 
NFS1, whereas the father and the mother were heterozygous (Figure 2.4.4). The 
unaffected sister was homozygous for the wild type allele (Figure 2.4.4). 
During our analysis, we identified a second variant within the autozygous region, 
c.499C>T, p.Arg167Cys in CDH22, a calcium-dependent cell adhesion protein 
predominately expressed in the brain (Saarimaki-Vire et al., 2011; Sugimoto et al., 1996). 
CDH22 p.Arg167Cys was predicted to be pathogenic by in silico analyses, co-segregated 
with disease status in the family, and has a MAF of 0.062% according to NHLBI ESP. 
However, our subsequent functional studies suggest p.Arg167Cys in CDH22 may not 
have a role in disease pathology given its specific tissue expression. 
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Figure 2.4.4 Mapping and exome sequencing of IMC23D family identifies a highly 
conserved and destabilizing missense mutation, p.Arg72Gln in NFS1. 
A: The NFS1 gene consists of 13 coding exons with a non-synonymous nucleotide 
change, c.215T>G in exon one. B: The structure of the NFS1 protein contains one 
domain, aminotransferase class V domain, shown from the N-terminal to C-terminal end. 
The amino acid p.Arg72 is harboured within the aminotransferase class V domain. C: 
Multiple alignments demonstrate high conservation of the amino acid residue p.Arg72 
across a set of species-specific NFS1 homologs. A ClustalW analysis of the NFS1 region 
encompassing the mutation site at residue p.Arg72 (highlighted in red) in aligned 
homologs with multiple divergent species is shown. The residues shaded in blue indicate 
fully conserved residues. D: DNA sequence analysis of p.Arg72Gln from DNA of a 
normal individual (IV-IV, top left electropherogram), a homozygous individual (IV-I, IV-
II, IV-III, bottom left electropherogram), and a p.Arg72Gln heterozygous individual (III-
V, III-VI, right electropherogram). For each electropherogram, amino acid codes are 
shown in the top line with nucleotide sequence and codon numbers below. The position 
of the mutated nucleotide is underlined. 
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2.4.5 Population screens demonstrate rarity of NFS1 p.Arg72Gln 
To determine the MAF of each variant, we began by genotyping 40 otherwise healthy 
controls from the Old Order Mennonite community. We did not identify any carriers for 
p.Arg72Gln in NFS1. However, we further genotyped 3,033 individuals from an 
ethnically diverse cohort and identified one heterozygote (0.016%), which was consistent 
with the reported MAF in the NHLBI ESP. We were unable to identify carriers for 
CDH22 p.Arg167Cys in both 40 Old Order Mennonite controls and 781 individuals from 
an ethnically diverse cohort. However, the NHLBI ESP reported eight heterozygotes in 
6,495 individuals, which suggests the likelihood of a homozygous genotype for 
p.Arg72Gln in NFS1 is 16 times rarer than for p.Arg167Cys in CDH22. Based on the few 
reported cases of IMC23D, suggesting that p.Arg72Gln in NFS1 is an extremely rare and 
private mutation within this founder population. 
 
2.4.6 Deficiency in NFS1 expression in patients with IMC23D 
We performed immnublotting to determine whether the variants in NFS1 and CDH22 
disrupt protein expression. We observed a 73% reduction in NFS1 protein levels (Figure 
2.4.6). We could not detect CDH22 protein expression by immunoblotting in wild type or 
patient cells. Next, we performed qRT-PCR using cDNA synthesized from patient 
fibroblast RNA, to test gene expression. We observed a 65% reduction in NFS1 transcript 
levels relative to a healthy control (Figure 2.4.6). As expected, CDH22 transcript levels 
were not detected in both patient and control samples, which is likely due to tissue 
specificity of CDH22, in that it is predominantly expressed in the brain (Saarimaki-Vire 
et al., 2011; Sugimoto et al., 1996).  
Using enzymology assays on muscle and liver tissue, we observed deficiency in 
mitochondrial respiratory chain complex II and III, which is consistent with decreased 
NFS1 protein levels and likely, a disruption in Fe-S cluster assembly (Table 2.4.1). 
Lastly, when wild type and patient fibroblast cells were subjected to co-
immunoprecipitation with an antibody against NFS1, ISD11 was co-precipitated with 
NFS1 in wild type but not in patient cells (Figure 2.4.6). This suggests that the NFS1-
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ISD11 complex is disrupted in patient cells. Interestingly, mutations in LYRM4, which 
encodes ISD11, also result in a compromised NFS1-ISD11 complex and leads to a 
clinical presentation similar to IMC23D (Lim et al., 2013). 
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Figure 2.4.6 Decreased NFS1 Protein and Transcript Levels in Patients with IMC23D. 
Immunoblotting (A) and qPCR (B) showing reduced NFS1cellular expression in fibroblast cells of patients affected with IMC23D. 
Bar graphs indicate means ± standard deviations from two sets of experiments, showing the relative NFS1 expression in affected 
individuals normalized to a healthy control quantified by densitometry. The autoradiographs provide a visual representation of NFS1 
protein level. The upper blot shows decreased protein expression in NFS1 R72Q relative to NFS1 wild type (WT). The lower blot 
shows the constitutive expression of α-tubulin in both experiments. C: NFS1-ISD11 interaction is disrupted in patient cells. ISD11 
was co-precipitated with NFS1 in wild type (NFS1 WT) but not patient cells (NFS1 R72Q). *represents P-value <0.05. 
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2.4.7 Characterization of IMC23D summary: NFS1 and CDH22 
Table 2.4.7 summarizes the tests performed on variants in NFS1 and CDH22 to determine which gene is causal of IMC23D. 
Table 2.4.7 Comparison of NFS1 and CDH22 as the cause of IMC23D 
Test NFS1 CDH22 Interpretation 
Identifying candidate genes in autozygous region    
Chromosome 20 autozygous 
region (unique to affected 
individuals only) 
Present Present Favours both  
Type of mutation Missense Missense Favours both, coding region 
cDNA location c.215G>A c.499C>T  
Amino acid change p.Arg72Gln (basic  polar) p.Arg167Cys (basic  polar) Favours both; amino acid properties changed 
CLC BIO verification Present Present Favours both; consistent with AR model 
GATK verification 
 
Present Present Favours both; consistent with AR model 
Bioinformatics approach to determine pathogenicity of mutations 
Location of mutation in 
protein structure 
Aminotransferase class 5 domain Low complexity region Favours NFS1 as it is harboured in a critical region 
Polyphen-2 Probably damaging Probably damaging Favours both 
SIFT Damaging Damaging Favours both 
PMUT Pathogenic Pathogenic Favours both 
Reported in HGMD Not reported Not reported Favours both; rare, novel disorder likely the result of a new, 
private mutation. Consistent with our disease model 
Species conservation Conserved in eukaryotic and 
prokaryotic domains 
 
Conserved primarily in 
vertebrate phylum 
Favours both, however strengthens the pathogenicity state of 
NFS1 as it is conserved throughout more lineages 
Population screening to determine minor allelic frequency (MAF) 
Co-segregated within family Affected are homozygous; 
unaffected are heterozygotes or wild 
type homozygous 
Affected are homozygous; 
unaffected are heterozygotes or 
wild type homozygous 
Favours both; mode of inheritance and AZ mapping is 
consistent 
Allele frequency 1/3,033 (0.016%) 8/6,495 (0.062%) Favours both. Strengthens support for NFS1 as it is a novel, 
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rare and previously uncharacterized disorder that is likely to 
be the result of a rare mutation 
 
Measuring functional dysfunction of candidate genes    
Tissue expression Ubiquitous Pituitary gland, brain, colon, 
lymphatic tissue. Controversial; 
likely expressed on in brain 
Favours NFS1 as clinical and pathological reports are 
consistent with many tissues being affected. Does not support 
CDH22 as clinical presentation and physical examination do 
not suggest brain, colorectal or lymphatic problems. 
 
Protein localization Mitochondria and some in the 
nucleus and cytoplasm 
Cell membrane  Favours NFS1 as pathological and clinical tests are highly 
suggestive of mitochondrial damage. Downstream damage is 
thought to be the result of mitochondrial deficiency and by-
product accumulation 
 
Protein quantification  
 
Decreased expression in affected No change was detected Favours NFS1 as clinical data are indicative of mitochondrial 
deficiency therefore, we would expect candidate protein 
levels to be decreased and this decrease is likely responsible 
for the mitochondrial dysfunction. 
 
It is also important to mention that skin fibroblasts were used 
for this experiment, which do not express CDH22. 
 
Transcript quantification Decreased NFS1 transcript levels in 
affected individuals versus controls 
No expression. Skin fibroblast 
cells were used, this gene is 
predominantly expressed in 
brain tissue 
Favours NFS1 as we see decreased transcript levels in 
patients, which is consistent with western analysis. Also, it is 
likely that CDH22 is expressed predominantly in brain tissue. 
Clinical data are in support of ubiquitous NFS1 deficiency as 
there are dysfunctional mitochondria in muscle and liver. 
 
It is also important to mention that skin fibroblasts were used 
for this experiment, which may not express CDH22. 
 
Enzymology assays - Dysfunction in electron transport 
chain where NFS1 is located 
 
- huNFS1 RNAi experiment 
enzymology assays are in parallel 
with ours (Complex II shows 
No link to brain, colon, or 
lymphatic tissue 
Favours NFS1; enzyme deficiency is primarily where NFS1 is 
located/expressed 
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decreased function; citrate synthase 
shows minimal change) 
 
Modelling dysfunction - Morphological dysfunction in 
mitochondria of HeLa cells, 
recapitulating phenotype 
 
- Protein expression observed 
similar to protein expression we 
observed 
 
Morphological dysfunction 
predominantly in adult brain 
tissue (in vivo assay in rats) 
Favours NFS1; NFS1 was specifically knocked down and 
mitochondrial phenotype is similar to the mitochondrial 
phenotype seen in patients. These data are collected from 
other experiments published elsewhere. 
Patient clinical presentation    
Clinical data Directly correlates with 
mitochondrial dysfunction 
 
Does not directly correlate with 
brain, colon, or lymphatic tissue 
Favours NFS1 as it is targeted to mitochondria 
Cause of death: cardiac failure 
in two of three patients 
  
Highest proportion of mitochondria 
(NFS1 localized) in cardiomyocytes 
 Indirectly favours NFS1 
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2.5 Discussion 
Mutations disrupting genes encoding Fe-S proteins are likely to be physiologically 
harmful due to their ubiquitous expression, and unique and diverse chemical properties, 
which have been conserved in nearly all organisms, including prokaryotes (Huber et al., 
2003; Sheftell et al., 2010). In this present study, we describe a novel autosomal recessive 
inherited disease observed within the Old Order Mennonites of Ontario likely caused by 
p.Arg72Gln in NFS1, a cysteine desulfurase that plays a pivotal role in Fe-S cluster 
biogenesis and assembly (Bridwell-Rabb et al., 2011; Schmucker et al., 2011). 
Autozygosity mapping identified a long stretch of identity by descent haplotypes, 
which mapped to 20p11.2-q13.1, spanning 27.7 Mb. Whole exome sequencing, which 
generates a list of variants harbored within coding regions of the genome, together with 
bioinformatic and in silico analyses identified two novel homozygous variants within the 
candidate locus: p.Arg72Gln in NFS1 and p.Arg167Cys in CDH22. We applied multiple 
in silico analyses to predict the pathogenicity of the candidate variants. Based on the 
markedly higher MAF reported from NHLBI ESP and the specific brain tissue expression 
of CDH22, it is unlikely that CDH22 p.Arg167Cys has a role in the development of 
infantile mitochondrial complex II/III deficiency (IMC23D). In contrast, NFS1 p.Arg72 
is highly conserved, even in prokaryotes, which is consistent with reports describing 
cysteine desulfurase as a primitive protein involved in evolutionarily ancient pathways 
(Huber et al., 2003). Population screens demonstrate p.Arg72Gln in NFS1 to likely be a 
private mutation given its exceptionally low MAF of 0.016% and its disproportionate 
prevalence in the founder population. Protein and transcript expression assays show a 
reducing in NFS1 levels, which is likely causative of respiratory chain complex II and III 
deficiency, in the affected individuals. 
 The role of NFS1 in Fe-S cluster assembly and iron homeostasis is beginning to 
be understood. Initially, NFS1 was reported to be predominantly expressed in the 
mitochondria while its less abundant isoform, which has reduced activity, was localized 
to the cytosol (Muhlenhoff et al., 2004). However, overexpression of the cytosolic 
isoform (c-Nfs1) in yeast demonstrated c-Nfs1 is an active cysteine desulfurase that 
undergoes efficient dimerization equivalent to its mitochondrial counterpart (Tong and 
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Rouault, 2006). Another study in yeast showed NFS1 is also localized to the nucleus by 
detecting NFS1 subpopulations first targeted to the mitochondria, then transferred to the 
cytosol and finally targeted to the nucleus (Naamati et al., 2009). The interaction network 
of proteins involved in Fe-S cluster assembly is becoming clearer in both yeast and 
mammalian cells. In particular, NFS1, ISCU, ISD11, and FXN form the Fe-S cluster core 
complex (Bridwell-Rabb et al., 2011; Prischi et al., 2010; Rouault, 2012; Schmucker et 
al., 2011; Tsai and Barondeau, 2010). Fe-S cluster formation begins with NFS1 forming a 
homodimer to which monomers of a scaffold protein ISCU, bind near the top and the 
bottom (Shi et al., 2010). A co-factor, pyridoxal 5’ phosphate, helps NFS1 provide 
inorganic sulfur from cysteine residues, which then bind to cysteine ligands supplied by 
ISCU, that further covalently bind to iron (Bandyopadhyay et al., 2008; Raulfs et al., 
2008). The core complex then recruits NFS1 binding protein, ISD11 (Adam et al., 2006; 
Wiedemann et al., 2006) and finally FXN (Prischi et al., 2010; Tsai and Barondeau, 
2010). Next, the Fe-S cluster is transferred to recipient apo-proteins via binding of ISCU 
to chaperone proteins (Craig and Marszalek, 2002; Rouault, 2012). In short, it is clear 
that Fe-S cluster assembly is a highly conserved multistep process requiring cysteine 
desulfurases, scaffold proteins, chaperones and iron donors to ultimately maintain iron 
homeostasis, execute catalysis and gene regulation (Lill et al., 2012; Rouault, 2012). 
Cooperatively, Fe-S clusters perform numerous essential cellular functions 
including electron transfer in oxidative phosphorylation of the respiratory chain, 
enzymatic catalysis of dehydratases, stabilization of protein structure, and regulation of 
gene expression, which are essential processes in human biology (Beinert, 2000; Bouton 
and Drapier, 2003). As a result, mutations in genes encoding Fe-S proteins are expected 
to cause human disease. For example, in Friedreich’s ataxia (FRDA) mutations within 
FXN lead to abnormal central and peripheral nervous system activity and may lead to 
heart failure (Campuzano et al., 1996; Koeppen, 2011). In contrast, mutations within 
ISCU cause ISCU myopathy, which is characterized by lactic acidosis and muscle fatigue 
(Kollberg et al., 2009). Although IMC23D shares some of its clinical and pathological 
features with FRDA and ISCU myopathy, it is clinically and genetically distinct. Until 
now three Fe-S proteins had not been linked to a human disease, namely NFS1, NBP35, 
and IOP1 (Sheftell et al., 2010). There are arguably two reasons for the lack of 
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observations: 1) such disorders have not yet been ascertained; or 2) a deficiency in these 
vital and well-conserved gene products is incompatible with life.  
Several studies have examined the cellular localization of NFS1 (Naamati et al., 
2009), its role in Fe-S cluster biogenesis and assembly (Tong and Rouault, 2006), as well 
as its role in other pathways such as donating sulfur to MOCS3 in the molybdenum 
cofactor biosynthesis pathway (Marelja et al., 2008). However, two studies examined the 
physiological consequence of cellular NFS1 depletion via small interfering RNA 
(siRNA)-mediated gene silencing approaches and are of particular interest to us 
(Biederbick et al., 2006; Fosset et al., 2006). In one study, depletion of mouse NFS1 (m-
Nfs1) in murine fibroblasts led to reduced activity of mitochondrial respiratory chain 
complex I, II, and aconitase, a citric acid cycle protein (Fosset et al., 2006). Interestingly, 
there was no change in mitochondrial malate dehydrogenase activity or cytosolic lactate 
dehydrogenase, neither of which contains Fe-S clusters (Fosset et al., 2006). The second 
study showed severe growth retardation and morphological changes in mitochondria 
following NFS1 gene silencing in HeLa cells (Biederbick et al., 2006). Similarly, the 
authors showed decreased activity in both mitochondrial and cytosolic Fe-S proteins 
(Biederbick et al., 2006). Interestingly, introduction of m-Nfs1 repaired growth and 
restored Fe-S protein activity (Biederbick et al., 2006). These findings further 
demonstrate the importance of proper Fe-S cluster assembly in mammalian cells and are 
consistent with an NFS1 dependent human deficiency state. These studies also shed light 
on novel gene therapy approaches using exogenous forms of Fe-S proteins to reverse the 
physiological consequence of NFS1 depletion. 
It is important to mention that although p.Arg167Cys in CDH22 co-segregated 
with disease status in the family and has a low MAF, there are currently no established 
mechanisms linking CDH22 to mitochondrial dysfunction. Although we have observed 
cellular depletion of NFS1 consistent with impaired respiratory chain enzyme activity, we 
ultimately cannot exclude the possible role of CDH22 in IMC23D. However, it is more 
likely that p.Arg167Cys in CDH22 is a rare variant with clinically insignificant effects. 
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2.6 Conclusion 
We report a novel variant within NFS1 as causative of a rare mitochondrial disease 
characterized by chronic lactic acidemia, hypotonia, respiratory chain complex II and III 
deficiency, multisystem failure, and abnormal mitochondria. Our detailed clinical 
description, bioinformatic and in silico analyses, population, and functional validation 
studies have described in part, the etiology of a novel disease. NFS1 encodes a cysteine 
desulfurase, which is an Fe-S protein that is highly involved in Fe-S cluster biogenesis, 
iron maintenance, and DNA repair. Notably, p.Arg72Gln in human mitochondrial NFS1 
is likely to disrupt a biochemical pathway owing to its high conservation within 
essentially all living organisms as well as its role in forming the Fe-S cluster core 
complex. Our findings highlight the physiological significance of proper Fe-S cluster 
biogenesis and assembly and their role in human health particularly, Fe-S cluster-related 
diseases. 
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Chapter 3 - Novel phenotype, known gene: mutations in 
heparan sulfate synthesis enzyme, EXT2 leads to seizure 
and developmental disorder, no exostoses. 
3 Study rationale 
Similar to the disorder described in Chapter 2, seizures-scoliosis-macrocephaly (SSM) 
syndrome affects an Old Order Mennonite family. The family agreed to participate in 
genetic testing, and SSM syndrome became another project funded by the FORGE 
Canada Consortium. 
During clinical visits, affected individuals were extensively examined for any 
known biochemical and genetic abnormalities with no promising diagnosis obtained. 
Nerve, muscle, and skin biopsies have been performed on two of the affected children 
with findings weakly suggestive of a mitochondrial disorder. Initially, some of the 
features observed in the affected children were consistent with FG syndrome (Opitz–
Kaveggia syndrome, OMIM 305450), which is an X-linked recessive disorder and is 
inconsistent with the most probable mode of inheritance in the pedigree. Lastly, the 
family visited Dr. Holmes Morton at the Clinic for Special Children in Pennsylvania, as 
he is especially knowledgeable in the genetic disorders of Amish and Mennonite 
communities. However, he was unable to suggest a diagnosis. 
Chapter 3 was published as an independent study: “Old gene, new phenotype: 
mutations in heparan sulfate synthesis enzyme, EXT2 leads to seizure and developmental 
disorder, no exostoses” in Journal of Medical Genetics in 2015 (Farhan et al., 2015) 
 
3.1 Overview 
Heparan sulfate proteoglycans are vital components of the extracellular matrix and are 
essential for cellular homeostasis. Many genes are involved in modulating heparan sulfate 
synthesis and when these genes are mutated, they can give rise to early-onset 
developmental disorders affecting multiple body systems. Herein, we describe a 
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consanguineous family of 4 sibs with a novel disorder, which we designate as seizures-
scoliosis-macrocephaly (SSM) syndrome, characterized by seizures, intellectual 
disability, hypotonia, scoliosis, macrocephaly, hypertelorism, and renal dysfunction. Our 
application of autozygosity mapping and exome sequencing allowed us to identify 
variants in the patients. To confirm the autosomal recessive mode of inheritance, all 
available family members were genotyped. We also studied the effect of these variants on 
protein expression and function in patient cells and also using an in vitro system. We 
identified two homozygous variants, p.Met87Arg and p.Arg95Cys in exostosin 2, EXT2, 
a ubiquitously expressed gene that encodes a glycosyltransferase, which is required for 
heparan sulfate biosynthesis. In patient cells, we observed diminished EXT2 expression 
and function. We also performed an in vitro assay to determine which variant has a larger 
effect on protein expression and observed reduced EXT2 expression in constructs 
expressing either one of the variants but a greater reduction when both residues were 
mutated. In short, we have identified the genetic basis of a novel recessive disorder, 
seizures-scoliosis-macrocephaly (SSM) syndrome. Our results have implicated a well-
characterized gene in a new developmental disorder and have further illustrated the 
spectrum of phenotypes that can arise due to errors in glycosylation. 
 
3.2 Introduction 
Heparan sulfate proteoglycans are ubiquitously expressed at nearly all cell surfaces as 
well as extracellular matrices, and modulate the activity of many growth and 
developmental factors such as FGF, BMP, TGF-β, Shh, and Wnt (Astudillo and Larrain, 
2014; Kreuger et al., 2006; Perrimon and Bernfield, 2000; Shimokawa et al., 2011; 
Venero Galanternik et al., 2015). Heparan sulfate proteoglycans are involved in cell 
migration, neuron elongation, synapse formation, and regulation of intracellular signaling 
pathways (Bandtlow and Zimmermann, 2000; Bishop et al., 2007). The heparan sulfate 
backbone is formed by the exostosins, EXT1 and EXT2, which are ubiquitous 
glycosyltransferases involved in a multistep process in the Golgi apparatus (Ahn et al., 
1995; McCormick et al., 2000; Stickens et al., 1996). Previous studies have demonstrated 
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that heparan sulfate synthesis enzymes EXT1 and EXT2, form a stable hetero-oligomeric 
complex in vivo and together have significantly higher glycosyltransferase activity than 
either enzyme alone (McCormick et al., 2000). These findings suggest that mutations in 
either exostosin can disrupt heparan sulfate biosynthesis in addition to halting growth 
factor signaling cascades (McCormick et al., 2000; Venero Galanternik et al., 2015). 
We have recently identified a novel, rare disease designated as seizures-scoliosis-
macrocephaly (SSM) syndrome, which was first observed in four Old Order Mennonite 
sibs. SSM syndrome is characterized by seizures, intellectual disability, hypotonia, 
scoliosis, macrocephaly, hypertelorism, and renal dysfunction. To the best of our 
knowledge, this is the first report describing SSM syndrome, which we believe is a 
heparan sulfate-related disease. Based on the small founder population and endogamy 
observed in the Mennonite community, leading to low genetic variability, we used 
homozygosity genetic mapping to identify homozygous regions within the genomes of 
SSM syndrome patients. We then used exome sequencing and identified two different 
homozygous, rare missense variants in EXT2. We confirmed disease mode of inheritance 
through genetic studies and performed several functional assays to demonstrate loss of 
EXT2 as the cause of SSM syndrome. 
 
3.3 Materials and methods 
3.3.1 Ethics 
As described in Chapter 2, subsection 2.3.1, ethics approval was obtained from the 
parents on behalf of all seven members of the family. 
 
3.3.2 Patients and biological materials 
Four children of a healthy Old Order Mennonite couple were clinically ascertained 
because they were experiencing seizures and also had macrocephaly. Blood and tissue 
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(skin-derived fibroblast cells) samples were collected from all four affected children, an 
unaffected sibling, and the two parents. 
 
3.3.3 DNA isolation 
DNA was isolated from all seven family members as described in Chapter 2, subsection 
2.3.3. 
 
3.3.4 Genotyping 
Genomic DNA (gDNA) extracted from all family members was genotyped for single 
nucleotide polymorphisms (SNPs) using Affymetrix® protocols as described in Chapter 
2, subsection 2.3.6. 
 
3.3.5 Autozygosity mapping 
GeneSpring GT v2.0 software was used to identify regions of homozygosity that are 
identical by descent in family members as described in Chapter 2, subsection 2.3.7. 
 
3.3.6 Exome sequencing 
Exome sequencing was performed using gDNA from two affected individuals (II-1 and 
II-4) using the protocols described in Chapter 2, subsection 2.3.8. 
 
3.3.7 Sequence alignment 
Sequence alignment was performed using the same procedures described in Chapter 2, 
subsection 2.3.9. 
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3.3.8 Variant calling and annotation 
Variant calling and annotation were performed using the same procedures described in 
Chapter 2, subsection 2.3.10. 
 
3.3.9 Variant discovery 
3.3.9.1 Prioritization of homozygous, non-synonymous, and rare variants 
We investigated whether there were any non-synonymous, rare variants within the 
homozygous regions on chromosomes 1, 7, 11, and 13. We also applied an unbiased, 
exome-wide approach to identify any homozygous, non-synonymous, and rare variants as 
described in Chapter 2, subsection 2.3.11.1. We scanned for variants in genes known to 
cause seizures and intellectual disability based on literature and OMIM, as well as all 
genes. 
 
3.3.9.2 In silico analyses 
To determine the predicted biological effect of non-synonymous variants on protein 
function, all non-synonymous variants identified as candidate variants (EXT2 
p.Met87Arg and p.Arg95Cys) were assessed using the same tools described in Chapter 2, 
subsection 2.3.11.2. 
 
3.3.10 Variant validation 
To determine whether p.Met87Arg and p.Arg95Cys in EXT2 segregated with disease 
status in the pedigree, we genotyped family members using standard Sanger sequencing 
methods as described in Chapter 2, subsection 2.3.12.1 and 2.3.12.2. 
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3.3.10.1 PCR 
Forward and reverse primers specific to amplify g.12424T>G and g.12447C>T in EXT2 
were: 5’- CTCTTCTCCATTGTCCTCC-3’ and 5’-TCTGAGATGGCCATGAGC-3’, 
respectively. The PCR conditions were as follows: initial denaturation at 95˚C for 5 
minutes; 30 cycles of denaturation at 95˚C for 30 seconds; annealing at 58˚C for 30 
seconds; extension 72˚C for 30 seconds and a final extension at 72˚C for 7 minutes. 
 
3.3.10.2 Imaging, purifying, and sequencing of PCR products 
Imaging, purifying, and sequencing of PCR products were performed using the same 
procedures described in Chapter 2, subsection 2.3.12.2. 
 
3.3.11 Population screening 
3.3.11.1 Genotyping of local population 
39 healthy Old Order Mennonite controls and 311 Caucasian controls were also 
genotyped by standard Sanger sequencing for EXT2 g.12424T>G and g.12447C>T, as 
aforementioned. 
 
3.3.11.2 Identifying overall MAF of EXT2 variants 
We also used 1000 Genomes (Genomes Project et al., 2012), Exome Variant Server 
available through the Exome Sequencing Project (Fu et al., 2013), and Exome 
Aggregation Consortium (ExAC) genome browser (Lek et al., 2015) to identify the 
carrier frequency of the variants, as these resources became available. 
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3.3.12 Cell culture 
3.3.12.1 Patient cells 
Skin fibroblasts from patients and healthy controls were cultured as described in Chapter 
2, subsection 2.3.14. 
 
3.3.12.2 Mutagenesis 
EXT2 variants: (1) p.Arg95Cys; (2); p.Met87Arg; and (3) p.Met87Arg and p.Arg95Cys, 
were introduced via site-directed mutagenesis using the Stratagene QuikChange II, 
QuikChange IIXLor Quik-Change Lightning kit (Agilent Technologies, Santa Clara, CA, 
USA) according to the manufacturer’s instructions. Wild type and variant constructs were 
transformed into E.coli DH5α cells (Subcloning efficiency, DH5α, Invitrogen by Life 
Technologies, Carlsbad, CA, USA) according to manufacturer’s instructions. Miniprep 
DNA isolation was completed to isolate EXT2 wild type and variant clones (1) 
p.Arg95Cys; (2); p.Met87Arg; and (3) p.Met87Arg and p.Arg95Cys, from bacterial 
cultures using QIAprep Spin Miniprep Kit (QIAGEN) in accordance with manufacturer’s 
instructions. All plasmid sequences were verified by standard Sanger sequencing as 
previously described. All primers were purchased from Sigma-Aldrich (Saint Louis, MO, 
USA). 
 
3.3.12.3 Transfection 
COS-7 and HEK293 cells were also cultured and cells were seeded at a density of 7x105 
per 60 mm dish 24 hours before transfection. One microgram of (1) wild type; or variant 
EXT2 plasmid DNA containing: (2) p.Arg95Cys; (3); p.Met87Arg; or (4) p.Met87Arg 
and p.Arg95Cys, was transfected using Effectene Transfection Reagent and Enhancer 
(Qiagen, Venlo, Limburg, Netherlands) in accordance with the manufacturer’s 
instructions. 
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3.3.13 Protein isolation 
Transfections: 48 hours post-transfections, cells were washed twice with 1xPBS and 
lysed in sodium dodecyl sulfate (SDS) buffer (50 mM Tris-CI, pH 6.8, 2% SDS, 10% 
glycerol) that had been preheated at 95˚C for 5 mins. Samples were then incubated at 
95˚C for 5 mins. Protein concentrations of whole cell lysates were determined using the 
DC Protein Assay kit (Bio-Rad Laboratories Inc, Hercules, CA, United States of 
America). The same protocol was used for isolating protein from patient fibroblast cells. 
 
3.3.14 Immunoblotting 
Protein expression was measured using immunoblotting as described in Chapter 2, 
subsection 2.3.15. 
 
3.3.15 Reverse transcriptase (RT)-PCR 
RNA was isolated from patient fibroblast cells using the RNeasy Mini Kit according to 
the manufacturer’s instructions (Qiagen, Valencia, CA, USA). RNA quality was 
measured using the Agilent 2100 Bioanalyzer RNA 6000 Nano. RNA was reverse 
transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit (Life 
Technologies, Carlsbad, CA, USA) to subsequently perform RT-PCR. 
 
3.3.16 Antibodies 
Anti-EXT2 (1:500, Abnova, Taipei City, Taiwan); anti-DDK (tagged to exogenous 
EXT2) (1:1000, Rockville, MD, USA); and anti-NDST1 (1:200, Santa Cruz 
Biotechnology, CA, USA) were used. For a positive control, α-tubulin (1:10,000, Sigma-
Aldrich, Saint Louis, Missouri) was used. Anti-mouse (1:10,000, Jackson 
ImmunoResearch Laboratories, Inc) was used as a secondary antibody. 
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3.3.17 Statistics 
Statistics were performed as described in Chapter 2, subsection 2.3.19. 
 
3.4 Results 
3.4.1 Clinical description of patients with SSM syndrome 
The content in this section was compiled and transcribed by me and extensively reviewed 
by Dr. Siu, Dr. Rupar, and Dr. Hegele. 
To the best of our knowledge, SSM syndrome is a novel developmental disorder. 
Four children (three males, one female) born to consanguineous (third cousin) Old Order 
Mennonite parents are affected (Figure 3.4.1). Features seen in all affected individuals 
include: moderate intellectual disability, seizure disorder with onset between two and five 
years of age, hypotonia, scoliosis, macrocephaly, coarse facies, bilateral cryptorchidism 
in males, long hypoplastic philtrum, and hypertelorism. For a full clinical description of 
patients with SSM syndrome, please refer to Table 3.4.1. Extensive metabolic workup did 
not yield any diagnostic possibilities (Table 3.4.1). 
Case II-1, now age 30, was identified as a floppy and weak child with a 
macrocephaly and delays in motor milestones. He did not sit until he was one year old, 
and began to walk at the age of three years. His motor skills showed regression as he 
entered his teenage years. Cardiac assessment disclosed a ventricular septal defect with a 
possible subaortic stenosis. While chronic constipation was a feature in early life, 
diarrhea has been a feature lately. Significant gastroesophageal reflux and associated 
ulceration of the esophagus were documented. At age three years, he developed seizures 
that were generalized tonic clonic in nature, lasting two to three minutes. In addition, he 
has significant scoliosis and kyphosis for which he wears a brace and his gait is stiff with 
out-toeing on a broad base. 
Similarly, case II-3, currently 25 years old, presented with general hypotonia at 
birth, exhibited dysmorphic features, delayed motor milestones, and developed seizures 
at the age of three years. He too suffers from dysfunctional gastrointestinal motility, as he 
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tends to vomit easily and has documented gastroesophageal reflux. At age 18 months, he 
developed hemolytic uremic syndrome and required peritoneal dialysis. Case II-4 had a 
very similar phenotype to her brothers' however, she had recurrent episodes of prolonged 
status epilepticus. During one episode at the age of five, she had a four-hour long seizure 
and sustained significant brain injury. She was rendered hemiplegic on the right side, and 
has been wheelchair bound since that event. She experiences breakthrough seizures 
frequently, which appear to be mostly complex partial and are self-limited events of short 
duration. 
The pregnancy with case II-5 was complicated by polyhydramnios. At four days 
of age, he was diagnosed with intestinal volvulus, which required surgical intervention. 
His early motor milestones were apparently delayed and at three years of age, he began 
having generalized seizures lasting up to two hours and occurring every six weeks. At 17 
years of age, after a mild respiratory illness, he developed status epilepticus and 
subsequently died. 
In terms of development, all four affected sibs were capable of independent 
ambulation although case II-4 lost her ability to walk after an episode of prolonged status 
epilepticus. They have minimal expressive speech, but are able to comprehend simple 
verbal commands. From a behavioral perspective, they appear shy, and do not sustain eye 
contact. The epileptic seizures though lacking a distinctive semiology and appear to be 
generalized except in subject II-4 where seizures are associated with non-specific slowing 
of background rhythms and focal spikes in the temporal region on EEG. Apart from the 
(kypho)scoliosis in all 4 affected sibs and possible segmentation defects in the upper 
spine in one individual, there are no obvious skeletal abnormalities, and specifically no 
evidence of exostoses. 
 
 
  
86 
 
 
Figure 3.4.1 Pedigree with four children affected with SSM syndrome. 
Squares depict males; circles depict females; affected individuals are shaded; diagonal 
lines across symbols indicate deceased individuals; a double line between two individuals 
represents consanguineous union.
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Table 3.4.1 Clinical description of patients with SSM syndrome. 
                                                               Affected individuals (year of birth) 
Clinical Features II-1 (1985) II-3 (1990) II-4 (1992) II-5 (1994, deceased) 
Gestation Full term Full term 39 weeks Full term 
Polyhydramnios +   + 
Delivery complications Breech; caesarean 
section 
SVD SVD; vertex Forceps 
Gestational hypertension +  + + 
Sex M M F M 
Karyotype 46,XY 46,XY 46,XX 46,XY 
Birth length (cm)   66  
Birth weight (g) 3,221 (70th 
percentile) 
3,583 (78th percentile) 3,583 (78th percentile) 4,037 (88th percentile) 
Age at last assessment 
(years) 
19 14 11 10 
Head circumference (cm) 59 (>98th percentile) 57 (90th percentile)  58 (98th percentile) 
Height (cm) 179 (75th percentile) 157 (10th percentile)  138 (50th percentile) 
Weight (kg) 65 (50th percentile) 42 (10-25th percentile)  32 (50-75th percentile) 
Hand length (cm) 19.7 (>98th 
percentile) 
17 (25th percentile) 15.8 (25th percentile)  
Middle finger length (cm) 8.5 (>97th percentile) 7.2 (25th percentile) 6.8 (25th percentile)  
Ear length (cm) 6.5 (75th percentile) 6.5 (75th percentile) 5.6 (25th percentile)  
Inner canthal distance (cm) 3.8 (>98th percentile) 3.2 (50-75th percentile)   
Outer canthal distance (cm) 10.7 (>97th 
percentile) 
8 (3rd percentile)   
Associated diagnoses     
Developmental delay + + + + 
Sleep apnea    + 
Tremor    Coarse 
Seizures, onset (years) +, 2.5 +, 4-5 +, 2-3 +, 5 
Brain hemorrhage  + +  
Circulation  Cold extremities Cold extremities  
Strabismus   +, left eye +, exotropia 
Hypotonia + + + + 
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Ventricular septal defect +  + - 
Macrocephaly + + + + 
Cryptorchidism + +  + 
Precocious puberty    + 
Scoliosis + + +  
Hiatus hernia +    
Bowel dysfunction +  + + 
Hypertension +    
Hematuria + +, Kidney failure   
Proteinuria + +   
Wide-based gait +  Loss of ambulation  
Overlapping toes +  +  
Hepatic dysfunction    + 
Bowel malrotation  +  + 
Volvulus    + 
Encopresis +    
Morning nausea + + + + 
Regression +   + 
Dysphagia +  Tube-fed  
Low bone density +  + + 
Sensitive skin + + + + 
Hearing problems - - - - 
Metabolic evaluations     
Mitochondrial respiratory 
chain 
N N A N 
NADH: cytochrome C 
reductase (complexes I +III) 
(normal: 22-139 
nmol/min/mg) 
93  26 77 
Succinate: cytochrome C 
reductase (complexes II + 
III) (normal: 70-268 
mmol/min/mg) 
210  38 105 
Cytochrome oxidase 
(complex IV) (normal: 173-
443 nmol/min/mg) 
457  115 193 
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Mitochondrial DNA mutations    
Mitochondrial 
encephalomyopathy, lactic 
acidosis, and stroke-like 
episodes (MELAS), 
c.3243A>G 
N  N  
Cardiomyopathy, 
c.3303C>T 
  N  
Neurogenic muscle 
weakness, ataxia, 
and retinitis pigmentosa 
(NARP)/Leigh syndrome, 
c.9883T>G/C 
  N  
mtDNA deletion N    
Urine oligosaccharides   N N 
Urine organic acids  A N N 
Urine amino acids N N N N 
Urine mucopolysaccharides 
screening 
N N N N 
Plasma amino acids  N N N 
Plasma carnitine free  N N N 
Plasma carnitine acyl N N N N 
Lactate N N N N 
Pyruvate N N N N 
Lactate/Pyruvate N N N N 
Medium chain acyl-CoA 
dehydrogenase deficiency 
screening 
N    
Carbohydrate-deficient 
glycoprotein syndrome 
screening  
N    
Niemann-Pick disease, Type A and Type B   
Sphingomyelinase (normal: 
16-54 nmol/hr/ mg) 
66    
Diagnostic imaging     
AP Pelvis/bilateral femurs, N    
  
90 
tibia, and fibula 
AP and lateral thoracic ad 
lumbosacral spine 
N    
Lateral cervical spine Failure of 
segmentation of C2-3 
and possibly C1-2 
   
AP and lateral skull N    
AP bilateral humerus/radius, 
ulna, and 
   hands 
N    
   Bilateral AP feet N    
Abbreviations are as follows: A, abnormal; N, normal; +, present; -, absent; AP, anterior posterior. Empty cells indicate unavailable information. Mitochondrial 
DNA mutation testing was examined on muscle tissue. 
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3.4.2 Genome-wide autozygosity mapping reveals highly 
significant homozygous regions 
Considering the consanguineous union between the parents, we modelled an autosomal 
recessive mode of inheritance and first performed homozygosity genetic mapping, which 
isolated four significant homozygous segments on chromosomes 1, 7, 11, and 13 (Figure 
3.4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
92 
 
 
Figure 3.4.2 Autozygosity mapping generates highly significant homozygous regions. 
The x- and y-axes show autosomal chromosomes and location scores, respectively. 
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3.4.3 Compound homozygous EXT2 variants in patients with SSM 
syndrome 
A non-synonymous, rare variant analysis was applied on exome sequencing data to 
identify candidate genetic variants within these isolated segments as well as an 
indiscriminate exome-wide approach. Both analyses yielded similar results and identified 
two homozygous variants in exostosin 2, EXT2: c.260T>G, p.Met87Arg; and c.283C>T, 
p.Arg95Cys (Figure 3.4.3A). Both variants were consistently predicted to be ‘disease-
causing’ by multiple in silico software programs and both are near but upstream of the 
highly conserved exostosin domain (Figure 3.4.3B). Both wild type residues are also 
well-conserved when aligned against a set of diverged species from the animal kingdom 
(Figure 3.4.3C).  
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Figure 3.4.3 Schematic of the genetic and bioinformatic studies in the SSM family. 
(A) Annotated variants in EXT2 identified via exome sequencing. In silico predictions 
were determined by gathering outputs of multiple programs. Co-segregation in family 
was determined via individual allele genotyping. Minor allele frequencies were 
determined using multiple publically available databases. Tissue expression was 
determined using The Human Protein Atlas and GeneCards. (B) The structure of the 
EXT2 protein is comprised of the exostosin domain and the glycose transferase 64 
domain, shown from N- to C-terminal. The variants identified are shown. (C) Multiple 
alignments demonstrate strong conservation of both wild type amino acid residues, 
p.Met87 and p.Arg95 across a set of species-specific EXT2 homologs. A ClustalW 
analysis of the EXT2 region encompassing the variant sites (highlighted in red) in aligned 
homologs with multiple divergent species is shown (in green). The asterisks below 
indicate fully conserved residues. 
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3.4.4 EXT2 variants segregate in SSM syndrome family 
Interestingly, the variants co-segregated within the family in an autosomal recessive, 
compound homozygous inheritance pattern with both variants transmitted to each 
affected individual from each parent (Figure 3.4.4A). Specifically, both parents were 
double heterozygotes for both variants, which were on the same chromosome (i.e. in cis) 
and all affected individuals were homozygous for both variants (Figure 3.4.4A and Figure 
3.4.4B). The unaffected sister was homozygous wild type for both variants. 
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Figure 3.4.4 EXT2 variants segregate with affected individuals in the family. 
(A) Within the pedigree, a grey circle represents one p.Met87Arg allele; a red circle 
represents one p.Arg95Cys allele; empty circles represent wild type alleles. (B) 
Electropherograms showing DNA sequence analysis of EXT2 from genomic DNA of 
heterozygous and homozygous individuals. The positions of the genetic variants are 
shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
97 
3.4.5 Population screening reveals EXT2 variants are ultra-rare 
To identify the local carrier frequency in the Old Order Mennonite community, 39 
individuals were subjected to genotyping for both EXT2 variants with three p.Met87Arg 
heterozygotes identified, yielding a local carrier frequency of 3.85%. We did not observe 
any homozygous or heterozygous p.Arg95Cys carriers. No double heterozygotes for 
p.Met87Arg and p.Arg95Cys were identified. We screened an additional 311 healthy 
Caucasian controls with no carriers identified for either EXT2 variant. According to the 
NHLBI ESP Exome Variant Server, the MAF of p.Met87Arg and p.Arg95Cys in 6500 
individuals is 0.054% and 0.015%, respectively (Figure 3.4.3A). 
 
3.4.6 Decreased EXT2 expression and activity in patients with 
SSM syndrome 
To determine whether the newly identified variants affect protein and transcript 
expression, we measured EXT2 expression levels via immunoblotting and RT-PCR, 
respectively in patient fibroblast-derived cells. We observed diminished EXT2 protein 
expression relative to a healthy EXT2-WT control (P<0.001) (Figure 3.4.6A). Similarly, 
we observed a modest but significantly lower difference in EXT2 transcript levels in 
patient cells compared to healthy controls (P<0.05) (Figure 3.4.6B). Previous studies 
have shown that EXT2 interacting protein, NDST1 is affected in EXT2 knockdown cell 
lines (Presto et al., 2008). Consequently, we explored whether the function of EXT2 is 
compromised in patient cells by measuring the expression of binding partner NDST1. 
Our findings indicate that cellular NDST1 protein levels are abolished in patient whole 
cell lysates (Figure 3.4.6C). Conversely and not surprisingly, NDST1 transcript 
expression is not affected in patient cells (Figure 3.4.6D) in agreement with previous 
studies, suggesting the absence of NDST1 protein expression is a product of an error in 
post-translational modification (Presto et al., 2008). 
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Figure 3.4.6 Decreased EXT2 expression and activity in patients with SSM 
syndrome.  
(A) EXT2 protein expression. (B) EXT2 transcript expression. (C) NDST1 protein 
expression. (D) NDST1 transcript expression. Protein and RNA were isolated from 
patient cells and a healthy, wild type control. Bars represent mean ± standard error. All 
expression targets were normalized with their respective constitutively active gene or 
gene product (α-tubulin and GAPDH for protein and transcript expression, respectively). 
*represents P-value <0.05; **represents P-value <0.01; ***represents P-value <0.001. 
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3.4.7 Both EXT2 variants are involved in the development of SSM 
syndrome 
Since two homozygous variants (both in the same gene) were identified, we sought to 
identify which of the two (or both) variants is (are) responsible for the decreased protein 
expression in the patients. We created three EXT2 constructs: 1) EXT2 p.Arg95Cys; 2) 
EXT2 p.Met87Arg; and 3) EXT2 p.Arg95Cys and p.Met87Arg. Using anti-EXT2, we 
measured EXT2 protein expression between endogenous and exogenous wild type EXT2 
in two cell lines as an experimental control and observed no significant difference 
providing confidence in our use of exogenous wild type EXT2 as a reference point 
(Figures 3.4.7B and Figure 3.4.7D). We observed statistically significant decreased 
protein levels in all three constructs relative to wild type exogenous and endogenous 
EXT2 but more noticeably when both residues were mutated (Figures 3.4.7A-D). 
Interestingly however, the EXT2 p.Arg95Cys variant seems to have a significantly larger 
effect on protein expression than EXT2 p.Met87Arg (P<0.05) (Figures 3.4.7A-D). The 
experiments were replicated multiple times (total n=20) with two different cell lines and 
two different antibodies and all produced similar results. These data suggest that the 
EXT2 variants synergistically but unequally, affect EXT2 protein levels. 
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Figure 3.4.7 Both EXT2 variants are necessary for the development of SSM 
syndrome.  
(A) EXT2 protein expression in COS-7 cells using anti-DDK-EXT2. (B) EXT2 protein 
expression in COS-7 cells using anti-EXT2. (C) EXT2 protein expression in HEK293 
cells using anti-DDK-EXT2. (D) EXT2 protein expression in HEK293 cells using anti-
EXT2. Protein expression was isolated from four different EXT2 constructs and a 
negative control (blank). Bars represent mean ± standard error. All expression assays 
were normalized with α-tubulin. *represents P-value <0.05; **represents P-value <0.01; 
***represents P-value <0.001. 
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3.5 Discussion 
Glycosylation is an essential, ubiquitous, and evolutionarily conserved process required 
for cellular function and development (Nadanaka and Kitagawa, 2008; Shevelev et al., 
2012). Not surprisingly, defects in genes encoding heparan sulfate biosynthesis enzymes 
can lead to a wide spectrum of human disorders including bone abnormalities, cancer, 
metabolic disorders, and even late-onset neurodegeneration (Nadanaka and Kitagawa, 
2008; Maeda et al., 2011; Stickens et al., 2000; Ropero et al., 2004; van Horssen et al., 
2003). In this Chapter, we describe a family with children affected with a novel heparan 
sulfate related disorder designated as SSM syndrome. By coupling autozygosity mapping 
and exome sequencing, we identified two homozygous variants in EXT2 that segregated 
in a distinctive, compound homozygous inheritance pattern in the family. EXT2 
p.Met87Arg and p.Arg95Cys are extremely rare variants, harbored in a highly conserved 
region within the protein, and as expected, given the drastic change in the amino acid 
properties, were consistently predicted to be ‘disease-causing’ by multiple in silico 
programs. We were able to assess the expression and function of EXT2 ex vivo in patient 
fibroblasts and in doing so, we observed decreased EXT2 expression and activity. In 
addition, we have shown using an in vitro system, that both variants contribute to 
decreased EXT2 expression potentially destabilizing the protein, disrupting heparan 
sulfate biosynthesis, and probably other developmental cascades requiring EXT2 for 
propagation, such as FGF and Wnt signalling, as was previously demonstrated in Ext2-
knockdown studies (Fischer et al., 2011; Norton et al., 2005; Nurcombe et al., 1993). 
Collectively, our findings have implicated a well-characterized gene in a new 
developmental disorder and have further exemplified the spectrum of phenotypes that can 
arise due to errors in glycosylation. 
Herein, we have also catalogued all reported heparan sulfate-related diseases due 
to defects in heparan sulfate genes (Table 3.5.1).  In doing so, we have identified 26 
genes that when mutated, can cause developmental disorders consisting of intellectual 
disability, distinct coarse facial features, and seizures—features linked to errors in 
glycosylation pathways. This exercise helped us distinguish the clinical features observed 
in all heparan sulfate-related diseases from those unique to SSM syndrome patients. Of 
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particular interest to us was a recently reported NDST1-associated intellectual disability 
in a consanguineous family, as NDST1 directly interacts with EXT2, and our findings 
show abolished NDST1 protein expression in affected individuals (Presto et al., 2008; 
Reuter et al., 2014).
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Table 3.5.1 Hereditary diseases with abnormal heparan sulfate levels. 
 
Gene Chromosomal 
location 
Protein Disease Predominant clinical features OMIM 
(locus, phenotype) 
B3GALT6 1p36.33 UDP-Gal: beta-gal beta-
1,3-galactosyltransferase 
polypeptide 6 
(1) Ehlers-Danlos syndrome, 
progeroid type 2 
(2) Spondyloepimetaphyseal 
dysplasia with joint laxity, type 1 
 
- Aged appearance, developmental delay, short stature, 
craniofacial disproportion, generalized osteopenia, 
hypotonic muscles, and loose skin. 
- Vertebral abnormalities leading to severe 
kyphoscoliosis, thoracic asymmetry, and respiratory 
failure. 
615291, 615349, 
271640 
B3GAT3 11q12.3 Beta-1,3-
glucuronyltransferase 3 
Multiple joint dislocations, short 
stature, craniofacial 
dysmorphism, and congenital 
heart defects 
- Dysmorphic facies, bilateral dislocations of the elbows, 
hips, and knees, short stature, and cardiovascular defects. 
606374, 245600 
B4GALT7 5q35.3 Xylosylprotein 4-beta-
galactosyltransferase, 
polypeptide 7 
Ehlers-Danlos syndrome, 
progeroid type 1 
- Aged appearance, developmental delay, short stature, 
craniofacial disproportion, osteopenia, hypotonia, and 
loose skin. 
604327, 130070 
COL4A2 13q34 Collagen, type IV, alpha-2 Porencephaly 2 - Delayed early development, poor motor skills, and 
seizures. 
120090, 614483 
COL4A3 2q36.3 Collagen, type IV, alpha-3 Alport syndrome, autosomal 
dominant, autosomal recessive 
- End-stage renal failure and hearing loss. 120070, 104200, 
203780 
DAG1 3p21.31 Dystrophin-associated 
glycoprotein 1 
Muscular dystrophy-
dystroglycanopathy (limb-girdle), 
type C, 9 
- Muscular dystrophy, mental retardation, and delayed 
motor development. 
128239, 613818 
EXT1 8q24.11 Exostosin 
glycosyltransferase 1 
(1) Hereditary multiple exostoses, 
type 1 
(2) Chondrosarcoma 
- Exostoses arising from long bones. 608177, 133700, 
215300 
EXT2 11q11.2 Exostin glycosyltransferase 
2 
Hereditary multiple exostoses, 
type 2 
- Exostoses arising from long bones. 608210, 133701 
FGF16 Xq21.1 Fibroblast growth factor 16 Metacarpal 4-5 fusion - Hand and foot malformation. 300827, 309630 
GNS 12q14.3 N-acetylglucosamine-6-
sulfatase 
Mucopolysaccharidosis type IIID - Mental retardation, coarse facies and hirsutism, 
developmental delay, and excessive HS in urine. 
607664, 252940 
GPC3 Xq26.2 Glypican 3 (1) Simpson-Golabi-Behmel 
syndrome, type 1 
(2) Wilms tumor 1 
- Pre- and post-natal overgrowth, coarse facies, and 
congenital heart defect. Stocky appearance with normal 
intelligence. 
- Childhood tumors from malignant transformation of 
renal stem cells. 
 
300037, 312870, 
194070 
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GPC6 13q31.3 Glypican 6 Omodysplasia 1 - Severe congenital micromelia with prominent forehead, 
frontal bossing. Variable findings include 
cryptorchidism, hernias, congenital heart defects, and 
cognitive delay. 
604404, 258315 
GUSB 7q11.21 Beta-glycuronidase Mucopolysaccharidosis VII - Hepatomegaly, skeletal anomalies, coarse facies, and 
variable degrees of mental impairment. 
611499, 253220 
HGSNAT 8p11.21 Heparan-alpha-
glucosaminide N-
acetyltransferase 
Mucopolysaccharidosis type IIIC - Dysmorphic features including coarse facies, 
hypertelorism, low-set ears, depressed nasal bridge, and 
coarse hair. Skeletal examination showed high lumbar 
vertebral bodies, delayed motor development, iliac 
flaring. Urinary HS was increased. 
610453, 252930 
HS6ST1 2q14.3 Heparan sulfate 6-O-
sulfotransferase 1 
Hypogonadotropic hypogonadism 
15 with/without anosmia 
- Absent or incomplete sexual maturation, other features 
include cleft palate, sensorineural hearing loss. 
604846, 614880 
HSPG2 1p36.12 Heparan sulfate 
proteoglycan of basement 
membrane 
(1) Dyssegmental dysplasia, 
Silverman-Handmaker type 
(2) Schwartz-Jampel syndrome, 
type 1 
- Lethal forms of neonatal short limbed dwarfism, 
anisospondyly. 
-Myotonia, skeletal dysplasia, reduced stature, 
kyphoscoliosis, irregular epiphyses. 
142461, 224410, 
255800 
IDS Xq28 Iduronate 2-sulfatase Mucopolysaccharidosis II - Multisystem disorder: airway obstruction, skeletal 
deformities, cardiomyopathy, and neurological decline. 
300823, 309900 
IDUA 4p16.3 Alpha-Iduronidase (1) Mucopolysaccharidosis Ih 
(2) Mucopolysaccharidosis Ih/s 
(3) Mucopolysaccharidosis Is 
- Variable phenotypes but generally all 3 disorders 
encompass coarse facies, corneal clouding, mental 
retardation, hernias, dysostosis multiplex, and 
hepatosplenomegaly. 
252800, 607014, 
607015, 607016 
IHH 2q35 Indian hedgehog Acrocapitofemoral dysplasia - Short stature with postnatal onset, brachydactyly 600726, 607778 
KAL1 Xp22.31 KAL1 gene Kallmann syndrome 1 
(Hypogonadotropic 
hypogonadism 1 with/without 
anosmia) 
- Absent or incomplete sexual maturation. Patients also 
show anosmia. 
300836, 308700 
MANBA 4q24 Mannosidase, beta A, 
lysosomal 
Mannosidosis, beta - Developmental delay and mental retardation. 609489, 248510 
NAGLU 17q21.2 N-Acetylglucosaminidase Mucopolysaccharidosis type IIIB - Progressive neurodegeneration, behavioral problems, 
mild skeletal changes, and shorted life span due to 
accumulation of HS. 
609701, 252920 
 
 
NDST1 5q33.1 N-deacetylase/N-
sulfotransferase (heparan 
glucosaminyl) 1 
Autosomal recessive intellectual 
disability 
- Intellectual disability, muscular hypotonia, epilepsy, 
and postnatal growth deficiency. 
600853, PMID: 
25125150 
SERPINC1 1q25.1 Serpin peptidase inhibitor, 
clade C, member 1 
Thrombophilia due to 
antithrombin III deficiency 
- Venous thrombosis. 107300, 613118 
SGSH 17q25.3 N-sulfoglucosamine 
sulfohydrolase 
Mucopolysaccharidosis type IIIA - CNS degeneration, severe neurological degeneration, 
due to impaired degradation of HS. 
605270, 252900 
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SMPD1 11p15.4 Sphingomyelin 
phosphodiesterase 1, acid 
lysosomal 
(1) Niemann-Pick disease, type A 
(2) Niemann-Pick disease, type B 
- Severe infantile form with neurologic degeneration 
resulting in death by 3 years of age (type A) to later-onset 
nonneurological form (type B). 
 
607608, 257200, 
607616 
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Notably however, the clinical features of patients with SSM syndrome are distinct 
from patients with hereditary multiple exostoses (HME, OMIM 133701), an autosomal 
dominant disorder characterized by benign, cartilage-capped tumours or “exostoses” 
localized to the growth plate of long bones (Busse-Wicher et al., 2014; Ryckx et al., 
2013). Typically, HME has an onset of 12 years of age and is caused by mutations in 
EXT1 or EXT2, with the majority of cases linked to EXT1 (Busse-Wicher et al., 2014; 
Huegel et al., 2013). None of the affected individuals in our family has evidence of 
exostoses, nor do either of the parents who are heterozygous for both p.Met87Arg and 
p.Arg95Cys in EXT2. To the best of our knowledge, there have not been any reports of 
autosomal recessive HME. Interestingly, there has only been one report of HME and 
seizures in a patient with a mutation in EXT2 (Stancheva-Ivanova et al., 2011). There 
have been multiple reports of patients with multiple exostoses, intellectual disability, and 
seizures, diagnosed with Potocki-Shaffer Syndrome (PSS, OMIM 601224), a rare 
contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2 region, 
encompassing EXT2 (Kim et al., 2012; Palka et al., 2012). In addition, partial loss of 
EXT2 sister protein, EXT1 and TRPS1, its neighboring gene, can give rise to another 
developmental disorder known as Langer-Giedion syndrome (OMIM 150230), which is 
characterized by multiple cartilaginous exostoses, dysmorphic facial appearance, and 
mild intellectual disability (Kozlowski et al., 1977; Ludecke et al., 1995). Together, our 
results supplemented with previous findings, suggest the phenotype is dependent on the 
location of the EXT2 (or EXT1) mutation, the consequential enzyme dosage, and whether 
adjacent genes are affected. 
 The EXT protein family has also been well characterized in many animal systems 
including zebrafish, flies, nematodes, and mice. Previous studies have shown Ext1-and 
Ext2-deficient mutant mouse embryos do not form proper heparan sulfate chains, fail to 
gastrulate, and ultimately, die at embryonic day 8.5 (Lin et al., 2000; Shimokawa et al., 
2011; Stickens et al., 2005). In contrast, some embryos with low expression of the 
enzymes survive longer as the enzymes can produce shorter but, normal heparan sulfate 
chains (Koziel et al., 2004; Yamada et al., 2004). This is due to normal expression of the 
other EXT protein, which still has glycosyltransferase activity although significantly less 
than the amount generated by the EXT1and EXT2 complex as the enzymes cannot 
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substitute for one another during co-polymerization (Busse et al., 2007; Busse and 
Kusche-Gullberg, 2003; Lind et al., 1998; McCormick et al., 2000). Therefore, while 
residual levels of heparan sulfate facilitate some cellular functions, they are not sufficient 
for proper neural development including brain morphology and midline axon guidance—
processes defective in Ext-mutants (Maeda et al., 2011; Shevelev et al., 2012). 
Collectively, these studies have demonstrated the importance of sufficient and 
spatiotemporal expression of heparan sulfate biosynthesis enzymes in the development of 
brain size and structure. Importantly, in the context of SSM syndrome patients, these 
studies help explain why SSM patients are alive but have macrocephaly and are severely 
delayed in their developmental course. 
 
3.6 Conclusion 
In conclusion, we have presented herein the first account of an autosomal recessive 
EXT2-mediated human disease designated as seizures-scoliosis-macrocephaly (SSM) 
syndrome. By coupling autozygosity mapping and exome sequencing, we identified two 
homozygous variants in heparan sulfate biosynthesis enzyme, EXT2, which is only 
partially expressed and active in patient cells. Our results have illustrated and further 
confirmed the importance of sufficient expression of heparan sulfate biosynthesis 
enzymes in human development. These results have also demonstrated the need for 
heparan sulfate biosynthesis enzyme replacement therapy. As the majority of heparan 
sulfate disorders are primarily due to a deficiency in heparan sulfate, a simple therapeutic 
intervention would be to elevate heparan sulfate levels. However, it would be naïve to 
administer heparan sulfate without knowledge of the patient’s genotype as some features 
of heparan sulfate-related diseases overlap with many other metabolic disorders and it is 
not clear if excess heparan sulfate is toxic to cells. Alternatively, early genetic diagnosis 
of a heparan sulfate deficiency potentially in utero, coupled with a heparan sulfate 
production stimulant via enzyme or gene replacement therapy at the proper 
developmental period, could be a promising therapeutic intervention. 
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Chapter 4 - Known phenotype, known gene: linkage analysis 
and exome sequencing identify a novel mutation in KCTD7 
in patients with progressive myoclonus epilepsy with ataxia. 
 
4 Study rationale 
Three females initially diagnosed with idiopathic epilepsy with ataxia, were born to a 
Low-German-Speaking Mexican Mennonite family originally from Durango, Mexico but 
now all reside in southwestern Ontario. All three females have a history of early onset 
seizures. They later became ataxic with intention tremor. There are no growth or 
metabolic abnormalities. The family agreed to participate in genetic testing, and the 
disorder, which was originally referred to as ‘epilepsy with ataxia’, became another 
project funded by the FORGE Canada Consortium.  
This project provides an excellent example of the genetics results successfully 
guiding clinicians to correctly diagnose the patients. Once we identified g.661041A>G, 
c.827A>G, p.Tyr276Cys in KCTD7, a known progressive myoclonus epilepsy gene, in 
the affected individuals, the clinicians reviewed our results, which complemented 
previous genetic reports of KCTD7-mediated progressive myoclonus epilepsy and 
together, agreed to diagnose the three females with ‘progressive myoclonus epilepsy with 
ataxia’. 
Chapter 4 was published as an independent study: “Linkage analysis and exome 
sequencing identify a novel mutation in KCTD7 in patients with progressive myoclonus 
epilepsy with ataxia” in Epilepsia in 2014 (Farhan et al., 2014; PMID: 25060828). 
Furthermore, the results of Chapter 4 were described and compared to other epilepsy 
subtypes in “Exploring the Epilepsiome I: Genetics of Age dependent Epileptic 
Encephalopathies” in Pediatric Epilepsy, 4th edition, Chapter 7 (Farhan and Prasad, 
2016, textbook in production). 
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4.1 Overview 
Epilepsy affects approximately 1% of the world’s population. Genetic factors and 
acquired etiologies, as well as a range of environmental triggers, together contribute to 
epileptogenesis. We have ascertained a family with three daughters affected with 
progressive myoclonus epilepsy with ataxia. Clinical details of the onset and progression 
of the neurological presentation, epileptic seizures, and the natural history of progression 
over a 10-year period are described. Using autozygosity genetic mapping, we identified a 
highly significant homozygous region on chromosome 7p12.1-7q11.22. We subsequently 
applied exome sequencing and used a rare, non-synonymous variant prioritization 
analysis within the homozygous region. We identified g.661041A>G, c.827A>G, 
p.Tyr276Cys in the potassium channel tetramerization domain-containing 7 gene, 
KCTD7, which is predominantly expressed in the brain. Mutations in KCTD7 have been 
previously implicated in epileptic phenotypes due to disturbances in potassium channel 
conductance. Pathogenicity of the mutation was supported by in silico analyses and 
KCTD7 p.Tyr276Cys homozygosity segregating with affected individuals only.  
 
4.2 Introduction 
Approximately 70 million people worldwide are living with some form of epilepsy, a 
multifactorial and chronic neurological condition characterized by recurrent seizures due 
to abnormal excessive or synchronous neuronal activity in the brain (Fisher et al., 2005). 
Epilepsy is multifactorial in its causation and its chronic nature results in a considerable 
economic burden estimated at $100 million per year in North America (Tator et al., 
2007). The major expense however, approximately $700 million, is not directly a result 
of epilepsy care but from lost productivity (Katchanov and Birbeck, 2012; Newton and 
Garcia, 2012; Tator et al., 2007). Common forms of epilepsy tend to be complex 
disorders in which a number of implicated genes and environmental factors together 
contribute to epileptogenesis (Buono, 2013). Based on this model, the inheritance of 
multiple susceptibility alleles coupled with high risk environmental conditions can result 
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in the eventual manifestation of epileptic seizures (Buono, 2013; de Araujo Furtado et al., 
2012). Conversely, some relatively rare forms of epilepsy are monogenic, where a 
mutation in a single gene encodes a dysfunctional protein that compromises a key 
pathway and produces the disease phenotype (Deng et al., 2013). While such molecular 
defects are individually rare, collectively they account for a large proportion of familial 
epilepsies (Deng et al., 2013). 
Recently, next generation sequencing technologies have successfully identified 
the molecular genetic basis of nearly 200 disorders since 2009 (Boycott et al., 2013). 
Briefly, next generation sequencing is a rapid and cost-effective sequencing approach that 
can be applied to study any genetic disease and is able to detect most types of genomic 
variation and in many cases, the casual variant in the affected patient or family (Boycott 
et al., 2013). One subtype of next generation sequencing, exome sequencing, sequences 
only protein-coding variants and has been a particularly robust diagnostic tool for 
monogenic disorders (Boycott et al., 2013). 
Herein, we describe a rare neurological disease designated as epilepsy with ataxia, 
with pediatric onset and an autosomal recessive mode of inheritance. Epilepsy with ataxia 
was first observed in three of eight children of a non-consanguineous Low-German-
Speaking Mexican Mennonite couple and is characterized primarily by tonic-clonic and 
myoclonic seizures, ataxia, and cognitive and language delay. We used genomic tools 
including homozygosity genetic mapping and exome sequencing to identify a novel, rare 
variant, p.Tyr276Cys in KCTD7, an epilepsy-associated gene, as the probable genetic 
cause of epilepsy with ataxia. 
 
4.3 Materials and methods 
4.3.1 Ethics 
As described in Chapter 2, subsection 2.3.1, ethics approval was obtained from the 
parents, the three affected females, and four unaffected siblings. 
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4.3.2 Patients and biological materials 
Three children of a healthy Low-German-Speaking Mexican Mennonite couple were 
clinically ascertained because they were experiencing epileptic seizures and ataxia. Blood 
samples were collected from all three affected daughters, four unaffected siblings, and the 
two parents. 
 
4.3.3 DNA isolation 
DNA was isolated from all nine family members as described in Chapter 2, subsection 
2.3.3. 
 
4.3.4 Genotyping 
Genomic DNA (gDNA) extracted from all family members was genotyped for single 
nucleotide polymorphisms (SNPs) using Affymetrix® protocols as described in Chapter 
2, subsection 2.3.6. 
 
4.3.5 Autozygosity mapping 
GeneSpring GT v2.0 software was used to identify regions of homozygosity that are 
identical by descent in family members as described in Chapter 2, subsection 2.3.7. 
 
4.3.6 Exome sequencing 
Exome sequencing was performed using gDNA from two affected individuals (II-6 and 
II-7) using the protocols described in Chapter 2, subsection 2.3.8. 
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4.3.7 Sequence alignment 
Sequence alignment was performed using the same procedures described in Chapter 2, 
subsection 2.3.9. 
4.3.8 Variant calling and annotation 
Variant calling and annotation were performed using the same procedures described in 
Chapter 2, subsection 2.3.10. 
 
4.3.9 Variant discovery 
4.3.9.1 Prioritization of homozygous, non-synonymous, and rare variants 
We investigated whether there were any non-synonymous, rare variants within the 
homozygous regions on chromosomes 7q11.21. We also applied an unbiased, exome-
wide approach to identify any homozygous, non-synonymous, and rare variants as 
described in Chapter 2, subsection 2.3.11.1. We scanned for variants in genes known to 
cause epileptics seizures or ataxia based on literature and OMIM, as well as all genes. 
 
4.3.9.2 In silico analyses 
To determine the predicted biological effect of non-synonymous variants on protein 
function, all non-synonymous variants identified as candidate variants (KCTD7 
p.Tyr276Cys) were assessed using the same tools described in Chapter 2, subsection 
2.3.11.2. 
 
4.3.10 Variant validation 
To determine whether p.Tyr276Cys in KCTD7 segregated with disease status in the 
pedigree, we genotyped family members using standard Sanger sequencing methods as 
described in Chapter 2, subsection 2.3.12.1 and 2.3.12.2. 
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4.3.10.1 PCR 
Forward and reverse primers specific to amplify g.661041A>G in KCTD7 were: 5’-
TATGACCTGCTGCACTGCCT-3’ and 5’-CTTCAGGGATCTTACTCCC-3’, 
respectively. The PCR conditions were as follows: initial denaturation at 95˚C for 5 
minutes; 30 cycles of denaturation at 95˚C for 30 seconds; annealing at 57˚C for 30 
seconds; extension 72˚C for 30 seconds and a final extension at 72˚C for 7 minutes. 
 
4.3.10.2 Imaging, purifying, and sequencing of PCR products 
Imaging, purifying, and sequencing of PCR products were performed using the same 
procedures described in Chapter 2, subsection 2.3.12.2. 
 
4.3.11 Population screening 
4.3.11.1 Identifying overall MAF of KCTD7 variant 
We also used 1000 Genomes (Genomes Project et al., 2012) and Exome Variant Server 
available through the NHLBI Exome Sequencing Project (Fu et al., 2013) to identify the 
carrier frequency of the variants. 
 
4.4 Results 
4.4.1 Clinical description of patients with progressive myoclonus 
epilepsy with ataxia 
The content in this section was compiled and transcribed by Lisa Murphy, a fourth year 
Biochemistry thesis student and myself, and extensively reviewed by Dr. Siu, Dr. Prasad, 
Dr. Rupar, and Dr. Hegele. 
  
118 
The three sisters are the youngest of eight children born to a non-consanguineous 
Low-German-Speaking Mennonite couple originally from Durango, Mexico (Figure 
4.4.1). II-6 became symptomatic at age two years when she first presented with seizures.  
Prior to the onset of seizures, signs of developmental delay, such as walking at 19 months 
and speech limited to single words, were evident. The initial seizures were associated 
with febrile events, and later afebrile generalized clonic seizures were reported without 
any obvious provocative triggers. The generalized seizures were associated with up 
rolling of the eyeballs, clonic activity in all four limbs and varied in duration but were 
self-limited. Postictal hemibody weakness was reported for variable periods. Additional 
seizure types including sudden head and shoulder drops associated with loss of posture 
and falls as well as episodes of staring and unresponsiveness were also reported after the 
onset afebrile seizures. 
Following the onset of seizures, developmental regression was noted, with loss of 
expressive language skills and eventual progression to a nonverbal state with limited 
comprehension of spoken language. The first neurological assessment disclosed the 
presence of significant hypotonia, motor incoordination, and gait ataxia. There were no 
signs of ocular movements, nystagmus, or cranial nerve deficits. By age seven, seizure 
control was vastly improved on a combination of lamotrigine (6 mg/kg/day) and 
clonazepam (0.02-0.05 mg/kg/day). However, neurological examination confirmed the 
presence of multifocal myoclonus and development of pyramidal signs (hyperreflexia, 
extensor plantar responses). A mild right hemiparesis was also noted and was explained 
by identification of a small epidural hematoma sustained during a fall associated with 
myoclonic astatic seizure. Addition of levetiracetam (35 mg/kg/day) significantly 
improved control of myoclonus and drop attacks. Between age 9 and 14 years, additional 
signs of progression were noted, with loss of independent ambulation, incontinence, 
ability to feed herself and manage activities of independent living. 
During her first evaluation at age three, II-7 was reported to have had normal 
development of milestones until age two. She then showed generalized clonic seizure 
activity, head and shoulder drops, and staring spells associated with eyelid fluttering. She 
began to show developmental regression after the onset of seizures. She lost expressive 
speech, and had significant sialorrhea (drooling). Her neurological examination disclosed 
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findings similar to her elder sibling: moderately increased tone in lower extremities, 
hyperreflexia, and gait ataxia. Her seizures were well controlled on a combination of 
valproic acid (15-20 mg/kg) and clonazepam (0.03-0.05 mg/kg). Since the age of five 
years, her seizures have remained well controlled, but her gait and myoclonus have 
continued to worsen.  However, she retains the ability to walk and feed herself. 
II-8 presented with a generalized seizure at 15 months. Prior to this, she showed 
signs of developmental delay in walking, but had a vocabulary of several words. She has 
continued to experience both febrile and afebrile events, occasional head drops, but no 
observed staring spells. Her seizures have remained relatively easy to control with 
monotherapy (valproic acid) initially, and with the appearance of myoclonic jerks 
clonazepam was added. She is currently 12 years of age, with mild neurological 
symptoms compared to her sisters with respect to gait, and coordination. She is capable 
of independent ambulation, and can feed and dress herself. She is cognitively delayed, 
and has limited expressive speech, but unlike her older sibling she has yet to show further 
decline in her functioning. 
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Figure 4.4.1 Pedigree with three daughters affected with epilepsy with ataxia. 
Squares depict males and circles depict females. Affected individuals are shaded. 
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Table 4.4.1 Clinical description of patients with epilepsy with ataxia. 
 
 Affected individuals (year of birth) 
Clinical features II-6 (2000) II-7 (2002) II-8 (2006) 
Gestation Full term Full term 8.5 months 
Sex F F F 
Karyotype 46,XX 46,XX 46,XX 
Birth weight (kg)  2.7 2.5 2.9 
Physical examination    
Facial/limb dysmorphology - - - 
Teeth inturned + + + 
High-arched palate + + + 
Wide palatine ridges + + + 
Seizures    
Seizure onset (months) 24 24 17 
Seizure type Febrile and generalized clonic seizures, 
atypical absences, and head drops, drop 
attacks 
Febrile and generalized clonic seizures, 
atypical absences, and head drops, drop 
attacks 
Febrile and generalized clonic seizures, 
atypical absences, and head drops, drop 
attacks 
Intention tremors + + + 
Growth and development    
Time of initial sitting (months) 8-9 8-9 8-9 
Time of initial walking (months) 19 16 Not walking at 22 months 
Time of initial speech (months) 24 16 18 
Neurological examination Abnormal  Abnormal Abnormal 
Gait and motor function Broad based ataxic gait, motor 
incoordination, distal myoclonus 
Ataxic gait, incoordination and distal 
myoclonus 
Ataxia on stressed gait manoeuvres  
Toilet training Later years incontinent In diapers In diapers 
Functional inquiry    
Vision Normal Normal Normal 
Hearing Normal Normal Normal 
Investigations    
Metabolic screening tests (Blood and 
Urine Amino acids, Urine Organic 
acids, Urine mucopolyscaccharides, 
oligosaccharides) 
Negative Negative Negative 
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CT scan/MRI Normal Normal Normal 
EEG Generalized epileptiform bursts and 
multiple independent spike foci, 
photoparoxysmal response 
Multiple independent spike foci, 
photoparoxysmal response 
Multiple independent spike foci, 
photoparoxysmal response 
Skin biopsy EM 
 
 
 
 Showed no accumulation of any 
storage material in all cytological 
elements examined 
 
Abbreviations are as follows: N, normal; +, present; -, absent. Blank cells indicate unavailable information. Other metabolic testing included ammonia, lactate, 
complete blood count differential, liver function tests, blood urea nitrogen, creatinine, creatine kinase, and calcium produced normal results.
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4.4.2 Electroencephalogram features 
Dr. Prasad prepared the results from the electroencephalogram. All three siblings share 
similarities in their seizure phenotype and electroencephalographic findings (Figure 
4.4.2). Background rhythms show poor organization and diffuse non-specific slowing. In 
the early stages, abundant paroxysmal bursts of generalized spike wave discharges were 
prominent, however with improving seizure control and increasing serial recordings 
showed multiple independent spike foci and regional expression of epileptiform activity 
distributed over bilateral central, temporal and parietal electrode chains, often with 
shifting asymmetry. In the instance of a single staring spell associated with behavioural 
arrest captured during a recording, the EEG showed focal spikes, with a posterior 
distribution and ictal rhythms that progressively spread from the occipital regions to 
become generalized with an abrupt onset and offset. All three siblings showed a 
photoparoxysmal response on photic stimulation, which was self-limited in nature 
(Figure 4.4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
124 
A. 
 
B. 
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Figure 4.4.2 EEG recording of the affected individuals.  
(A) Patient 1. A snap shot of the EEG recording at age 11 years of age, abundant 
multifocal independent spikes, as well as synchronized, bihemispheric generalized spike 
waves superimposed on slow background rhythms with superimposed fast rhythms (beta 
frequencies) attributable to a benzodiazepine effect. (B) Patient 1. At 14 years of age, on 
a coronal montage, generalized 2-3 Hz multiphasic spike and wave discharges with a 
predominant distribution over midline parasagittal and bitemporal regions. 
(C) Patient 3. Excess fast background rhythms are seen, with focal repetitive spike and 
waves in the right hemisphere, and wave maxima over C4, P4 and T4-T6 electrodes. (D) 
Patient 3. At 6 Hz flash frequency a generalized and self-limited photoparoxysmal 
response is seen. 
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4.4.3 Genome-wide autozygosity mapping generated a high 
priority region on chromosome 7p12.1-7q11.22 
Although the family is unaware of any consanguinity, we modelled an autosomal 
recessive disease inheritance given the known founder effect within the Mennonite 
community. Genome-wide autozygosity mapping generated a high priority locus on 
chromosome 7p12.1-7q11.22, ~14.3 Mb in length with a significant location score of 492 
(Figure 4.4.3). 
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Figure 4.4.3 Homozygous region on chromosome 7 unique to affected individuals. 
The x and y axes show autosomal chromosomes and location scores, respectively. 
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4.4.4 KCTD7 p.Tyr276Cys in patients with progressive myoclonus 
epilepsy with ataxia 
Next, we performed exome sequencing and applied a non-synonymous, rare variant 
filtering analysis (Figure 4.4.4.A). We identified a novel variant within the autozygous 
region: g.66104176A>G, c.827A>G, p.Tyr276Cys in KCTD7, the potassium channel 
tetramerization domain-containing 7 gene. KCTD7 is predominantly expressed in the 
brain specifically in cortical neurons, in granular and pyramidal cell layers of the 
hippocampus, and in cerebellar Purkinje cells and is involved in hyperpolarization of the 
cell membrane via interaction with a component of the ubiquitin ligase complex (Azizieh 
et al., 2011; Kousi et al., 2012; Staropoli et al., 2012) (Figure 4.4.4.A, 4.4.4.B, and 
4.4.4.C). Furthermore, KCTD7 p.Tyr276Cys was consistently predicted to be ‘disease-
causing’ by multiple in silico analyses, suggesting deviation from the wild type amino 
acid residue (tyrosine) may disrupt protein function (Figure 4.4.4.D). According to the 
Exome Variant Server, the MAF of p.Tyr276Cys in KCTD7 is 0.008% in the general 
population. 
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Figure 4.4.4 Schematic of mutation discovery. 
(A) Using exome sequencing, we identified a rare, non-synonymous variant. (B) KCTD7 
is located on chromosome 7q11.21, within the autozygous region. (C) BTB/POZ domain 
is the only domain in the KCTD7 protein. (D) Multiple alignments of KCTD7 
demonstrate high homology of amino acid residue p.Tyr276 across a set of divergent 
species. The residues shaded in blue indicate fully conserved residues. 
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4.4.5 KCTD7 p.Tyr276Cys segregates with disease phenotype in 
the family 
We performed subsequent variant validation analysis and observed KCTD7 p.Tyr276Cys 
to segregate with disease status in the family (Figure 4.4.5). All three affected individuals 
are homozygous for the variant and unaffected siblings are either heterozygous or 
homozygous for the wild type allele. As expected, both parents are heterozygotes. 
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Figure 4.4.5 KCTD7 g.661041A>G segregates with affected individuals in the family. 
KCTD7 g.661041A>G segregated with the three affected females as shown by a ‘G/G’ 
genotype, heterozygotes have a ‘A/G’ genotype, and homozygotes for the wild type allele 
have a ‘A/A’ genotype. 
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4.4.6 KCTD7 is a known disease gene 
When reviewing the KCTD7 literature, we identified additional KCTD7 variants 
observed in individuals affected with progressive myoclonus epilepsy. In total, we 
identified 11 disease-causing KCTD7 variants in 19 patients (Blumkin et al., 2012; Kousi 
et al., 2012; Krabichler et al., 2012; Staropoli et al., 2012; Van Bogaert et al., 2007). 
These variants and their corresponding phenotypes are summarized in Table 4.4.6. 
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Table 4.4.6 Comparison of all reported patients with KCTD7 variants. 
 
Study 
Blumkin et al., 
2012 
Kousi et al., 
2012 
Krabichler et 
al., 2012 
Van Bogaert et 
al., 2007 
Kousi et al., 
2012 
Kousi et al.,  
2012 
Staropoli et al., 
2012 
Kousi et al.,  
2012 
Kousi et al., 
2012 
Our study Kousi et al., 
2012 
# of patients 
carrying same 
listed mutation 
in study 
1 1 1 3 2 1 2 2 (from 2 
separate families) 
1 3 2 
Sex M M M F, F, F F, M M F, M F, M M F, F, F F, M 
Age of onset 
(months) 
10 10 10 16-24 12-24 12-24 8-9 6-12 12-24 24 12-24 
Ethnicity Unknown Turkish Turkish Moroccan Pakistani Turkish Mexican Turkish Turkish Mennonite Turkish 
KCTD7 variant 1.) p.Arg84Trp 
2.) Del3+4 
p.Arg94Trp p.Arg94Trp p.Arg99X p.Leu108Met 1.) p.Asp115Tyr 
2.) p.Asn273Ile 
p.Arg184Cys p.Ile199SerfsX74 p.Asn273Ile p.Tyr276Cys p.Trp289X 
Zygosity of 
patient(s) 
Compound 
heterozygous 
Homozygous Homozygous Homozygous Homozygous Compound 
heterozygous 
Homozygous Homozygous Homozygous Homozygous Homozygous 
Consanguineous 
marriage of 
parents 
No No Yes Yes Yes No No First family: yes; 
second family: 
no 
No No Yes 
Presenting 
symptoms 
Myoclonic 
seizures, oral 
automatisms, 
severe 
dysarthria, 
opsoclonus-like 
eye movements 
Myoclonic 
atonic 
Myoclonic 
seizures, tonic 
episodes, 
hypotonia, 
dystonia, 
dyskinesia 
Myoclonic 
seizures, 
hypotonic 
Myoclonic 
and atonic 
seizures 
Myoclonic 
seizures, 
generalized 
tonic-clonic 
seizures 
Myoclonic 
seizures, spasticity 
and vision loss. 
Myoclonic 
seizures,  
generalized 
tonic-clonic 
seizures 
Myoclonic 
seizures 
Myoclonic 
seizures, tonic 
episodes,  
dysarthria 
Myoclonic, 
generalized 
tonic-clonic 
seizures 
Ataxia Yes No No Yes Yes Yes No Yes Yes Yes Yes 
Cognitive 
function 
Impaired Impaired Impaired Impaired Impaired Impaired Impaired Impaired Impaired Impaired Impaired 
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4.5 Discussion 
Progressive myoclonus epilepsy is an umbrella term encompassing a group of central nervous 
system disorders leading to involuntary muscle contractions and seizures, which worsen with 
time (Girard et al., 2013). Onset is usually around two years of age and is often accompanied 
with developmental regression and in some cases, prominent ataxia, speech and language 
impediments, and intellectual disability (Girard et al., 2013). Notably, progressive myoclonus 
epilepsy is a genetically and clinically heterogeneous group of disorders however, the clinical 
presentation and progression often overlap with other progressive myoclonus epilepsy 
syndromes, which are classified based on their underlying genetic etiology. 
Typically, autosomal recessive (homozygous and compound heterozygous) mutations in 
the potassium channel tetramerization domain containing protein 7 (KCTD7) gene, a member of 
the KCTD gene family, cause progressive myoclonus epilepsy (Deng et al., 2014). In this 
Chapter, we coupled autozygosity mapping with exome sequencing to identify a novel variant in 
KCTD7 in three patients affected with epilepsy with ataxia. Currently, the biological function of 
KCTD7 in epilepsy is not fully known; however, given that mutations within KCTD7 have been 
previously observed in epileptic patients, and the protein is predominantly expressed in the brain, 
it is likely that KCTD7 is involved in a highly regulated electric circuit. Therefore, abnormal 
KCTD7 function leads to epileptogenesis. 
KCTD7 is a member of the KCTD gene family (Deng et al., 2013). The family of 
proteins shares an N-terminal BTB/POZ domain that demonstrates sequence homology to the TI 
domain in voltage gated potassium channels (Staropoli et al., 2012). To date, there have been 11 
KCTD7 mutations observed in 19 different patients presenting with some form of progressive 
myoclonus epilepsy (Table 4.4.6). These patients share many clinical symptoms including 
myoclonic seizures and cognitive impairment however, only a subset of these patients have 
ataxia and/or dystonia, which may suggest that that disorder is more severe depending on the 
type of mutation and its location (Table 4.4.6). However, all 11 mutations are within the coding 
region of KCTD7 with five in its only known functional domain, BTB/POZ. Interestingly, 
mutations within the BTB/POZ domain do not lead to a more severe clinical phenotype. 
The epilepsy phenotype in the three siblings followed over 10 years shows a distinctive 
natural history. Features of the first phase include motor and speech delay prior to onset of 
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seizures. In the second phase, initial complex febrile seizures evolve into multiple seizures types 
including generalized clonic seizures, atypical absences and myoclonic head and shoulder drops. 
Developmental regression involving loss of language is accompanied by prominent ataxia, 
incoordination, and non-epileptic myoclonus. There appears to be a plateau in the third phase 
lasting several years, wherein seizure control improves. Late deterioration was seen in the most 
severely affected child, involving loss of ambulation and incontinence. There is considerable 
variability in the severity of symptoms across the 3 siblings, with the youngest being most mildly 
affected and not yet having experienced significant deterioration in function. 
The EEG features again suggest an evolution that mirrors the clinical neurological 
progression, with abundant multifocal spikes as well as generalized epileptiform activity in the 
initial stages followed in later years by a more regional expression of spike wave activity. Photic 
stimulation is associated with the development of photoparoxysmal responses that are self-
limited and do not outlast the stimulus train. The seizures appear to respond particularly well to 
treatment with several agents alone or in combination, including valproic acid, lamotrigine, 
clonazepam and levetiracetam. The latter has been particularly helpful in reducing myoclonic 
seizures and falls. The clinical presentation and progression share some features with other 
progressive myoclonus epilepsy syndromes such as neuronal ceroid lipofuscinoses (Staropoli et 
al., 2012). 
Within the progressive myoclonic epilepsies, there is also Baltic myoclonus epilepsy 
(Unverricht Lundborg); action myoclonus-renal failure syndrome; Lafora body disease, 
myoclonic epilepsy associated with ragged-red fibers (MERRF) syndrome, and the neuronal 
ceroid lipofuscinosis disorders. 
Baltic myoclonus epilepsy (also named myoclonic epilepsy of Unverricht and Lundborg 
for the clinicians who first described the disease in Finland in the late 1800s) is an autosomal 
recessive disorder characterized by onset of neurodegeneration between 6 and 16 years of age 
(Kalviainen et al., 2008). It differs from other progressive myoclonus epilepsy as it is progressive 
only in adolescence. Typically, there is dramatic worsening of myoclonus and ataxia in the first 6 
years after onset (Ramachandran et al., 2009). The disease stabilizes in early adulthood, and in 
some patients, myoclonus and ataxia may even improve while cognitive function is relatively 
preserved (Ramachandran et al., 2009). Mutations in cystatin B (CSTB) have been identified in 
patients with Baltic myoclonus epilepsy (Joensuu et al., 2008). Cystatin B is a cysteine protein 
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inhibitor and is thought to be involved in preventing proteinases leaking from lysosomes 
(Joensuu et al., 2008). In an animal study performed by Pennacchio et al., Cstb mice knockouts 
succumbed to myoclonic seizures and ataxia thus, recapitulating features seen in patients with 
Baltic myoclonus epilepsy (Pennacchio et al., 1998). 
In action myoclonus-renal failure (AMRF) syndrome, patients present with progressive 
action myoclonus, dysarthria, later development of ataxia, intermittent generalized seizures, and 
in some patients, renal failure (Badhwar et al., 2004). AMRF syndrome is most often caused by 
mutations in the scavenger receptor class B, member 2 gene (SCARB2) inherited in autosomal 
recessive pattern (homozygous and compound heterozygous mutations have been observed) 
(Dibbens et al., 2011; Dibbens et al., 2009). SCARB2 is involved in lysosomal mannose-6-
phosphate-independent trafficking of β-glucocerebrosidase, the enzyme deficient in patients with 
Gaucher disease (Zeigler et al., 2014). 
The Lafora type of progressive myoclonic epilepsy, which was first described by Lafora 
and Glueck in 1911, is an autosomal recessive disorder characterized by insidious onset of 
progressive neurodegeneration between 8 and 18 years of age (Ramachandran et al., 2009). 
Clinical symptoms can include headaches, academic difficulties, myoclonic jerks, generalized 
seizures, and frequent visual hallucination, which continue to worsen with time (Ramachandran 
et al., 2009). This is accompanied by progressive cognitive decline, resulting in dementia. 
Typically, 10 years following disease onset, patients are in near-continuous myoclonus with 
absence seizures, experience generalized seizures, and become severely demented 
(Ramachandran et al., 2009). Histologic examination of brain, muscle, liver, and heart biopsies 
show intracellular Lafora bodies, which are characterized by an accumulation of abnormal 
glycogen molecules (polyglucosans) (Andrade et al., 2003). Two genes have been linked to 
Lafora body disease namely, the NHL repeat-containing 1 gene (NHLRC1) and the epilepsy, 
progressive myoclonic 2A gene (EPM2A) (Chan et al., 2003; Serratosa et al., 1999). NHLRC1 
encodes malin, which is a single subunit E3 ubiquitin ligase; and EPM2A encodes laforin, a 
protein phosphatase that hydrolyzes phosphotyrosine and phosphoserine/threonine substrates 
(Gentry et al., 2005; Worby et al., 2006). Gentry et al. determined that laforin is a substrate for 
malin by showing that malin interacts with laforin leading to its polyubiquitination and eventual 
degradation (Gentry et al., 2005). As malin regulates cellular protein concentration of laforin, not 
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surprisingly, mutations in either NHLRC1 or EPM2A disrupt this interaction and lead to the 
formation of aggregates. 
The neuronal ceroid lipofuscinoses (NCL) are a clinically and genetically heterogeneous 
group of neurodegenerative disorders characterized by an accumulation of lipofuscin in various 
cell types, which resemble aspects of classical lysosomal storage diseases (Boustany, 2013). The 
clinical course of patients with NCL includes cognitive and motor impairments, seizures, 
progressive blindness, and early deaths (Boustany, 2013). There is significant genetic 
heterogeneity in the NCL disorders as 14 loci have been implicated in different NCL subtypes, 
each of which varies in age of onset (infantile, late infantile, juvenile, and adult onset) and 
severity of the disease (Radke et al., 2015). Each subtype is linked to a disruption in a specific 
gene defect but some pathways have been observed in multiple subtypes including apoptosis 
(Kim et al., 2006); clearance of degraded proteins (Walus et al., 2010); and most often, 
disordered intracellular trafficking to lysosomes (Schmiedt et al., 2010). Furthermore, each 
subtype can be visualized based on the type of lipopigment storage material pattern they produce 
(Mole et al., 2005). For example, granular osmiophilic deposits (GROD) are seen in the first 
subtype (CLN1) while CLN2 and CLN3 display 'curvilinear' and 'fingerprint' profiles, 
respectively and CLN4, CLN5, CLN6, CLN7, and CLN8 show a mixture of granular, 
curvilinear, fingerprint, and rectilinear patterns (Mole et al., 2005). 
Therefore, knowledge of the clinical profile, seizure types, and EEG features of the 
disease phenotype associated with the specific mutation as described above aids in improving 
diagnostic precision. Identification of the causative mutation is also important for 
prognostication and genetic counseling, and provides a sound basis of treatment decisions and 
symptom management. 
 
4.6 Conclusion 
In summary, using autozygosity mapping and exome sequencing, we identified a novel 
homozygous variant, p.Tyr276Cys in KCTD7, in three sisters affected with progressive 
myoclonus epilepsy with ataxia. KCTD7 is a known progressive myoclonus epilepsy gene and is 
predominantly expressed in the brain. Variants in KCTD7 have been previously implicated in 
epileptic phenotypes due to disturbances in potassium channel conductance. Our results further 
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support the role of KCTD7 in epileptic seizures. During our analysis, we also identified three 
siblings (II-2, II-3, and II-4) to be carriers of KCTD7 p.Tyr276Cys, which can have significant 
clinical utility. The newly discovered mutation is now a genetic marker and can be used in 
genetic counseling for the siblings and their prospective mates and eventually, for other relatives 
from the same Low-German-Speaking Mexican Mennonite community. 
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Chapter 5 - Known phenotype, novel gene: loss of a novel 
synaptic protein, TMTC3, in patients with nocturnal seizures with 
developmental delay. 
 
5 Study rationale 
Four siblings, three females and one male, were born to a healthy non-consanguineous Pakistani 
couple and are equally affected with nocturnal seizures and developmental delay, which is a 
previously described phenotype. The four affected individuals did not demonstrate significant 
loci that mapped to any of the known genes associated with nocturnal frontal epilepsy, which 
suggests that nocturnal seizures with developmental delay, is likely caused by novel genomic 
loci. The family agreed to participate in genetic testing and the project was funded by the 
FORGE Canada Consortium as well as the Rare Diseases: Models & Mechanisms Network. 
Following gene identification, we collaborated with Dr. Jamie Kramer and Dr. Michael 
Poulter to study the function of TMTC3 using model organisms. Our goal here is to apply 
comprehensive neuro-phenotyping of the Drosophila melanogaster TMTC3 ortholog, which may 
reveal novel functions for this protein in the central nervous system. Furthermore, we intend on 
applying specialized assays to model seizures and developmental delay in a model organism, 
which may recapitulate clinical features of the four children, and also further characterize the 
role of TMTC3 in seizure development. 
Chapter 5 was prepared as an independent study: “Loss of TMTC3, a synaptic protein, in 
patients with nocturnal seizures and intellectual disability”, and has been submitted for 
publication (Farhan et al., 2016). 
 
5.1 Overview 
Herein, we provide evidence that loss of the transmembrane and tetratricopeptide repeat 
containing 3 (TMTC3) protein causes nocturnal seizures and intellectual disability (ID) in a 
family with four affected children. Using exome sequencing, we identified compound 
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heterozygous variants (p.Arg71His and p. Leu729ThrfsTer6) in the TMTC3 gene in this family. 
All four affected siblings had this combination of mutations demonstrating autosomal recessive 
inheritance. Expression analysis using patient-derived cells confirmed reduced TMTC3 transcript 
levels and loss of the TMTC3 protein when compared to cell lines taken from both parents and 
an additional healthy control. As TMTC3 function is currently unexplored in brain, we gathered 
support for a neurobiological role for TMTC3 by generating flies with postmitotic neuron-
specific knockdown of the highly conserved Drosophila melanogaster TMTC3 ortholog, 
CG4050. Knockdown of this gene in flies showed increased susceptibility to mechanically 
induced seizures, a phenotype that was ameliorated by reintroducing the human TMTC3 protein 
into fly neurons. Furthermore, we show that TMTC3 is localized to pre-synaptic terminals and 
boutons in GABAergic inhibitory neurons of the rat hypothalamus and piriform cortex. By 
demonstrating that loss of TMTC3 leads to seizure susceptibility in both humans and flies, and 
by characterizing the synaptic localization of this protein, our results uncover a novel role for 
TMTC3 in the regulation of synaptic function and neuronal physiology. 
 
5.2 Introduction 
Epilepsy, defined by recurrent unprovoked seizures, is a clinically diverse disorder with a 
complex etiology (Farhan et al., 2014). Early genetic studies in families with a history of 
epilepsy revealed a role for synaptic ion channels, such as the nicotinic acetylcholine receptors 
(nAChRs) (Aridon et al., 2006; De Fusco et al., 2000; Steinlein et al., 1995). This led to the 
hypothesis that dysregulation of ion channels is an important mechanism underlying epilepsy. 
More recent studies using massively parallel sequencing indeed support the role of ion channels 
in the etiology of epilepsy, but also reveal a heterogeneous group of genes with other functions 
that contribute to various types of epilepsy (Myers and Mefford, 2015; Thomas and Berkovic, 
2014). 
Some forms of epilepsy are characterized by nocturnal seizures, which occur almost 
exclusively during sleep. Nocturnal seizures are seen in association with certain syndromes, 
including focal epilepsy with speech disorder (FESD - OMIM 245570), and autosomal dominant 
nocturnal frontal lobe epilepsy (ADNFLE - OMIM 600513, 603204, 605375, 610353, 615005) 
(Bazil, 2004). FESD, a clinically diverse disorder that is often comorbid with intellectual 
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disability, is caused by mutations in GRIN2A (Lemke et al., 2013; Lesca et al., 2013; 
Venkateswaran et al., 2014). GRIN2A is a subunit of the NMDA receptor, a ligand- and voltage-
gated calcium channel. Similar to FESD, ADNFLE is also often comorbid with speech and 
psychiatric disorders, or intellectual disability (Nobili et al., 2014). ADNFLE has been 
recurrently associated with multiple loci encoding components of the synaptic nAChRs 
(Becchetti et al., 2015), which are ligand-gated non-selective ion channels. Causative variants 
have been identified in CHRNA4 (Steinlein et al., 1995), CHRNB2 (De Fusco et al., 2000), and 
CHRNA2 (Aridon et al., 2006). Recently, ADNFLE was also linked to mutations in KCNT1, 
encoding a sodium-gated potassium channel (Heron et al., 2012). The effects of these variants 
are further exemplified as murine models harboring the same variants causal of ADNFLE, 
recapitulate the epileptic seizures observed in the human disease state (Lim et al., 2016; Shiba et 
al., 2015). Thus, in general, epilepsy syndromes that are characterized by nocturnal seizures 
appear to be predominantly associated with defects in ion channel function (Kim et al., 2014; 
Lim et al., 2016). 
Here, we have ascertained a family with four affected siblings who presented with 
nocturnal seizures and mild to moderate intellectual disability. Through whole exome 
sequencing, we identified compound heterozygous mutations in the transmembrane and 
tetratricopeptide repeat containing 3 (TMTC3) gene in this family. TMTC3 mutations have not 
been previously identified as a cause of human disease. Tmtc3 deficient mice exhibit neonatal 
lethality with only a few significantly smaller mice surviving for up to three weeks (Yun and Vu, 
2012), however, there is no knowledge regarding the role of TMTC3 in nervous system 
development or function. In this report, we demonstrate a neuron-specific role for TMTC3 in 
mechanically induced seizures in Drosophila, and provide evidence for pre-synaptic localization 
of TMTC3 in the mammalian brain. Taken together, our results strongly support that TMTC3 
defects can cause nocturnal seizures and ID in humans, and uncover a novel and evolutionarily 
conserved role for TMTC3 in synaptic function and seizure susceptibility. 
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5.3 Materials and methods  
5.3.1 Ethics 
As described in Chapter 2, subsection 2.3.1, ethics approval was obtained from the parents on 
behalf of all six members of the family. 
 
5.3.2 Patients and biological materials 
Four children of a healthy non-consanguineous Pakistani couple were clinically ascertained 
because they were experiencing nocturnal seizures and also had developmental delay. Blood and 
tissue (skin-derived fibroblast cells) samples were collected from all four affected children and 
the two parents. 
 
5.3.3 DNA isolation 
DNA was isolated from all six family members as described in Chapter 2, subsection 2.3.3. 
 
5.3.4 Exome sequencing 
Exome sequencing was performed using gDNA from two affected individuals (II-1 and II-4) 
using the protocols described in Chapter 2, subsection 2.3.8. 
 
5.3.5 Sequence alignment 
Sequence alignment was performed using the same procedures described in Chapter 2, 
subsection 2.3.9. 
 
5.3.6 Variant calling and annotation 
Variant calling and annotation were performed using the same procedures described in Chapter 
2, subsection 2.3.10. 
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5.3.7 Variant discovery 
5.3.7.1 Prioritization of autosomal recessive, non-synonymous, and rare variants 
We investigated whether there were any autosomal recessive variant (homozygous or compound 
heterozygous) non-synonymous, rare variants in the exomes of the patients. We scanned for 
variants in genes known to cause seizures and/or intellectual disability based on literature and 
OMIM, as well as all genes. 
 
5.3.7.2 In silico analyses 
To determine the predicted biological effect of non-synonymous variants on protein function, 
candidate variants (TMTC3 p.Arg71His and p.Leu728fs*6) were assessed using the same tools 
described in Chapter 2, subsection 2.3.11.2. 
 
5.3.8 Variant validation 
To determine whether p.Arg71His and p.Leu728fs*6 in TMTC3 segregated with disease status 
in the pedigree, we genotyped family members using standard PCR and Sanger sequencing 
methods as described in Chapter 2, subsection 2.3.12.1 and 2.3.12.2. 
 
5.3.8.1 PCR 
Forward and reverse primers specific to amplify g.11018G>A in TMTC3 were: 5’-
CAGTGATGAGCTTTTGTACCC-3’ and 5’-CACACTACTCTTGTTGTCC-3’, respectively; 
and primers for TMTC3 g.52793insA were: 5’-AAGCCGACTTCCGAAGTGCT-3’ and 5’- 
TTCCTTGCACATTGCTTGG-3’. The PCR conditions for both primer pairs were as follows: 
initial denaturation at 95˚C for 5 minutes; 30 cycles of denaturation at 95˚C for 30 seconds; 
annealing at 58˚C for 30 seconds; extension 72˚C for 30 seconds and a final extension at 72˚C 
for 7 minutes. 
 
5.3.8.2 Imaging, purifying, and sequencing of PCR products 
Imaging, purifying, and sequencing of PCR products were performed using the same procedures 
described in Chapter 2, subsection 2.3.12.2. 
 
  
148 
5.3.9 Cell culture 
Skin fibroblasts from patients, both parents, and a healthy control were cultured as described in 
Chapter 2, subsection 2.3.14. 
 
5.3.10 Protein isolation 
Protein isolation was performed as described in Chapter 3, subsection 3.3.13. 
 
5.3.11 Immunoblotting 
Protein expression was measured using immunoblotting as described in Chapter 2, subsection 
2.3.15. 
 
5.3.12 Reverse transcriptase (RT)-PCR 
RT-PCR was performed as described in Chapter 3, subsection 3.3.15. 
 
5.3.13 Model organisms 
In collaboration with Dr. Jamie Kramer, we are studying the functional effect of TMTC3 
deficiency in Drosophila melanogaster. 
 
5.3.13.1 Gateway cloning technology 
This step was performed by Dr. Heleen Arts and myself. 
A pTW destination vector was obtained from the Drosophila Genomics Resource Center 
(Bloomington, Indiana, USA) for fly rescue experiments. Once the UAS site was sequence 
verified, the vector was sent to the SPARC BioCentre at The Hospital for Sick Children 
(Toronto, Ontario, Canada) for insertion of full length TMTC3 cDNA (Internal ID 53914 of the 
hORFeome V5.1 of the CCSB Human Orfeome Collection and Entrez Gene ID 160418) through 
regular Gateway cloning (Life Technologies, Carlsbad, CA). Following growth of LB agar plates 
with colonies resulting from LR reaction, we picked several colonies for mini cultures in LB 
medium with ampicillin (50 ug/ml) and incubated these overnight in a shaker at 37C°. Plasmid 
DNA was isolated with a DNA isolation kit according to the manufacturer’s instructions 
(NucleoSpin Plasmid Easy Pure, Machery Nagel, Düren, Germany). Clones were validated 
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through restriction analysis with ApaLI (New England Biolabs, Ipswich, MA, USA). The insert 
and flanking sequences were analyzed via Sanger sequencing as previously described.  
A verified construct was retransformed in DH5α bacteria (Subcloning Efficiency DH5α 
Competent Cells, Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s 
protocol. Bacteria containing the pTW TMTC3 vector were selected on LB plates with ampicillin 
(50 ug/ml). 100 ml of LB medium with antibiotics was inoculated directly from a single colony 
and grown overnight. A Plasmid Midi Kit (Qiagen, Hilden, Germany) was used for DNA 
isolation according to the manufacturer’s instructions. Vector DNA was validated through 
restriction analysis with ApaLI and sent for generation of transgenic flies. 
 
5.3.13.2 Drosophila stocks 
These experiments were performed in Dr. Kramer’s lab. 
Fly lines expressing transgenic RNAi encoding inverted repeats for the CG4050 gene 
(33248 and 110199, here referred to as UAS-tmtc3-IR1 and UAS-tmtc3-IR2, respectively) and 
the appropriate genetic background control lines (60000 and 60100, respectively) were obtained 
from the Vienna Drosophila Resource Center (Vienna, Austria). elav-Gal4; UAS-dcr2 was a gift 
from A. Schenck. UAS-dcr2 (24644 and 24650), Rut-Gal4 (48667) UAS-mcD8::GFP (5130) and 
477-Gal4, UAS-mcD8::GFP (8746) were obtained from the Bloomington Drosophila Stock 
Center (Indiana, USA). For creation of transgenic flies with inducible expression of human 
TMTC3 (UAS-hTMTC3-1 and UAS-hTMTC3-2), TMTC3 cDNA (Internal ID 53914 of the 
hORFeome V5.1 of the CCSB Human Orfeome Collection and Entrez Gene ID 160418) was 
inserted into the pTW vector (Drosophila Genomics Resource Center, Bloomington, Indiana, 
USA) at the SPARC BioCentre at The Hospital for Sick Children (Toronto, Ontario, Canada) 
using standard Gateway cloning (Life Technologies, Carlsbad, CA). The resulting pTW-TMTC3 
plasmid was validated by restriction digest and Sanger sequencing of the insert and flanking 
regions. Creation of transgenic flies using the validated plasmid was performed by BestGene Inc. 
(California, USA) using standard procedures. 
 
5.3.13.3 RT-qPCR 
Quantitative Real-Time PCR (RT-qPCR) was performed to evaluate the potency of UAS-tmtc3-
IR1 and UAS-tmtc3-IR2. RNAi lines and the appropriate genetic background controls were 
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crossed the ubiquitous Actin-Gal4 driver line and third instar larvae were selected for analysis. 
RNA was extracted using the RNeasy Lipid Tissue Mini Kit (Quiagen). DNAse digestion was 
carried out using the RNAse-free DNAse Set (Qiagen) and cDNA was made using the iScript 
cDNA synthesis kit (BioRad). RT-qPCR was performed using the BioRad CFX 384 and the 
SYBRgreen mastermix (Biorad) with primers directed against CG4050, and the reference genes, 
betacop, eIF2B, and rpII140. All primer sets were validated for efficiency according to standard 
protocols.  CG4050 expression was compared in control and RNAi genotypes using a Student’s 
t-test. 
 
5.3.13.4 Bang sensitivity 
Bang sensitivity assays were performed using 5-9 day old male flies, raised at 29 C. The 
following genotypes were analyzed: elavGal4/+; UAS-dcr2/+ (Control), elavGal4/+;UAS-
dcr2/UAS-tmtc3-IR1, elavGal4/UAS-hTMTC3-1; UAS-dcr2/UAS-tmtc3-IR1, and elavGal4/UAS-
hTMTC3-2; UAS-dcr2/UAS-tmtc3-IR1. Male flies were collected in groups of ten to twelve and 
aged for several days. On the testing day 5-9 day old flies were transferred to empty food vials 
without the use of CO2. After a five-minute acclimatization period, the vials were vortexed at the 
highest setting for 20 seconds. Immediately after vortexing, the behavioural response was video 
recorded. Videos were observed for seizure-like responses, including complete immobilization 
on the back and uncontrollable movement. The time for each fly to right itself was recorded. 
Outliers (defined by righting times of greater than five standard deviations from the mean and 
accounting for 7 of 538 data points with equal distribution between genotypes) were removed 
and a Dunn’s test for multiple comparisons using the Benjamini-Hochberg correction was used 
to compare the average righting time of each genotype. The differences in the proportion of flies 
that demonstrated seizure-like behavior in each genotype were compared using a two-proportion 
z-test. 
 
5.3.13.5 Immunohistochemistry, image acquisition, and analysis 
In collaboration with Dr. Michael Poulter, we are studying the localization of Tmtc3 in rat brains. 
Rat brains: sections were washed with 1x PBS with 0.2% Triton X-100 three times for 5 
min and blocked in 10% goat serum and 10% donkey serum in 1x PBS with 0.025% Triton X-
100 and 1% bovine serum albumin (BSA) for 1h. The primary antibodies were diluted in 1x PBS 
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with 1% BSA and 0.025% Triton X-100. The sections incubated with primary antibodies, anti-
mouse VGat antibody (1:200, Synaptic Systems, 131011) and anti-rabbit TMTC3 (1:500, Abcam 
ab81473), for 24 h at 4°C. Sections were then washed two times with 1x PBS with 0.2% Triton 
X-100 for 5 min. They were incubated with secondary antibodies for 1h at room temperature; 
Alexa Fluor 647 donkey anti-rabbit IgG (A31573) and Alexa Fluor 488 donkey anti-mouse IgG 
antibody (Molecular Probes, A-21202) diluted 1:1000 in PBS with 1% BSA and 0.025% Triton 
X-100. Sections were then washed three times with PBS with 0.2% Triton X-100 for 10 min and 
incubated in 1% Sudan Black B (Sigma-Aldrich, S2380) in 70% ethanol for 5 min. Sections 
were rinsed twice with 70% ethanol for 1 min, followed by two 5 min washes with 1x PBS. 
Sections were mounted on glass slides with glass cover slips using Prolong Gold Antifade 
Reagent with DAPI mounting medium (Molecular Probes, P36935). Confocal images were taken 
on an Olympus IX 60 inverted microscope outfitted with a Perkin Elmer spinning disk confocal 
attachment with either a 60 × (Numerical aperture = 1.4) immersion oil, 40 × (N.A. = 0.75), 20 × 
(N.A. = 0.5), or 10 × (N.A. = 0.3) objective. The microscope was equipped with a Hamamatsu 
Orca ER CCD camera (1300 × 1030 pixels; pixel size 6.5 μm) and images were acquired using 
Volocity software. Each image shown represents a stack of 10 images spaced 0.2 μm apart in the 
z-plane, for each wavelength. 
Fly multidendritic neurons: The following genotypes were dissected as third instar larvae 
and fixed in 4% paraformaldehyde: 477-Gal4, UAS-mcD8::GFP/+ (control) and +/+; 477-Gal4, 
UAS-mcD8::GFP/UAS-tmtc3-IR1. Tissue was incubated in PBT (PBS with 0.3% triton-X 100) 
for 40 minutes and blocked in PBT supplemented with 5% normal goat serum. Larvae were 
incubated for two nights with anti-GFP (1:25, mouse, developmental studies hybridoma bank 
[DSHB]) and anti-mCD8 (1:100, rat, Life Technologies) primary antibodies diluted in PBT with 
5% NGS. After washing in PBT, larvae were incubated overnight with secondary antibodies 
anti-mouse-DyLight488 (1:400, goat, ThermoFisher) and anti-rat-DyLight488 (1:400, goat, 
ThermoFisher).  Dorsal type IV multidendritic neurons were imaged using a Zeiss LSM 510 
DUO Vario confocal microscope. The entire neuron was captured by combining several fields of 
view using the tile scan function. Image stacks were imported to Neuron Studio and traced 
(Wearne et al., 2005). Centrifugal edge labeling was performed and analyzed using the 
LMeasure program to quantify various features of the neurons (Scorcioni et al., 2008). A 
student’s t-test was used to determine if any significant differences were present between the 
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number of bifurcations, number of branches, number of tips, and overall length of the control and 
UAS-tmtc3-IR1 Type IV multidendritic neurons.  
Fly neuromuscular junction (NMJ): the genotypes elavGal4/+; UAS-dcr2/+ (control) and 
elavGal4/+; UASdcr2/UAS-tmtc3-IR1, were processed as described above, with the following 
changes. Primary antibodies used were: anti-HRP (1:500, rabbit, Jackson Immuno Research) and 
anti-brp (nc82, 1:15, mouse, DSHB). Secondary antibodies used were anti-rabbit-DyLight488 
(1:400, goat, ThermoFisher) and anti-mouse-DyLight594 (1:400, goat, ThermoFisher). To 
determine whether the knockdown of the tmtc3 gene had any effect on the morphology of the 
Drosophila NMJ, images of the NMJ were loaded into the open-source image analysis software, 
Fiji (Schindelin et al., 2012). Using the algorithm, ‘Drosophila_NMJ_Morphometrics’(Nijhof et 
al., 2016) features of the NMJ were quantified for analysis. A Mann-Whitney test for non-
parametric data was used to determine if any significant differences were present between the 
number of branches, active zones, and the overall length and area of the control and UAS-tmtc3-
IR1 NMJ.  
Fly mushroom bodies: The mushroom body specific rut-Gal4 driver line (Jenett et al., 
2012) was used to express tmtc3 RNAi constructs and GFP. Adult male fly brains were dissected 
from the genotypes UAS-dcr2/mcD8::GFP; rut-Gal4/UAS-tmtc3-IR1, and UAS-dcr2/mcD8GFP; 
rut-Gal4/+, and fixed for 1 hour in 4% paraformaldehyde. GFP labeled mushroom bodies were 
imaged using a Zeiss LSM 510 DUO Vario confocal microscope. 
 
5.3.14 Antibodies 
Anti-TMTC3 (1:100, Santa Cruz Biotechnology, Dallas, Texas) was used as a primary antibody. 
For a positive control, α-tubulin (1:10,000, Sigma-Aldrich, Saint Louis, Missouri) was used. 
Anti-mouse (1:10,000, Jackson ImmunoResearch Laboratories, Inc) was used as a secondary 
antibody. 
 
5.3.15 Statistics 
Statistics were performed as described in Chapter 2, subsection 2.3.19. 
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5.4 Results 
5.4.1 Clinical presentation of patients with nocturnal seizures with 
developmental delay 
The content in this section was compiled and transcribed by me and extensively reviewed by Dr. 
Siu, Dr. Rupar, and Dr. Hegele. 
Four siblings, three females and one male, were born to a healthy non-consanguineous 
Pakistani couple and are equally affected with nocturnal seizures and developmental delay 
(Figure 5.4.1). The history of all four sibs is quite similar (Table 5.4.1). They display 
developmental delay, crowding of the dentition with anterior overbite, and have a history of 
nocturnal seizures with an onset at two years of age. Nocturnal seizures in these children last 
from a few seconds up to one minute and consist of stiffening of the limbs, trembling, and rolling 
of the eyes. The frequency of seizures ranges between once daily to once or twice per month 
with the two younger children having more frequent seizures ranging from one to two per week. 
The children have no staring spells and have never had diurnal seizures. Furthermore, all four 
children displayed cognitive delays at about two years of age however, there has not been any 
regression of skills in any of the children. Some of the children have behavioral problems 
consisting of aggression, agitation, irritability, and self-harm. 
Although the clinical presentation observed in these children is quite consistent, there is 
variability in the severity of clinical features. Individual II-I (DOB, 1987) has been treated with 
anticonvulsants, carbamazepine and valproic acid, which have decreased the frequency of her 
seizures to only one-two times per year. Individual II-II (DOB, 1989) is the most cognitively 
functional of all four children but still quite delayed. His seizures have occurred only once every 
three years and he is not on any medications at this time. II-III (DOB, 1993) and II-IV (DOB, 
1994) seem to be more affected, displaying a lower level of cognitive functioning. Like her 
siblings, II-III presents with a constellation of nocturnal, probably complex partial seizures, 
intellectual disability, and behavior problems. Specifically, she awakes at night and cries, her 
arms are stiff and flexed, her hands are clenched and there may be a coarse tremor of the upper 
limbs lasting about a minute. Her seizures are more frequent occurring every six months with 
anticonvulsants, carbamazepine and nitrazepam. Her gross and fine motor functions are normal. 
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Her facial appearance is different from her sibs, and consists of midfacial hypoplasia with a very 
low nasal bridge, mild synophrys, and small anteverted nares. II-IV was a very active child 
however, she did display cognitive delay. Her nocturnal seizures occurred 1-2 times per week but 
have reduced to once every four months following treatment with valproic acid and nitrazepam. 
 
 
 
 
 
 
Figure 5.4.1 Pedigree with four children affected with nocturnal seizures with 
developmental delay. 
Squares depict males; circles depict females; affected individuals are shaded. 
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Table 5.4.1 Clinical features of patients with nocturnal seizures with ID. 
                                                            Affected individuals 
Clinical Features II-1 II-2 II-3  II-4 
Gestation   41 weeks  
Delivery complications   Breech, caesarean section Repeat caesarean section 
Sex F M F F 
Karyotype 46,XX 46,XY 46,XX 46,XX 
Birth length (cm)     
Birth weight (g)   3,855  
Age at last assessment (years) 30 28 23 21 
Head circumference (cm) 53.5 (2nd %ile) 55.8 (25-50th %ile) 53.7 (5th %ile) 53.3 (25th %ile) 
Height (cm) 164 (50th %ile) 168 (10th %ile) 150 (<3rd %ile) 159.5 (20th %ile) 
Weight (kg) 54.4 (25-50th %ile) 66.5 (25-50th %ile) 46.2 (4th %ile) 64.8 (60th %ile) 
Hand length (cm) 17 (25th %ile) 18.5 (75th %ile) 15.8 (3rd %ile) 17 (25th %ile) 
Middle finger length (cm) 7.2 (25th %ile) 7.8 (75th %ile) 6.8 (10th %ile) 6.8 (12th %ile) 
Ear length (cm) 5.5 (25th %ile) 6 (50th %ile) 5.8 (25-50th %ile) 5.2 (10th %ile) 
Inner canthal distance (cm) 3.4 (75th %ile) 3 (50th %ile) 3.3 (75th %ile) 3.3 (75th %ile) 
Outer canthal distance (cm) 8.3 (10th %ile) 8.3 (25rd %ile) 8.5 (25th %ile) 8.5 (25th %ile) 
Foot length (cm) 23.2 (25th %ile) 25.3 (25th %ile) 21.2 (3rd %ile) 23.3 (25-50th %ile) 
Associated diagnoses     
Age to walk 9 months < 1 year < 1 year < 1 year 
Age to talk 1 year < 1 year 4 years < 1 year 
Able to read + + - - 
Age at onset of nocturnal seizures 
(years) 
2 5 3 3 
Enamel hypoplasia + - + + 
Palate N N High arched N 
Anterior Overbite + - + + 
Medial deviation of mandibular 
dentition 
+ - - + 
Tongue hyperpigmentation +, single location - +, extensive - 
Flexion contracture of 5th PIP + - + + 
Hair follicle hyperpigmentation - + + - 
Lymphaedema - - + - 
3+ DTRs + + + + 
Hallux Valgus + + + + 
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5.4.2 Compound heterozygous TMTC3 variants in patients with 
nocturnal seizures with developmental delay 
As the family pedigree is suggestive of an autosomal recessive disorder (Figure 5.4.2 A), a 
recessive disease model was applied to determine the genetic cause of nocturnal seizures with 
developmental delay. Through whole exome sequencing, we observed two novel compound 
heterozygous variants in the affected individuals: c.432G>C, p.Arg71His; and c.2404insA, 
p.Leu728fs*6 in TMTC3, which encodes the transmembrane and tetratricopeptide repeat 
containing 3 protein. These alleles have not been reported in publically accessible databases of 
genomic variation, including NCBI dbSNP, 1000 Genomes, NHLBI Exome Variant Server, and 
the Exome Aggregation Consortium (ExAC). Overall, there are no homozygous TMTC3 protein 
truncating variants found in ExAC, which further supports candidate pathogenicity of the 
TMTC3 variants. 
TMTC3 contains 914 amino acids and is characterized by 9 transmembrane domains and 
9 tetratricopeptide repeat (TPR) domains (Figure 5.4.2 B). Multiple in silico analyses predicted 
the p.Arg71His mutation to be detrimental to protein function. This amino acid is conserved 
across many mammalian species, zebrafish, and Drosophila, which further supports the probable 
pathogenicity of this variant. The p.Leu728fs mutation is predicted to cause truncation of the 
protein leading to complete loss of the final three TPR domains (Figure 5.4.2 B). TPR domains 
are critical for protein interactions and are known to be functional only in groups of 3 or 4. These 
domains represent the main functional component of TMTC3, and therefore their loss is likely to 
have a dramatic impact on the protein. Furthermore, both TMTC3 variants segregated with 
disease status in the family (Figure 5.4.2 A). All four children are heterozygous for both variants, 
whereas the father is only heterozygous for p.Leu728fs and the mother is heterozygous for 
p.Arg71His. 
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Figure 5.4.2 Compound heterozygous TMTC3 variants in patients with nocturnal seizures 
with developmental delay. 
(A) Pedigree and electropherograms of the mutation identified in individuals with nocturnal 
seizures with developmental delay. Different coloured circles in pedigrees represent different 
mutations. (B) Protein structure and associated domains of TMTC3 with respective mutations 
identified. 
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5.4.3 Loss of TMTC3 in patients with nocturnal seizures and 
developmental delay 
To determine the effect of the TMTC3 variants on protein and transcript expression, we 
evaluated TMTC3 expression levels via immunoblotting and RT-PCR, respectively, 
using patient derived fibroblast cells. We observed complete loss of TMTC3 protein in 
fibroblast cells extracted from two affected individuals relative to both parents and a 
healthy TMTC3 wild type control (Figure 5.4.3 A). TMTC3 transcript expression was 
detected in patient cells but at significantly lower levels than both parents and a control 
(P<0.01) (Figure 5.4.3 B). Since the TMTC3 antibody used here is directed against the 
C-terminal of the protein, we cannot rule out the production of a truncated protein 
product from the p.Leu728fs*6 allele, however, our data does demonstrate that any 
protein product from the p.Arg71His missense mutation is degraded. These findings 
suggest that the observed TMTC3 mutations likely underlie nocturnal seizures and 
developmental delay. 
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Figure 5.4.3 Depleted TMTC3 protein and reduced transcript expression in cells of 
patients affected by nocturnal seizures with developmental delay. 
(A) Immunoblotting analysis showing depleted TMTC3 protein expression in fibroblast 
cells of patients. The upper blot shows protein expression of TMTC3, relative to TMTC3 
wild type (WT), TMTC3 p.Arg71His/+ (parent 1) and TMTC3 p.Leu728fs/+ (parent 2). 
The lower blot shows the constitutive expression of α-tubulin in both experiments. (B) 
RT-PCR show TMTC3 transcript expression in patients, both parents, and a healthy 
control. Bar graphs indicate means ± standard deviations. ** represents P-value <0.01. 
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5.4.4 Neuronal knockdown of Drosophila tmtc3 causes increased 
susceptibility to mechanically induced seizures 
Having observed loss of the TMTC3 protein in individuals with a neurodevelopmental 
disorder characterized by nocturnal seizures, we sought to understand the function of 
TMTC3 in neurons. The TMTC3 protein is highly conserved (60% amino acid similarity 
and 46% identity) and displays a one-to-one orthology with the Drosophila protein 
encoded by CG4050, here referred to as tmtc3. We tested two inducible RNAi transgenes 
encoding inverted repeats (IR) homologous to Drosophila tmtc3, UAS-tmtc3-IR1 and 
UAS-tmtc3-IR2. When RNAi expression was induced using the ubiquitous actin promoter 
there was a 70% reduction in tmtc3 mRNA with UAS-tmtc3-IR1 and only a 20% 
reduction with UAS-tmtc3-IR2 (Figure 5.4.4 A), therefore our analysis focuses on UAS-
tmtc3-IR1.  
We investigated the function of tmtc3 in flies using an established seizure 
paradigm known as bang sensitivity (Ganetzky and Wu, 1982; Howlett et al., 2013). In 
this assay seizure like behaviors are induced by mechanical disturbance (vortexing). The 
response is measured as the amount of time that individual flies are immobilized. To test 
for a role in mechanically induced seizures, we used flies with a neuron-specific RNAi 
knockdown of tmtc3 (elav-Gal4 + UAS-tmtc3-RNAi) and compared these to a genetic 
background control (elav-Gal4). Knockdown flies and controls were exposed to an initial 
round of vortexing (bang 1) followed by a second round (bang 2) after 10 minutes, and 
the time to recovery was recorded at both time points for each individual fly. Notably, the 
proportion of flies experiencing immobilization in response to vortexing was increased 
by more than 2-fold upon neuron specific knockdown of tmtc3 (Figure 5.4.4 B). 
Importantly we also tested two rescue genotypes that express human TMTC3 (UAS-
TMTC3-1 and UAS-TMTC3-2) in the presence of UAS-tmtc3-IR1. Expression of both 
human transgenes did cause a reduction in the proportion of flies immobilized in 
response to vortexing (Figure 5.4.4 B). This trend was statistically significant for UAS-
TMTC3-2 (bang 1: P=0.029; bang 2: P=0.004), and showed a trend approaching 
statistical significance for UAS-TMTC3-1 (bang 1: P=0.062; bang 2: P=0.12). Therefore, 
it appears that tmtc3 knockdown in neurons increases susceptibility to mechanically 
  
162 
induced seizure in Drosophila, and this phenotype can be recovered by transgenic rescue 
in a humanized fly. 
In addition to seizure susceptibility at the population level, we also examined the 
duration of immobilization in response to vortexing for each individual fly. On average, 
tmtc3 knockdown flies had a significantly longer recovery time after bang 2 when 
compared to controls (P=0.011), and showed a trend towards a longer recovery time after 
bang 1 (P=0.079) (Figure 5.4.4 C). The total average recovery time is very short, in the 
range of 1-2 seconds, because a large number of tested flies in all genotypes (70% to 
90%) were not immobilized at all in response to vortexing (Figure 5.4.4 B). When 
considering only flies that were immobilized, the average recovery time is in the range of 
8-12 seconds and there is no significant difference between tmtc3 knockdown flies, 
controls, and humanized rescue genotypes. In general, however, controls and humanized 
rescue genotypes all showed a distinct trend towards decreased recovery time from bang 
1 to bang 2, while knockdown flies showed no difference in recovery time between bang 
1 and 2 (Figure 5.4.4 D). Therefore, the overall difference in recovery time between 
tmtc3 knockdown flies, control flies, and humanized rescue flies (Figure 5.4.4 C) is not 
due to the severity of immobilization, but rather the higher proportion of knockdown flies 
that are immobilized in response to vortexing (Figure 5.4.4 B), and their lack of change in 
recovery time between bang 1 and bang 2 (Figure 5.4.4 D). Taken together, these results 
suggest that neuron-specific tmtc3 knockdown affects susceptibility to mechanically 
induced seizures, and the post-seizure recovery period between bang 1 and bang 2.   
To further elucidate the underlying mechanisms of the observed bang sensitivity 
phenotypes, we investigated whether the knockdown of Drosophila tmtc3 may cause 
changes in neuronal morphology. We identified no morphological differences upon 
examination of several different neuronal structures in tmtc3 knockdown flies; including 
gros mushroom body morphology (Figure 5.4.5 A and 5.4.5 B), dendrite arborization in 
type 4 multidendrite neurons (Figure 5.4.5 C-G), and synaptic morphology at the 
neuromuscular junction (Figure 5.4.5 H-L). These structures represent model systems for 
the analysis of synapse, dendrite, and axon morphogenesis, respectively. This suggests 
that Drosophila tmtc3 does not have a widespread role in the regulation of neuronal 
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morphogenesis, and likely influences the response to mechanical stimulation through a 
role in the regulation of neuronal physiology. 
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Figure 5.4.4. Tmtc3 deficiency confers susceptibility to seizures in Drosophila melanogaster.  
(A) Quantitative PCR results showing the average transcript levels of the CG4050 gene (±SEM) 
in flies expressing the UAS tmtc3-RNAi relative to their respective controls. UAS tmtc3-RNAi 1 
(M=0.34, SEM=0.06) showed significantly lower expression of the CG4050 gene than UAS 
tmtc3-RNAi 2 (M=0.82, SEM=0.11) as determined by a Student’s t-test (p<0.05). (B) Average 
time of seizure in affected flies. The UAS tmtc3-RNAi 1 flies showed an increase in average 
seizure time from bang 1 to bang 2 whereas the control and human rescue flies displayed an 
overall decrease in average seizure time from bang 1 to bang 2. (C) Average righting time 
(±SEM) for male flies of each genotype. The average righting time for the UAS tmtc3-RNAi 1 
knockdown during bang 2 was significantly longer than that of the control and UAS tmtc3-RNAi 
1 + UAS tmtc3 human 2 rescue (p=0.011 and p=0.014, respectively) as determined by a 
Benjamini-Hochberg corrected Dunn’s Test. The UAS tmtc3-RNAi 1 + UAS tmtc3 human 1 
genotype demonstrated a decreasing trend in average righting time during bang 2 when 
compared to the UAS tmtc3-RNAi 1 genotype (p=0.141). (D) Percentage of flies that 
demonstrated seizure-like behavior. For both bang 1 and bang 2, the UAS tmtc3-RNAi 1 
genotype had a significantly higher proportion of flies that demonstrated seizure-like behavior 
than the control and UAS tmtc3-RNAi1 + tmtc3 human 2 genotypes as determined by a two-
proportion z-test. The UAS tmtc3-RNAi 1 + UAS tmtc3 human 1 genotype demonstrated a 
trend-like decrease in seizure-like behavior when compared to the UAS tmtc3-RNAi 1 genotype 
(bang 1: p=0.062, bang 2: p=0.115). *P-value<0.05, **P-value<0.01. 
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Figure 5.4.5 Tmtc3 is not implicated in neuromorphogenesis.  
(A) Mushroom body of the control fly. (B) Mushroom body of UAS-tmtc3-IR1 expressed under 
the rutGal4 driver. Expression of UAS-tmtc3-IR1 does not affect the development of the 
mushroom body. (C) Image of a Type IV multidendritic neuron traced in Neuron Studio. (D) 
Average (±SEM) number of bifurcations in the Type IV multidendritic neuron. There is no 
significant difference between the number of bifurcations in the control flies and the UAS-tmtc3-
IR1 flies. (E) Average (±SEM) number of branches in the Type IV multidendritic neuron. There 
is no significant difference between the number of branches in the control flies and the UAS-
tmtc3-IR1 flies. (F) Average (±SEM) number of tips in the Type IV multidendritic neuron. There 
is no significant difference between the number of branches in the control flies and the UAS-
tmtc3-IR1 flies. (G) Average (±SEM) dendritic length of the Type IV multidendritic neuron. 
There is no significant difference between the average dendritic length in the control flies and the 
UAS-tmtc3-IR1 flies. (H) Image of the neuromuscular junction (NMJ) prepared by the 
Drosophila-_NMJ_Morphometrics FIJI algorithm. (I) Average (±SEM) number of branches in 
the NMJ. There is no significant difference between number of branches in the control flies and 
the UAS-tmtc3-IR1 flies. (J) Average (±SEM) area of the NMJ. There is no significant 
difference between the areas of control NMJ and the UAS-tmtc3-IR1 NMJ. (K) Average (±SEM) 
length of the NMJ. There is no significant difference between the lengths of control NMJ and the 
UAS-tmtc3-IR1 NMJ. (L) Average (±SEM) number of active zones in the NMJ. There is no 
difference in the number of active zones between the control NMJ and the UAS-tmtc3-IR1 NMJ.  
  
5.4.5 TMTC3 is localized at presynaptic terminals in rat brains 
TMTC3 is a predicted membrane protein containing 9 transmembrane domains and has been 
shown to partially co-localize with an endoplasmic reticulum marker in cultured odontoblasts 
(Racape et al., 2011). Considering that TMTC3 has a functional role in Drosophila neurons and 
appears to play a conserved role in seizure susceptibility in both flies and humans, we sought to 
investigate the localization of TMTC3 at synapses in the mammalian brain, using rat brain 
sections. We used an anti-TMTC3 antibody directed against the human protein, which is 
predicted to interact with rat Tmtc3 based on a 90% amino acid identity between the two 
proteins. In the rat brain TMTC3 was detectable in the piriform cortex and hypothalamus, but not 
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the hippocampus (Figure 5.4.6). We performed colocalization analysis with the vesicular GABA 
transporter (VGAT), a presynaptic marker for inhibitory synapses. VGAT and TMTC3 are 
colocalized in puncta surrounding cell bodies along the third ventricle (Figure 5.4.6 A-D) and in 
the piriform cortex (Figure 5.4.6 E).  These data show that TMTC3 is localized in a 
subpopulation of GABAergic synaptic terminals and boutons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
169 
 
Figure 5.4.6. TMTC3 co-localizes with vesicular GABA transporter (VGAT) in 
hypothalamus and piriform cortex of rat.  
(A) VGAT staining along the third ventricle. (B) TMTC3 immunoreactivity is shown. (C) 
TMTC3 and VGAT are co-localized in puncta (shown in white) surrounding cell bodies (20X 
mag scale bar is 20 μm). (D) high magnification co-localization of TMTC3/VGAT at 60 X 
magnification (scale bar is 10 μm). (E) TMTC3/VGAT co-localize around cell bodies in layer II 
and III of the piriform cortex. 
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5.5 Discussion 
Here, we provide evidence that disruption of the TMTC3 gene causes a neurological 
disorder characterized by nocturnal seizures and ID. Previously, TMTC3 has not been 
implicated in any human disease and there is very limited knowledge about its function in 
the human, Drosophila, or rat nervous system. Here, we demonstrate a neuron specific 
role for tmtc3 in Drosophila seizure susceptibility, and show that Tmtc3 is localized at 
synapses in the rat brain. This data is in keeping with the current state of knowledge 
regarding the role of synaptic ion channels in the etiology of nocturnal epilepsy. 
Nocturnal seizures are most commonly described in the context of ADFLE and a 
spectrum of other disorders falling under the classification of FESD, which include 
Landau-Kleffner syndrome (LKS), continuous spike and waves during slow-wave sleep 
syndrome (CSWSS), and Rolandic epilepsy (Bazil, 2004). Our current knowledge 
indicates that these disorders are caused primarily by dominant heterozygous inherited or 
de novo mutations in components of gated synaptic ion channels (Aridon et al., 2006; De 
Fusco et al., 2000; Steinlein et al., 1995). Here, we describe an autosomal recessive 
inheritance pattern for nocturnal seizures resulting in loss of the TMTC3 protein. The 
identified variants have not been reported in any publicly accessible database of genetic 
variation and our whole exome analysis did not reveal any other plausible candidate 
genetic variants in the four affected siblings. The ExAC database does not report a single 
example of homozygous loss of function or damaging missense mutations in TMTC3, 
indicating that disruption of the TMTC3 protein is likely to be detrimental to cell 
function. Together, these data suggest that we have identified a novel, rare, autosomal 
recessive disorder characterized by nocturnal epilepsy and ID. 
In addition to the compelling genetic and molecular evidence, we have 
functionally implicated TMTC3 in seizure susceptibility in Drosophila. The “bang 
sensitivity” test employed here is a classic assay for mechanically induced seizure, 
characterized by immobilization in response to a strong mechanical stimulus (Song and 
Tanouye, 2008). Loss of Drosophila tmtc3 specifically in post-mitotic neurons nearly 
doubles the rate of immobilization in response to vortexing, suggesting that loss of tmtc3 
renders neurons susceptible to seizure. Here, we have created a humanized fly model and 
  
171 
demonstrated that fly seizure phenotypes resulting from tmtc3 knockdown can be 
eliminated by expression of a human TMTC3 transgene. Therefore, although the seizure 
paradigm employed here is not directly comparable to the human condition, we can 
conclude that the human protein is functionally relevant in the context of mechanically 
induced seizures in Drosophila. These data suggest that TMTC3 has an evolutionarily 
conserved role in the regulation of neuronal physiology and that disruption of this protein 
family leads to seizure susceptibility. 
 Genetic and functional studies have shown that disruption or dysregulation of 
synaptic ion channels is an important mechanism in the etiology of nocturnal seizures 
(Becchetti et al., 2015; Lemke et al., 2013; Lesca et al., 2013; Nobili et al., 2014; 
Venkateswaran et al., 2014). Here, we show that TMTC3 is localized at inhibitory 
GABAergic synapses in the hypothalamus and piriform cortex of the rat brain. 
Interestingly, the piriform cortex is predicted to play an important role in facilitating and 
amplifying seizures in focal epilepsy (Vaughan and Jackson, 2014). It is possible that 
TMTC3 is required at these inhibitory synapses in the piriform cortex to prevent 
uncontrolled neuronal excitation that is a hallmark of epilepsy, but its molecular role at 
the synapse remains unclear. TMTC3 contains 9 transmembrane domains, and 9 
tetratricopeptide (TPR) domains. TPR-domains mediate protein-protein interactions and 
are involved in a wide array of biological functions (D'Andrea and Regan, 2003). 
Interestingly, the TMTC3 paralogs, TMTC1 and TMTC2, have been predicted to 
act as adaptors that nucleate the formation of large protein complexes involved in the 
regulation of calcium transport across the ER membrane (Sunryd et al., 2014). Based on 
the similar domain structure seen in TMTC3, it is possible that this protein plays a similar 
role at the synapse, and that disruption of TMTC3 would affect neuronal physiology by 
disruption of normal ion transport mechanisms. This possibility is supported by protein-
protein interaction data for TMTC3 from several proteomic studies (Gupta et al., 2015; 
Hein et al., 2015; Huttlin et al., 2015; Rolland et al., 2014), which are annotated through 
the BioGRID database (Chatr-Aryamontri et al., 2015). Of the 21 TMTC3 interactors 
listed in BioGRID, six are involved in gated ion channel activity (CHRND, HTR3C, 
HTR3A, ZACN, GABRE, and SCN3B) and five are localized at the synapse (CHRND, 
HTR3A, NRG1, GABRE, and DAB1) (Annotations from PANTHER) (Mi et al., 2005). 
  
172 
Thus, in keeping with the known genetic etiology of nocturnal seizures, there is a body of 
evidence, including the protein localization demonstrated here, that supports a role for 
TMTC3 in the regulation of synaptic ion channels. 
 
5.6 Conclusion 
In summary, we have implicated loss of TMTC3 as novel cause of autosomal recessive 
nocturnal seizures and ID, and have revealed a previously unknown and conserved 
function for this family of proteins in seizure susceptibility. Our data, as well as publicly 
available proteomic data, support a role for TMTC3 in synaptic ion channel activity, 
providing a basis for further investigation of the role of this protein family in neuronal 
physiology. 
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Chapter 6 - The ONDRISeq panel: custom designed next 
generation sequencing of genes related to 
neurodegeneration as part of the Ontario Neurodegenerative 
Disease Research Initiative 
 
6 Study rationale 
The next two Chapters describe the application of next generation sequencing in 
identifying the genetic basis of complex diseases including familial and sporadic forms of 
neurological diseases. 
As described in Chapter 1, within ONDRI, ONDRI Genomics focuses on 
identifying genetic variants that may contribute to disease onset and progression. As a 
member of the ONDRI Genomics team, which is led by Dr. Hegele, I was directly 
involved in the development of the ONDRISeq panel, which is a custom designed next 
generation sequencing based on neurodegeneration genes specific to the ONDRI 
diseases. This included the development, optimization, and integration of ONDRISeq in 
the ONDRI study. Chapter 6 was prepared as an independent study to describe the 
methodologies used within ONDRI genomics and the manuscript: “The ONDRISeq 
panel: custom designed next generation sequencing of genes related to 
neurodegeneration” has been accepted for publication in npj Genomic Medicine. Also, 
the methods describing ONDRISeq have been successfully filed with the United States 
Patent and Trademark Office in 2016: ‘Neurodegeneration targeted resequencing panel’. 
Inventors: Michael Strong, John Robinson, Sali Farhan, Robert Hegele, and Tom 
Mikkelsen. United States Provisional Patent Application ID: 62/333,369. 
 
6.1 Overview 
The Ontario Neurodegenerative Disease Research Initiative (ONDRI) is a multimodal, 
multi-year, prospective observational cohort study to characterize five diseases: 1) 
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Alzheimer’s disease (AD) or amnestic single or multidomain mild cognitive impairment 
(aMCI) (AD/MCI); 2) amyotrophic lateral sclerosis (ALS); 3) frontotemporal dementia 
(FTD); 4) Parkinson’s disease (PD); and 5) vascular cognitive impairment (VCI). The 
ONDRI Genomics subgroup is range of genes associated with neurodegeneration for 
their contribution to each of these disease processes, and most specifically to the 
occurrence of neuropsychological dysfunction. We have developed a custom next 
generation sequencing based panel, ONDRISeq that targets 80 genes known to be 
associated with neurodegeneration. We processed DNA collected from 216 individuals 
diagnosed with one of the five diseases, on ONDRISeq. All runs were executed on a 
MiSeq and subjected to rigorous quality control assessments. We also independently 
validated a subset of the variant calls using NeuroX (a genome-wide array for 
neurodegenerative disorders), TaqMan allelic discrimination assay, or Sanger 
sequencing. ONDRISeq consistently generated high quality data and all targets were 
sufficiently covered with a mean coverage of 76x. We also observed 100% concordance 
for the variants identified via ONDRISeq and validated by other genomic technologies. 
We were successful in detecting known as well as novel rare variants in 72.2% of cases 
although not all variants are disease-causing. Using ONDRISeq, we also found that the 
APOE E4 allele had a frequency of 0.167 in these samples. Our optimized workflow 
highlights next generation sequencing as a robust tool in elucidating the genetic basis of 
neurodegenerative diseases by screening multiple candidate genes simultaneously. 
 
6.2 Introduction 
Dementia encompasses a heterogeneous group of neurodegenerative diseases 
characterized by a progressive decline in cognitive function, language deficiency, and in 
some cases, motor impairment and behavioural anomalies. Currently, dementia has a 
global prevalence of 47.5 million cases and an incidence of 7.7 million new cases 
annually (2008; 2015; Robinson et al., 2015). While today there are no direct treatments 
available to alter the progressive disease course, early diagnosis has been one of the best 
predictors of disease outcome (Hebert et al., 2013; Robinson et al., 2015). Further 
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understanding of the molecular basis of dementia can lead to earlier diagnosis and the 
eventual development of targeted and efficacious treatment modalities. 
Genetics is an important risk factor for neurodegenerative disease. Approximately 
5-10% of cases with neurodegenerative diseases are familial and can be attributed to 
variants in several genes (Guerreiro et al., 2014; Renton et al., 2014; Rohrer et al., 2015). 
However, it is likely we are underestimating the incidence of familial cases based on 
clinical ascertainment, as the death of pre-symptomatic individuals may be due to other 
medical or extra-health incidents prior to the development of the neurodegenerative 
syndrome. Furthermore, genetic testing is not universally recommended in the clinical 
management guidelines of neurodegenerative diseases (Goldman et al., 2011; Grimes et 
al., 2012; Jack et al., 2011; Miller et al., 2009a, b; Strong et al., 2009). As such, most 
neurologists, if they choose to pursue genetic testing, only screen for a small subset of 
genes and often choose to genotype their patients for highly penetrant and known variants 
rather than agnostically sequencing all neurodegenerative disease genes. Together, these 
common clinical ascertainments as well as the high costs associated with genetic testing 
skew the incidence rates to significantly less than what is perhaps biologically accurate. 
The five neurodegenerative disorders under study could partly be caused by single, rare, 
pathogenic variants (monogenic) or multiple, small effect variants acting synergistically 
to mediate disease expression (oligogenic). 
Advancements in next generation sequencing (NGS) have allowed for efficient 
genetic variant detection at reduced costs. Currently, there are three main types of NGS 
applications including: 1) whole genome sequencing (WGS); 2) whole exome sequencing 
(WES); and 3) targeted gene panels (Farhan and Hegele, 2014). WGS is an 
indiscriminate approach that evaluates the genetic information in an individual’s entire 
genome. In contrast, WES targets only the protein-coding regions of the genome as 
disease-associated variants are significantly over-represented in coding regions (Farhan 
and Hegele, 2014). Consequently, WES has been one of the most widely used NGS 
approaches, however it still presents with several challenges. First, the cost of WES with 
adequate coverage (i.e. minimum 30x) still remains high at approximately $700. This 
makes the cumulative cost for studies with a large sample size prohibitively expensive. 
Secondly, the amount of genetic variation generated from the exome is excessive and 
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often overwhelming for many researchers and more so for clinicians who may require the 
patient’s genetic diagnosis to determine if any genotype specific treatments are available. 
Thirdly, WES can generate secondary findings unrelated to the disease of interest, which 
should be reported to the patient’s primary healthcare provider, in accordance with the 
guidelines proposed by the American College of Medical Genetics (Richards et al., 
2015). Thus, in both a clinical and research application, WGS or WES data are still often 
reduced to focus on likely pathogenic disease specific loci. In contrast, the use of a 
targeted gene panel that is clinically focused on the genes underlying the disease(s) of 
interest, overcomes these issues that often arise when sifting through WGS and WES 
data.  
 
6.3 Materials and methods 
6.3.1 Design of ONDRISeq 
Using multiple databases, we catalogued the literature pertaining to neurodegeneration 
genetic studies. We surveyed 25 content experts (professors, scientists, and clinicians 
within ONDRI as well as my input) in molecular genetics of neurodegeneration, and used 
their consensus opinions to select 80 genes within the human genome that were involved 
in one or more of the five neurodegenerative disorders under study. Most genes were 
selected based on being implicated in neurodegeneration from human genetic studies; 
however, some of the genes were added based on pathway analysis. 
We designed a composition for detecting variants in the protein-coding regions of 
80 genes summing to 1,649 targets. The 80 genes selected have a total target size of 
972,388 base pairs. Using the NGS chemistry Nextera Rapid Custom Capture (Illumina, 
San Diego, CA), we designed a total of 14,510 target specific probes that are each ~80 
base pairs in length. For regions that were difficult to sequence, we incorporated 
additional probes to ensure sufficient coverage during sequencing thereby producing 
fewer false discoveries. Chromosome scaffold coordinates were obtained from the 
University of California Santa Cruz Genome Browser using the February 2009 
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GRCh37/hg19 genome build (19) and were submitted to the Illumina Online Design 
Studio (Illumina, San Diego, CA).
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Table 6.3.1 Genes associated with amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer’s disease, Parkinson’s 
disease, or vascular cognitive impairment as represented on the ONDRISeq targeted resequencing panel. 
 
Gene Chromosomal 
location 
Affected protein Associated phenotype Mode of inheritance OMIM numbers 
(locus, phenotype) 
Amyotrophic lateral sclerosis/frontotemporal dementia 
ALS2 2q33.1 Alsin ALS2 AR (HZ), juvenile onset 606352, 205100 
ANG 14q11.2 Angiogenin ALS9 ADm, late onset 105850, 611895 
ARHGEF28 5q13.2 Rho guanine nucleotide exchange 
factor 28 
ALS and FTD AR (HZ) and ADm, late onset 612790, PMID: 23286752 
(phenotype not updated 
on OMIM) 
ATXN2 12q24.12 Ataxin 2 ALS13 ADm, late onset 601517, 183090 
CENPV 17p11.2 Centromere protein V ALS Genetic association, late onset 608139, PMID: 22959728 
(phenotype not updated 
on OMIM) 
CHMP2B 3p11.2 CHMP family member 2B ALS17, FTD ADm, late onset 609512, 614696 
DAO 12q24.11 D-amino acid oxidase ALS, schizophrenia ADm, late onset 124050, 105400, 181500 
DCTN1 2p13.1 Dynactin 1 ALS, HMN7B, Perry syndrome ADm, late onset 601143, 105400, 607641, 
168605 
FIG4 6q21 FIG4 homolog, SAC1 lipid 
phosphatase domain containing 
ALS11, CMT disease, YV 
syndrome 
ADm, late onset; AR (HZ and CH), 
infantile onset; AR (HZ and CH), 
infantile onset 
609390, 612577, 611228, 
216340 
FUS 16p11.2 Fused in sarcoma ALS6, FTD, HET4 AR (HZ), ADm, late onset 137070, 608030, 614782 
GRN 17q21.31 Granulin precursor FTD, NCL ADm, late onset; AR (HZ), juvenile 
onset 
138945, 607485, 614706 
HNRNPA1 12q13.13 Heterogeneous nuclear 
ribonucleoprotein A1 
ALS20, inclusion body 
myopathy with early-onset 
Paget disease with/without FTD 
3 
ADm, late onset; ADm, early onset 164017, 615426, 615424 
HNRNPA2B1 7p15.2 Heterogeneous nuclear 
ribonucleoprotein A2/B1 
Inclusion body myopathy with 
early-onset Paget disease 
with/without FTD 2 
ADm, early onset 600124, 615422 
MAPT/STH 17q21.31 Microtubule-associated protein 
tau 
ALS, FTD with parkinsonism, 
PD, AD, Pick disease, 
supranuclear palsy, tauopathy 
ADm, late and early onset 157140, 105400, 600274, 
168600, 104300, 172700, 
601104, 260540 
NEFH 22q12.2 Neurofilament protein, heavy ALS1 ADm, late onset 162230, 105400 
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polypeptide 
OPTN 10p13 Optineurin ALS12, glaucoma AR (HZ) and AD, early onset 602432, 613435, 606657 
PFN1 17p13.2 Profilin 1 ALS18 ADm, earlier onset 176610, 614808 
PNPLA6 19p13.2 Patatin-like phospholipase 
domain-containing protein 6 
Spastic paraplegia, Boucher-
Neuhauser syndrome 
AR (HZ and CH), early onset  603197, 612020, 215470 
PRPH 12q13.12 Peripherin ALS1 ADm, late onset 170710, 105400 
SETX 9q34.13 Senataxin ALS4, spinocerebellar ataxia 1 ADm and AR, juvenile onset 608465, 602433, 606002 
SIGMAR1 9p13.3 Sigma nonopioid intracellular 
receptor 1 
ALS16, FTD AR (HZ); ADm, early onset 601978, 614373, 105550 
SOD1 21q22.11 Superoxide dismutase 1 ALS1 AR (HZ and CH), ADm, age of onset 
varies from 6-94 years old 
147450, 105400 
SQSTM1 5q35.3 Sequestosome 1 Paget disease of bone ADm, late onset 601530, 167250 
TAF15 17q12 TAF15 RNA polymerase II, 
TATA box binding protein 
associated factor 
Chondrosarcoma  601574, 612237 
TARDBP 1p36.22 Tar DNA-binding protein ALS10, FTD ADm, late onset 605078, 612069 
UBQLN2 Xp11.21 Ubiquilin 2 ALS15, FTD X-linked, juvenile and late onset 300264, 300857 
UNC13A 19p13.11 Unc-13 homolog A (C. elegans) ALS Genetic association, late onset 609894, PMID: 22921269 
(phenotype not updated 
on OMIM) 
VAPB 20q13.33 Vesicle-associated membrane 
protein (VAMP)-associated 
protein B and C 
ALS, spinal muscular atrophy 
(Finkel type) 
ADm, early and late onset 605704, 608627, 182980 
VCP 9p13.3 Valosin-containing protein ALS14, FTD, inclusion body 
myopathy with early-onset 
Paget disease with/without  
FTD 1 
 
ADm, early onset 601023, 613954, 167320 
Alzheimer’s disease/mild cognitive impairment 
ABCA7 19p13.3 ATP-binding cassette, subfamily 
a, member 7 
AD Genetic association, late onset 605414, 104300 
APOE 19q13.32 Apolipoprotein E AD2, lipoprotein 
glomerulopathy, sea-blue 
hystiocyte disease, macular 
degeneration 
ACD, ADm, AR (HZ and CH), late 
onset 
107741, 104310, 611771, 
269600, 603075 
APP 21q21.3 Amyloid beta A4 precursor 
protein 
AD 1, cerebral amyloid 
angiopathy 
ADm and AR (HZ), early and late 
onset 
104760, 104300, 605714 
BIN1 2q14.3 Bridging integrator 1 AD Genetic association, late onset 601248, PMID: 25365775 
(phenotype not updated 
on OMIM) 
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CD2AP 6p12.3 CD2-associated protein AD Genetic association, late onset 604241, PMID: 25092125 
(phenotype not updated 
on OMIM) 
CD33 19q13.41 CD33 antigen AD Genetic association, late onset 159590, PMID: 23982747 
(phenotype not updated 
on OMIM) 
CLU 8p21.1 Clusterin AD Genetic association, late onset 185430, PMID: 25189118 
(phenotype not updated 
on OMIM) 
CR1 1q32.2 Complement component  
receptor 1 
AD Genetic association, late onset 120620,  PMID: 
25022885 (phenotype not 
updated on OMIM) 
CSF1R  5q32 Colony-stimulating factor 1 
receptor 
HDLS with dementia ADm, early and late onset 164770, 221820 
DNMT1  19p13.2 DNA methyltransferase 1 HSN1E with dementia ADm, early onset dementia 126375, 614116 
ITM2B 13q14.2 Integral membrane protein 2B Dementia ADm, early and late onset 603904, 176500, 117300 
MS4A4E 11q12.2 Membrane-spanning 4-domains, 
subfamily A, member 4E 
AD Genetic association, late onset 608401, PMID: 21460840 
(phenotype not updated 
on OMIM) 
MS4A6A 11q12.2 Membrane-spanning 4-domains, 
subfamily A, member 6A 
AD Genetic association, late onset 606548, PMID: 21460840 
(phenotype not updated 
on OMIM) 
PICALM 11q14.2 Phosphatidylinositol-binding 
clathrin assembly protein 
AD Genetic association, late onset 603025, PMID: 24613704 
(phenotype not updated 
on OMIM) 
PLD3 19q13.2 Phospholipase D family,  
member 3 
AD19 Genetic association, late onset 615698, 615711 
PSEN1 14q24.2 Presenilin 1 AD3, dilated cardiomyopathy, 
FTD, Pick disease, acne inversa 
ADm, early onset 104311, 607822, 613694, 
600274, 172700, 613737 
PRNP  20p13 Prion protein Dementia ADm, early onset 176640, 606688 
PSEN2 1q32.13 Presenilin 2 AD4, dilated cardiomyopathy ADm, early onset 600759, 606889, 613697 
SORL1 11q24.1 Sortilin-related receptor AD  ADm, combined gene burden, late 
onset 
602005, 104300; PMID: 
25382023 (phenotype not 
updated on OMIM) 
TREM2 6p21.1 Triggering receptor expressed on 
myeloid cells 2 
AD Nasu-Hakola disease 
(dementia and psychotic 
symptoms) 
Genetic association, late onset 605086, PMID: 25596843 
(phenotype not updated 
on OMIM), 221770 
TYROBP 19q13.12 Tyro protein tyrosine kinase-
binding protein 
Nasu-Hakola disease (dementia 
and psychotic symptoms) 
AR (HZ), juvenile onset 604142, 221770 
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Parkinson’s disease 
ADH1C 4q23 Alcohol dehydrogenase 1C, 
gamma polypeptide 
PD, alcohol dependence 
protection 
Genetic association, late onset 103730, 168600, 103780 
ATP13A2 
(PARK9) 
1p36.13 ATPase, type 13A2 PD, ceroid lipofuscinosis, 
dementia 
Genetic association, early onset and 
late onset 
610513, 606693 
DNAJC13 3q22.1 DNAJ/HSP40 homolog, 
subfamily C, member 13 
PD ADm, late onset  614334, PMID: 25330418 
(phenotype not updated 
on OMIM) 
EIF4G1 3q27.1 Eukaryotic translation initiation 
factor 4-gamma 
PD18 ADm, late onset 600495, 614251 
FBXO7 22q12.3 F-box only protein 7 PD15 AR (HZ and CH), early onset 605648, 260300 
GAK 4p16.3 Cyclin G-associated kinase PD Genetic association, late onset 602052, PMID: 21258085 
(phenotype not updated 
on OMIM) 
GCH1 14q22.2 GTP cyclohydrolase I PD, dystonia Genetic association, early onset 600225, 128230 
GIGYF2 2q37.1 GRB10-interacting GYP protein 2 PD11 Genetic association, early and late 
onset 
612003, 607688 
HTRA2 2p13.1 HTRA serine peptidase 2 PD13 ADm and genetic association, early 
and late onset 
606441, 610297 
LRRK2 12q12 Leucine-rich repeat kinase 2 PD8 ADm and genetic association, early 
and late onset 
609007, 607060 
MC1R 16q24.3 Melanocortin 1 receptor PD; melanoma, UV induced 
skin damage 
Genetic association, late onset 155555, 613099, 266300, 
168600 
NR4A2 2q24.1 Nuclear receptor subfamily 4, 
group A, member 2 
PD Genetic association, late onset 601828, 168600 
PANK2 20p13 Pantothenate kinase 2 Neurodegeneration AR (HZ and CH), early onset 606157, 234200 
PARK2 (PRKN) 6q26 Parkin PD2 AR (HZ and CH), juvenile onset; 
heterozygotes have late onset 
602544, 600116 
PARK7(DJ1) 1p36.23 Oncogene DJ1 PD7 AR (HZ and CH), early onset 602533, 606324 
PARL 3q27.1 Presenilin-associated rhomboid-
like protein 
PD (based on biological 
mechanisms, no linkage 
confirmed) 
NA 607858, PMID: 21355049 
(phenotype not updated 
on OMIM) 
PINK1 1p36.12 Pten-induced putative kinase 1 PD6 AR (HZ and CH), ADm, early onset 608309, 605909 
PLA2G6 22q13.1 Phospholipase A2, group VI PD14, NBIA2A, NBIA2B AR (HZ and CH), early and late onset 603604, 612953, 256600, 
610217 
PM20D1 1q32 Peptidase M20 domain  
containing 1 
PD16 Genetic association, late onset Locus ID not available on 
OMIM ,613164 
RAB7L1 
 
1q32.1 RAB7-like 1 PD Genetic association, late onset 603949, PMID: 25040112  
(phenotype not updated 
on OMIM) 
  
185 
SNCA 4q22.1 Alpha-synuclein PD1, PD4, LBD ADm, early onset 163890, 168601, 605543, 
127750 
UCHL1 4p13 Ubiquitin carboxyl-terminal 
esterase L1  
PD5, neurodegeneration with 
optic atrophy 
ADm, AR (HZ), juvenile-onset 191342, 613643, 615491 
VPS35 16q11.2 Vacuolar protein sorting 35  PD17 ADm, early and late onset 601501, 614203 
 
Vascular cognitive impairment 
ABCC6 16p13.11 ATP-binding cassette, subfamily 
C, member 6 
Arterial calcification; 
pseudoxanthoma elasticum; 
pseudoxanthoma elasticum 
forme fruste 
AR (HZ), infantile onset; AR; ADm 603234, 614473, 264800, 
177850 
COL4A1 13q34 Collagen type IV, alpha-1 Angiopathy, brain small vessel 
disease, porencephaly 1, 
intracerebral haemorrhage 
susceptibility 
ADm, infantile onset 120130, 611773, 607595, 
175780, 614519 
COL4A2 13q34 Collagen type IV, alpha-2 Porencephaly 2, intracerebral 
haemorrhage susceptibility 
ADm, infantile onset 120090, 614483, 614519 
HTRA1 10q26.13 HTRA serine peptidase 1 CARASIL syndrome, macular 
degeneration 
AR (HZ), early onset 602194, 600142, 610149 
NOTCH3 19p13.12 Notch homology protein 3 Infantile myofibromatosis 2, 
CADASIL 
ADm, early onset 600276, 615293, 125310 
SAMHD1 20q11.23 SAM domain and HD domain 1  Aicardi-Goutieres syndrome 5, 
Chilblain lupus 2 
AR (HZ and CH), AD, infantile onset 606754, 612954, 614415 
TREX1 3p21.31 3-prime repair exonuclease 1 Aicardi-Goutieres syndrome 1, 
Chilblain lupus,  
Vasculopathy, retinal, with 
cerebral leukodystrophy 
AR (HZ and CH), juvenile onset, AD, 
AD 
606609, 225750, 610448, 
192315 
      
Abbreviations are as follows: ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; HMN7B, neuropathy, distal 
hereditary motor, type VIIB; CMT disease, Charcot-Marie-Tooth disease; YV syndrome, Yunis-Varon syndrome; HET4, hereditary 
essential tremor, 4; NCL, neuronal ceroid-lipofuscinoses; PD, Parkinson’s disease; AD, Alzheimer’s disease; HDLS, 
leukoencephalopathy, diffuse hereditary, with spheroids; HSN1E, hereditary sensory neuropathy type 1E; NBIA2A, 
neurodegeneration with brain iron accumulation 2A; NBIA2B, neurodegeneration with brain iron accumulation 2B; LBD, Lewy body 
dementia; CARASIL syndrome, cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy; 
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CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; AR, autosomal recessive; 
HZ, homozygous; ADm, autosomal dominant; CH, compound heterozygous; ACD, autosomal co-dominant; OMIM, Online 
Mendelian Inheritance in Man; PMID, PubMed identification. Age of onset was classified as ‘late onset’ if greater than 65 years of 
age.
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6.3.2 Sample collection and DNA isolation 
The following steps were completed by Adam McIntyre with assistance from Allison 
Dilliott at the Hegele lab. 
Blood samples were collected from 216 subjects following appropriate and 
informed consent in accordance with the Research Ethics Board at Parkwood Hospital 
(London, Ontario, Canada); London Health Sciences Centre (London, Ontario, Canada); 
Sunnybrook Health Sciences Centre (Toronto, Ontario, Canada); University Health 
Network-Toronto Western Hospital (Toronto, Ontario, Canada); St. Michael's Hospital 
(Toronto, Ontario, Canada); Centre for Addiction and Mental Health (Toronto, Ontario, 
Canada); Baycrest Centre for Geriatric Care (Toronto, Ontario, Canada); Hamilton 
General Hospital (Hamilton, Ontario, Canada); McMaster (Hamilton, Ontario, Canada); 
Elizabeth Bruyère Hospital (Ottawa, Ontario, Canada); and The Ottawa Hospital 
(Ottawa, Ontario, Canada).  
All clinical diagnoses were supplied by each patient’s healthcare provider in 
accordance with the criteria from the general ONDRI protocol (Farhan et al., 2015; in 
revision). DNA was isolated from 4-8 ml of blood collected from every participant as 
described in Chapter 2, subsection 2.3.3. DNA quality and concentration were initially 
measured by NanoDrop-1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA, USA) and followed by subsequent serial dilutions to obtain ~5 ng/µl. Qubit 2.0 
fluorometer technology (Invitrogen, Carlsbad, CA) was then used to measure lower 
concentrations of DNA at a higher resolution. 
 
6.3.3 Library preparation 
The following steps were completed by Dr. Henian Cao. I performed the library 
preparation for three runs. 
Libraries were prepared in house using the Nextera Rapid Custom Capture 
Enrichment kit in accordance with manufacturer’s instructions. DNA samples were 
processed in sets of 12. DNA samples were fragmented followed by ligation of Nextera 
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Custom Enrichment Kit-specific adapters, amplified via PCR using unique sample 
barcodes, equimolar pooled, and hybridized to target probes (two cycles of 18 hr each). 
Samples were then amplified again to ensure specificity and greater DNA yield. A small 
aliquot of each library was analyzed using the Agilent 2100 BioAnalyzer (Agilent 
Technologies, Palo Alto, CA) to ensure adequate yield. The quantity and quality of the 
final libraries were measured using the KAPA quantitative PCR library quantification kit 
(KAPA Biosystems, Woburn, MA) using the ViiA 7 Real-Time PCR System (Thermo 
Fisher Scientific, Waltham, MA, USA). 
 
6.3.4 Next generation sequencing 
All samples were sequenced on the Illumina MiSeq Personal Genome Sequencer 
(Illumina, San Diego, CA, USA) using the MiSeq Reagent Kit v3 in accordance with 
manufacturer’s instructions. Indexed samples were pooled in equimolar ratios of 500 ng. 
Once combined, 16 pM of denatured pooled library was loaded on to a standard flow-cell 
on the Illumina MiSeq Personal Sequencer using 2×150 bp paired-end chemistry. Viral 
PhiX DNA was added as a positive control to ensure sequencer performance. Sequencing 
quality control was assessed using multiple parameters in Illumina MiSeq Reporter and 
visualized either in Illumina BaseSpace or locally using Illumina Sequencing Analysis 
Viewer. 
 
6.3.5 Sequence alignment 
After demultiplexing and adapter trimming, FASTQ files were aligned to the consensus 
human genome sequence build GRCh37/hg19 using a customized workflow within CLC 
Bio Genomics Workbench v6.5 (CLC Bio, Aarhus, Denmark). Software default settings 
of two built-in protocols were used to enhance read mapping including a local 
realignment for insertion-deletion variation and removal of duplicates introduced during 
PCR similar to Picard tools described in Chapter 2, subsection 2.3.9.  
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6.3.6 Variant calling 
A quality-based variant detection tool was used to call sequence variants according to a 
minimum 10-fold coverage and 20% read frequency. These thresholds, while low were 
selected to minimize false negatives by calling variants in low-coverage regions, which 
can later be validated using Sanger sequencing. These parameters however can produce a 
higher false positive call rate. In addition, for each ONDRI sample, target region 
summary statistics were generated and variant reports were exported in VCF files for 
subsequent analysis. Variants identified in target regions and within 10 bp bordering 
targets, were functionally annotated. 
 
6.3.7 Variant annotation 
Variant annotation was performed using ANNOVAR (Wang et al., 2010), a publically 
available functional annotation pipeline using the authors’ recommended guidelines and 
automated scripts. Additional databases such as ExAC (Lek et al., 2015), CADD (Kircher 
et al., 2014), HGMD (release 2015.1.), ClinVar (Landrum et al., 2014), and our own in 
house databases were integrated using customized scripts optimized by Eric Liang, a 
former undergraduate student in the Hegele lab. 
 
6.3.8 Variant classification and prioritization 
In general, I followed the guidelines for the interpretation of sequence variants proposed 
by the American College of Medical Genetics and Genomics and the Associated for 
Molecular Pathology (Richards et al., 2015). I screened for rare variants, which in were 
considered here to be variants with MAF <1% based on 1000 Genomes, NHLBI Exome 
Sequencing Project, and the ExAC databases. Among rare variants, I investigated 
whether there were any non-synonymous changes (nucleotide substitutions, insertions, or 
deletions) that resulted in missense, nonsense, splicing, or frameshift variation. Variants 
were also assessed in silico using a compilation of prediction programs: PolyPhen-2, 
SIFT, and CADD. HGMD and ClinVar were also integrated to determine the novelty or 
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recurrence of any genetic variation with a specific disease state. More specifically, I was 
interested in determining how many variants were previously deposited into disease 
databases. In the study, variants were marked as clinically relevant if they were rare, 
exerted non-synonymous changes, were previously observed in individuals with the same 
disease state, and had values consistent with ‘disease-causing’ based on prediction 
outcomes of PolyPhen-2, SIFT, and CADD, as recommended by ACMG Standards and 
Guidelines. Importantly, I grouped the variants according to the categories set forth by 
the ACMG Standards and Guidelines. Alternatively, variants with uncertain clinical 
significance were variants that were not reported in disease databases and observed in 
genes that are not typically causative of the disease in which the individual is diagnosed 
with, as represented on Table 6.3.1. Finally, all ONDRI samples were compared to each 
other to resolve whether any variants were observed in multiple individuals with the same 
disease diagnosis. I used this approach to also determine whether the same variant(s) was 
present in a large subset of ONDRI samples and therefore, was more likely to be an 
artifact of sequencing or alignment. 
 
6.3.9 APOE genotyping 
Furthermore, using the ONDRISeq, in addition to screening all samples for variants 
within APOE, we genotype all individuals for the APOE risk alleles rs429358(CT) and 
rs7412(CT). The combination of both individual alleles determines the APOE genotype 
and is known to be one of the major genetic risk factors for late onset AD (Bertram et al., 
2007). If there are no deletions at these loci, six potential APOE allele combinations are 
possible (2 alleles x 3 possible genotypes): 1) e2/e2; 2) e2/e3; 3) e2/e4; 4) e3/e3; 5) e3/e4; 
and 6) e4/e4, the latter of which is associated with up to an 11x increased risk in 
developing AD (Bertram et al., 2007; Ghebranious et al., 2005). 
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6.3.10 Variant validation 
To validate variants detected by ONDRISeq, we used three independent genotyping 
techniques, namely 1) NeuroX, which is an array of specific genotypes that confer risk to 
several neurodegenerative disease phenotypes (Ghani et al., 2015), 2) TaqMan allelic 
discrimination, and 3) Sanger sequencing. We processed 115 samples on the NeuroX and 
the TaqMan allelic discrimination assay and determined the concordance rate between 
each assay and ONDRISeq. We also randomly selected ~10% of variants to genotype 
using Sanger sequencing to determine the occurrence if any, of false positives. To test for 
true negatives, we used DNA from four individuals who were diagnosed with ALS. 
These individuals were previously tested for genetic variation within SOD1 with no 
variants identified. Similarly, we did not identify any variants in SOD1 using 
ONDRISeq. The NeuroX genotyping, TaqMan allelic discrimination assay, and the prior 
SOD1 testing of ALS samples was performed independently without knowledge of the 
variants generated using ONDRISeq. Furthermore, different lab personnel completed 
each validation step to ensure objectivity when evaluating concordance of results. 
 
6.3.10.1 Variant validation 1: NeuroX 
The following steps were conducted by Dr. Mahdi Ghani and Christine Sato from Dr. 
Rogaeva’s lab at the Tanz Institute for Neurodegenerative disease research at the 
University of Toronto. 
DNA samples were genotyped on NeuroX exome array (Illumina, San Diego, CA, 
USA) according to manufacturer’s instructions. NeuroX data were loaded to 
GenomeStudio (Illumina, San Diego, CA, USA) and all markers were clustered using the 
default Gen Call threshold (0.15); duplicate samples (N=2) revealed identical genotypes 
for all markers with available genotypes (N=268,399) (Ghani et al., 2015). Genotypes 
were converted to PLINK input files, and allele frequencies were calculated. In total, the 
115 samples revealed 71,714 polymorphic autosomal markers including 43,129 exonic 
and 216 splicing variants; among them 39,390 polymorphisms were non-synonymous, as 
well as 423 stop-gain and 32 stop-loss variants, according to ANNOVAR analyses 
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(Ghani et al., 2015). Average sample call rate was 99.6%, indicating high genotype 
quality. 
Next, 1,047 polymorphic markers, which included 252 exonic variants (229 
nonsynonymous and 1 splicing) within the 80 genes of the ONDRISeq targeted 
sequencing panel, were further processed by  removing all noncoding, synonymous,  and 
common variants with frequency minor allele frequency >1% in any database of 
1000Genomes (1000g2014oct_all), Exome Variant Server (esp6500si_all) and Exome 
Aggregation Consortium (ExAC). Variants overlapping segmental duplications were also 
excluded to avoid possible genotyping error. The remaining variants were filtered to 
those predicted to have a potential damaging effect on protein function, according to 
either PolyPhen-2 or SIFT analyses implemented in ANNOVAR. 
 
6.3.10.2 Variant validation 2: TaqMan allelic discrimination assay 
The following steps were completed by Allison Dilliott with guidance from Adam 
McIntyre and me. 
APOE SNP genotyping was performed using the TaqMan allelic discrimination 
assay for 115 samples on the 7900HT Fast Real-Time PCR System (Life Technologies, 
Foster City, CA, USA), and genotypes were identified using automated software (SDS 
2.3; Life Technologies). Two TaqMan assays were used to determine the APOE 
genotype, namely 1) C_3084793_20 (rs429358: APOE 112) and 2) C_904973_10 
(rs7412; APOE 158). 
 
6.3.10.3 Variant validation 3: Sanger sequencing 
Variants within DNA samples from the ONDRI study were also validated using Sanger 
sequencing as described in Chapter 2, subsection 2.3.12.1 and 2.3.12.2. 
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6.3.10.3.1 PCR 
For a complete list of the primers used with their respective PCR conditions, please see 
the table in Appendix B. 
 
6.3.10.3.2 Imaging, purifying, and sequencing of PCR products 
Imaging, purifying, and sequencing of PCR products were performed using the same 
procedures described in Chapter 2, subsection 2.3.12.2. 
 
6.3.10.4 Variant validation 4: SOD1 testing 
Screening for genetic variants in the SOD1 gene was performed by PCR followed by 
standard Sanger sequencing methods, on DNA from four individuals diagnosed with 
ALS. These steps were performed in other research laboratories prior to this study. Using 
ONDRISeq, we sequenced DNA from these four individuals to determine whether there 
were any SOD1 genetic variants. This step allows us to evaluate any true/false negative 
discoveries. 
 
6.3.11 C9orf72 genotyping 
The following steps were conducted by Dr. Ming Zhang and Christine Sato from Dr. 
Rogaeva’s lab at the Tanz Institute for Neurodegenerative disease research at the 
University of Toronto. 
 All participants were genotyped for the G4C2-expansion in C9orf72 using a two-
step method: 1) amplicon length analysis and 2) repeat-primed PCR. Experimental 
procedures are described elsewhere (Xi et al., 2012). 
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6.3.12 Statistical analysis 
The Student’s t-test was used to determine the significance of the difference among 
quantitative patient characteristics within the different neurodegenerative disease cohorts, 
where appropriate. Chi-square analyses were used to compare discrete traits and allele 
frequencies.  SAS version 9.2 was used for all statistical comparisons. 
 
6.4 Results 
6.4.1 Study subjects 
We recruited 216 participants affected with one of the following disorders: 1) AD/MCI, 
N=40; 2) ALS, N=22; 3) FTD, N=21; 4) PD, N=56; and 5) VCI, N=77 as part of the 
ONDRI study (Table 6.4.1). The average + standard deviation age of our participants was 
69.4±7.8 years. Not surprisingly, individuals diagnosed with ALS were the youngest in 
our cohort with an average age of 61.9±9.1 years. AD/MCI cases were the oldest patients 
(mean age of 74.5±6.6 years). The youngest participant is a 40 year old male diagnosed 
with ALS; the oldest are four 85 year old participants (3 males, 1 female); two diagnosed 
with AD/MCI and two with VCI. In general, sex ratios showed an over representation of 
males (male:female, 1.8:1.0), which was largely driven by the PD and VCI cases (3.3:1.0 
and 2.0:1.0, respectively) similar to the known sex distribution of these disorders in prior 
population studies. In contrast, in the AD/MCI, ALS, and FTD cohorts, the male:female 
ratios did not differ considerably (1.5:1.0, 1.2:1.0; and 0.9:1.0, respectively). The self-
reported ethnicity of the participants was predominantly Caucasian (82.3%) with some 
admixture. Overall, participants did not have a family history of neurodegenerative 
disease and were considered sporadic cases here as determined by participant recall, 
which was confirmed by the participant’s caregiver. Potential confounders such as age, 
sex, ethnicity, and family history did not affect our objectives or analysis.
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Table 6.4.1 Patient demographics. 
 
Disease ID Cases Mean age  
(years±SD) 
Min age 
(years) 
Max age 
(years) 
Male:Female Self-reported ethnicity 
as Caucasian (%) 
Family history of 
neurodegeneration? 
Total 216 69.4±7.8 40 85 140:76 82.3 Sporadic 
Alzheimer’s disease/mild cognitive 
impairment (AD/MCI) 
40 (18.5%) 74.5±6.6 59 85 24:16 93.3  
Amyotrophic lateral sclerosis (ALS) 22 (10.2%) 61.9±9.1 40 77 12:10 67.9  
Frontotemporal dementia (FTD) 21 (9.8%) 68.8±6.6 55 79 10:11 82.6  
Parkinson’s disease (PD) 56 (25.9%) 68.0±5.9 57 82 43:13 83.8  
Vascular cognitive impairment (VCI) 
 
77 (35.6%) 70.2±7.4 55 85 51:26 84.0  
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6.4.2 Quality assessment of ONDRISeq data 
In total, 9 independent runs of 24 samples were processed on ONDRISeq (Table 6.4.2). 
All targets across the 216 DNA samples were sufficiently covered (>30x; mean coverage 
76±18x) (Table 6.4.2). On average, 22.8 million of 29.8 million reads passed quality 
filter (PF) equating to 77%. With the exception of the poorest performance run, all 
ONDRISeq runs had reads PF of >80%.  Overall, 92.7% of all reads were mapped with 
95% and 78% of reads mapped in the best and poorest performing runs, respectively. All 
other ONDRISeq runs had >90% of reads mapped. Of the mapped reads, 87.1% had a 
Phred quality score of >30 representing a base call accuracy of 99.9%. Similarly, with the 
exception of the poorest performing run, all ONDRISeq runs had >85% of reads with 
scores >Q30. Although the poorest performing run produced less than adequate results 
compared to the other 8 ONDRISeq runs, 100% of its targets were covered >30x and 
were still analysed in our study. 
 Furthermore, an additional four DNA samples were extracted from brain tissue of 
deceased individuals. Post-autopsy, sections of the brain from all four individuals were 
frozen for over a decade. However, we were still able to generate adequate sequence 
calls. Among the four samples, 96% of reads were mapped and each sample had an 
average coverage of 71x. 
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Table 6.4.2. Quality control metrics for sequencing runs on ONDRISeq. 
 
Parameters Mean (± SD) Best performance Poorest performance 
Cluster density (x103/mm2) 1433.6 (±165) 1320 1835 
Target size (bp) 971,388 971,388 971,388 
Total reads (x106) 29.8 (±2.5) 29.1 35.6 
Reads PF (x106) 22.8 (±0.9) 24.1 22.1 
Reads PF (%) 77 (±5.8) 83 62 
Targets bases ≥30 (%) 92.0% 95.3 84.9 
Mean target coverage 76 (±18) NA NA 
Max target coverage 259 NA NA 
Min target coverage 
 
0 NA NA 
Mean of 9 runs. NA, not applicable.
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6.4.3 ONDRISeq is concordant with NeuroX, TaqMan allelic 
discrimination assay, and Sanger sequencing 
Three independent genomic techniques, NeuroX, a genome-wide exome array for 
neurodegenerative disorders, TaqMan allelic discrimination assays, and Sanger 
sequencing were used to assess the concordance with ONDRISeq in variant detection. 
The NeuroX array captures known polymorphic variants within the genes represented on 
ONDRISeq; therefore, we evaluated whether ONDRISeq could detect the same variants 
as NeuroX. In doing so, we processed 115 DNA samples and ONDRISeq detected all 122 
non-synonymous variants initially detected by NeuroX. Furthermore, Dr. Mahdi Ghani 
assessed rare and common, non-synonymous and synonymous variants called by the two 
platforms and observed 100% concordance between calls. Of note, there were variants 
detected by ONDRISeq but not included on the NeuroX array. However, there were no 
false negatives with ONDRISeq: all variants detected by NeuroX were also detected by 
ONDRISeq. Furthermore, we used a TaqMan allelic discrimination assay to genotype the 
same 115 DNA samples for APOE. Similarly, we observed 100% concordance between 
APOE genotyping calls on ONDRISeq and TaqMan. 
To explore the rate of false positive variant calls by ONDRISeq, we performed an 
independent concordance study for ~10% (20) of randomly selected variants from 
samples that were called as variants by ONDRISeq using Sanger sequencing. Similar 
with the results of NeuroX and TaqMan allelic discrimination assay, we observed 100% 
concordance in variants initially detected by ONDRISeq and validated via Sanger 
sequencing.  Thus, there were no false positives with ONDRISeq: all variants called as 
variants by ONDRISeq were also called as variants by validation using Sanger 
sequencing. 
 
6.4.4 Genetic variation in patients with neurodegenerative disease 
In these sections, I will discuss all genetic variation identified in patients within the study. 
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6.4.4.1 C9orf72 hexanucleotide expansion in patients with 
neurodegenerative disease 
All DNA samples were independently screened for a hexanucleotide expansion (G4C2) 
within C9orf72, a type of DNA variation that was not detectable by ONDRISeq or 
NeuroX. Of the 216 samples, only three (1.4%) carried an expansion within C9orf72, two 
were diagnosed with ALS and one with FTD (Table 6.4.4.1). 
 
6.4.4.2 Genetic variation identified in patients with neurodegenerative 
disease using ONDRISeq 
In total, only 60 out of 216 samples (27.8%) were completely free from rare potentially 
pathogenic variants (missense, nonsense, frameshift, in frame insertions and/or deletions, 
splicing, and minor allele frequency <1%) in ONDRISeq genes (Table 6.4.4.2.1). Of the 
remaining 156 cases, the AD/MCI and FTD cases had the highest variant rate based on 
ONDRISeq (>80%), although not necessarily disease causative. In the ALS and PD 
cases, we identified rare coding variants in 72.7% and 71.4% of individuals, respectively. 
The VCI disease cohort had the lowest number of variant carriers (65%) although still 
significantly higher than previous reports (Dwyer et al., 2013; Sun et al., 2015). While 76 
(48.7%) of 156 individuals carried one variant, 57 (36.5%) carried two variants, and 23 
(14.8%) carried three or more variants (Table 6.4.4.2.1). 
Among the 156 cases with potentially pathogenic variants, a total of 266 unique 
non-synonymous, rare variants (Table 6.4.4.2.2) were identified, including 107 (40.2%) 
within genes known to cause the disease with which the patient had been diagnosed (e.g. 
variation in an AD gene in an AD patient). An additional 159 variants (59.8%) were 
found in genes that were not previously associated with the respective clinical phenotype 
of the patient, but within a gene responsible for another disease (e.g. variation in FTD 
gene in an AD patient). Of the 266 variants, 62 (23.3%) were previously reported in 
HGMD and/or ClinVar; while 204 (76.7%) were absent from disease databases and were 
thus classified here as novel variants (Table 6.4.4.2.2). The majority of novel variants 
detected were observed in FTD and PD cases (88.9% and 82.6%, respectively); while the 
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majority of known variants were observed in ALS and VCI cases (35.7% and 28%, 
respectively) (Table 6.4.4.2.2). On average, we observed 4 rare variants (minor allele 
frequency <1%) per individual; and 1 variant per individual that met criteria set by 
ACMG and was considered here, as candidate variants. More rare variants were observed 
in individuals of African descent (16 rare variants per individual; 2 variants that met 
ACMG guidelines, per individual). Individuals of South Asian and Chinese origin on 
average carried 4.5 and 4 rare variants; and 2.5 and 2 variants meeting ACMG guidelines, 
respectively. These observations are likely due to ascertainment bias in the databases as 
they typically contain significantly more individuals of European descent than any other 
ethnic cohort. 
 
6.4.4.3 APOE genotypes in patients with neurodegenerative disease 
Importantly, ONDRISeq is able to provide genotypes for APOE, which is not available 
by NeuroX and other arrays. In 216 cases, we did not identify a single case of APOE 
e2/e2 (Table 6.4.4.1). We identified 26 (12%) individuals who had an APOE e2/e3 
genotype and 131 (60.6%) individuals who had an APOE e3/e3 genotype (Table 6.4.4.1). 
In total, 46 (21.3%) individuals were heterozygous for APOE e4 by possessing either an 
APOE e2/e4 or APOE e3/e4 genotype; while 13 (6.02%) individuals were homozygous 
for APOE e4 (Table 6.4.4.1). Not surprisingly, of the 13 APOE e4/e4 individuals, 7 
(53.8%) were diagnosed with AD (Table 6.4.4.1). 
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Table 6.4.4.1 Other risk variants identified in a cohort of 216 disease cases. 
 
Disease ID C9orf72 expansion 
carriers 
APOE e2/e2 
genotype 
APOE e2/e3 
genotype 
APOE e2/e4 
genotype 
APOE e3e/3 
genotype 
APOE e3/e4 
genotype 
APOE e4/e4 
genotype 
Total (n=216) 3 (1.40%) 0 (0.00%) 26 (12.0%) 1 (0.46%) 131 (60.6%) 45 (20.8%) 13 (6.02%) 
AD/MCI (n=40) 0 (0.00%) 0 (0.00%) 1 (2.50%) 0 (0.00%) 17 (42.5%) 15 (37.5%) 7 (17.5%) 
ALS (n=22) 2 (9.09%) 0 (0.00%) 4 (18.2%) 0 (0.00%) 12 (54.5%) 6 (27.3%) 0 (0.00%) 
FTD (n=21) 1 (4.76%) 0 (0.00%) 1 (4.76%) 0 (0.00%) 13 (61.9%) 5 (23.8%) 2 (9.52%) 
PD (n=56) 0 (0.00%) 0 (0.00%) 10 (17.9%) 1 (1.79%) 39 (69.6%) 5 (8.90%) 1 (1.79%) 
VCI (n=77) 0 (0.00%) 
 
0 (0.00%) 10 (13.0%) 0 (0.00%) 50 (64.9%) 14 (18.2%) 3 (3.90%) 
 
 
Table 6.4.4.2.1 Diagnostic yield of ONDRISeq in a cohort of 216 disease cases. 
 
Disease ID Individuals without 
any variants 
Individuals with 
variants 
Individuals with 
1 variant 
Individuals with 
2 variants 
Individuals with 
≥3 variants 
Total (n=216) 60 (27.8%) 156 (72.2%) 76 (48.7%) 57 (36.5%) 23 (14.8%) 
AD/MCI (n=40) 7 (17.5%) 33 (82.5%) 18 (54.5%) 10 (30.3%) 5 (15.2%) 
ALS (n=22) 6 (27.3%) 16 (72.7%) 6 (37.5%) 8 (50.0%) 2 (12.5%) 
FTD (n=21) 4 (19.0%) 17 (81.0%) 9 (52.9%) 7 (41.2%) 1 (5.9%) 
PD (n=56) 16 (28.6%) 40 (71.4%) 22 (55.0%) 13 (32.5%) 5 (12.5%) 
VCI (n=77) 27 (35.1%) 
 
50 (64.9%) 21 (42.0%) 19 (38.0%) 10 (20%) 
Variant criteria were based on non-synonymous, rare variants (<1% in ExAC). The variants in Table 6.4.4.1 and Table 6.4.4.2.1 are 
the same but tabulated differently. 
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Table 6.4.4.2.2 Variants identified in a cohort of 216 disease cases as detected by ONDRISeq. 
 
Disease ID Individuals with 
variants 
ONDRISeq 
variants 
Variants in disease 
gene as diagnosed 
Variants in other 
ONDRISeq disease genes 
Variants in 
disease databases 
Variants not found in 
disease databases 
Total (n=216) 156 (72.2%) 266 107 (40.2%) 159 (59.8%) 62 (23.3%) 204 (76.7%) 
AD/MCI (n=40) 33 (82.5%) 55 19 (34.5%) 36 (65.5%) 12 (21.8%) 43 (78.2%) 
ALS (n=22) 16 (72.7%) 28 17 (60.7%) 11 (39.2%) 10 (35.7%) 18 (64.3%) 
FTD (n=21) 17 (81.0%) 27 12 (44.4%) 15 (55.6%) 3 (11.1%) 24 (88.9%) 
PD (n=56) 40 (71.4%) 63 31 (49.2%) 32 (50.8%) 11 (17.5%) 52 (82.6%) 
VCI (n=77) 50 (64.9%) 93 28 (30.1%) 65 (69.9%) 26 (28.0%) 67 (72.0%) 
 
‘ONDRISeq variants refers to the total number of variants identified in each disease cohort or the total number of neurodegenerative disease cases. ‘Variants in 
disease gene as diagnosed’ refers to variants in genes known to cause the disease the patient is diagnosed with. ‘Variants in other ONDRI disease genes’ refers to 
variants identified in genes that are not typically associated with the disease the patient is diagnosed with as categorized on the ONDRISeq gene panel. ‘Variants 
in disease databases’ were calculated by dividing the number of variants reported in HGMD or ClinVar by the total variants value for each disease. Similarly, 
‘Variants not found in disease databases’ were classified as variants absent from HGMD or ClinVar. The variants in Table 5 and Table 6 are the same variants 
but tabulated differently.
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6.4.4.4 Case study: strong evidence of pathogenicity for APP p.Ala713Thr in 
AD patient 
We provide an example of a single neurodegenerative disease case to demonstrate the 
clinical utility of ONDRISeq and our complementary bioinformatics workflow. 
The patient is a 73 year old male diagnosed with AD. We identified a heterozygous 
variant, namely g.11248G>A (c.2137G>A), resulting in a missense variant p.Ala713Thr 
in APP, a gene known to be associated with familial autosomal dominant AD (Figure 1A) 
(Bertram et al., 2007). The introduction of a polar amino acid within beta APP domain 
(amino acid residues 675-713) is predicted to effect protein function according to 
multiple in silico analyses and generated a CADD score of 5.483 (Figure 6.4.4.2 A, B). 
The affected codon is also highly conserved in evolution within the APP protein when 
aligned to a set of diverged species within the animal kingdom (Figure 6.4.4.2 C). The 
variant is very rare with a minor allele frequency of 0.006% according to ExAC and is 
absent from the 1000 Genomes database and the National Heart, Lung, and Blood 
Institute Exome Variant Server. Furthermore, the patient is the only carrier of 
p.Ala713Thr in APP, among the 216 samples in our study. However, the variant has been 
previously observed in AD cases as it is reported in both HGMD and ClinVar databases 
and has been previously reported in multiple publications (Armstrong et al., 2004; 
Bernardi et al., 2009; Rossi et al., 2004). Indeed the variant had sufficient coverage of 
94x, nevertheless, we independently validated the presence of the variant using NeuroX 
and Sanger sequencing. The patient is also homozygous for APOE e3/e3.  
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Figure 6.4.4.4 APP variant in AD case 
(A) Schematic of the gene and variant discovery process in a neurodegenerative disease 
case. AD, Alzheimer’s disease, patient 1; *MAF was retrieved using ExAC database. (B) 
APP protein structure shown from N- to C-terminal, 1: amyloid A4 N-terminal heparin-
binding domain; 2: copper-binding of amyloid precursor; 3: Kunitz/Bovine pancreatic 
trypsin inhibitor domain; 4: E2 domain of amyloid precursor protein; 5: beta-amyloid 
peptide domain; 6: beta-amyloid precursor protein C-terminus domain. The gold star 
represents the location of the missense variant. (C) Multiple alignments demonstrate high 
conservation of wild type amino acid residue p.Ala713 (in bold; the variant residue 
p.Thr173 is shown in red) across a set of species-specific APP homologs. The asterisks 
below indicate fully conserved residues. (D) The ONDRISeq output showing 
heterozygosity at the position of the genetic variant, 21:27264108G>A. ONDRISeq 
output produced 94x coverage. (E) An electropherogram showing the DNA sequence 
analysis of APP from a patient diagnosed with Alzheimer’s disease. Our reported cDNA 
and amino acid positions are based on NM_000484.3 and NP_000475.1, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
  
206 
6.5 Discussion 
Herein, we describe a NGS based custom-designed resequencing panel to assess genes 
related to neurodegenerative diseases and small vessel disease. ONDRISeq is a rapid and 
economical diagnostic approach that screens 80 neurodegenerative genes in parallel. We 
have processed a total of 216 samples on ONDRISeq in 9 runs with 24 batched samples 
and evaluated each run using highly stringent quality assessment criteria. With 
ONDRISeq, we have consistently generated high quality data and when coupled with our 
bioinformatics workflow, we have been able to identify rare genetic variants in >70% of 
patients diagnosed with one of five diseases: diseases: AD/MCI, ALS, FTD, PD, or VCI. 
The ONDRISeq calls were highly reliable based on validation by three 
established genetic techniques: NeuroX, a rapid and economical genome-wide 
genotyping based neurodegeneration array, TaqMan allelic discrimination assay, and 
Sanger sequencing. While NeuroX is able to genotype >250,000 SNPs, the advantage of 
ONDRISeq is that it is sequencing based and able to detect novel variants (Ghani et al., 
2015). This way, we can agnostically screen individuals for any novel or known variants 
within the 80 neurodegenerative genes. Furthermore, while the TaqMan allelic 
discrimination assay is a rapid genotyping approach, specific probes have to be designed 
for all SNPs of interest becoming ultimately costly and inefficient. Also, unlike Sanger 
sequencing, ONDRISeq is rapid, efficient, and economical. Following library 
preparation, we are able to analyze the genetic data for 24 samples in less than 30 hours. 
We calculated the cost of sequencing 80 genes using standard Sanger sequencing. 
The total size of ONDRISeq is 971,388 base pairs, which can be processed via ~1,943 
PCR reactions (estimation of 500 base pairs per reaction). Had we processed the 
sequencing reactions in bulk, the cost per sample for Sanger sequencing would have been 
$38,860 CND per individual. Using NGS based approaches like WGS or WES with 
adequate coverage, the price still remains relatively high at $1,400 and $700 CND, 
respectively (prices based on The Centre for Applied Genomics, Ontario, CA; 
www.tcag.ca). Conversely, through strategic cost management we were able to bring our 
overall expenditures to a highly competitive price of $340 per sample—a reduction of 
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>99% in cost of Sanger sequencing; a >75% reduction relative to WGS, and >50% 
reduction relative to WES.  
Despite its efficiency and rapidity, there are still some limitations with 
ONDRISeq. First, it can only capture variants within the selected 80 genes, which 
prevents the discovery of novel disease loci. However, its custom design allows its 
genetic content to be altered to include novel genomic regions of interest. Second, 
ONDRISeq is unable to capture multi-nucleotide repeat expansions in genes, a limitation 
across all NGS platforms (Singleton, 2011). Many neurological diseases such as 
Huntington's disease, myotonic dystrophy, Friedreich's ataxia, Fragile X syndrome, and a 
subset of spinocerebellar ataxias arising due to multi-nucleotide repeat expansions cannot 
be detected with current NGS methodologies (La Spada et al., 1994; Stevens et al., 2013). 
More recently, a hexanucleotide (G4C2) repeat expansion in C9orf72 has been observed in 
familial and sporadic ALS and FTD cases, and very rarely in PD cases (DeJesus-
Hernandez et al., 2011; Renton et al., 2011b; Xi et al., 2012). Since its discovery in 2011, 
it has been one of the top investigated genes as both a diagnostic marker and a therapeutic 
target (DeJesus-Hernandez et al., 2011; Renton et al., 2011b). C9orf72 alleles can range 
from 2-20 repeats, which are common in the healthy population and are likely benign; 
20-few hundred, which confer risk; or >few hundred repeats and are pathogenic (Rohrer 
et al., 2015; Xi et al., 2015). As such, we independently examined all individuals in our 
cohort for the C9orf72 expansion using: 1) an amplicon length PCR analysis and 2) a 
repeat primed PCR analysis. In doing so, we identified that 1.4% of the participants were 
carriers of a C9orf72 repeat expansion, which is less than expected. However, when 
considering the ALS and FTD cohorts independently (n=22, n=21), C9orf72 expansion 
carriers make up 9.09% and 4.76% of the cohorts, respectively; and 6.98% jointly. These 
observations are consistent with C9of72 expansions explaining up to 10% of sporadic 
ALS cases with/without features of FTD (Renton et al., 2014). 
 
6.6 Conclusion 
Despite these limitations and the complex heterogeneity in the neurodegenerative 
diseases, we were able to capture rare variants with a probable, but not certain disease 
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association, based on allele frequency in the general population and the predictive score 
of multiple in silico software in 72.2% of cases. As the etiology of neurodegenerative 
diseases is often heterogeneous and multiple factors such as genetics, dietary intake, 
traumatic brain injury, or serious infections including toxin exposure, can confer risk to 
disease onset, we intend to functionally validate the genetic variants, especially the novel 
variants, to determine their effect size and contribution to disease. Of particular interest 
are variants in genes with multiple disease associations as they may provide clues on the 
potential for development of therapy to treat symptoms common across all five 
neurodegenerative diseases. 
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Chapter 7 - Oligogenic inheritance in families with 
amyotrophic lateral sclerosis and frontotemporal dementia 
 
7 Study rationale 
In addition to the neurodegeneration samples collected through ONDRI, we have 
clinically ascertained three independent families with amyotrophic lateral sclerosis (ALS) 
in which several family members had also been assessed for the presence of 
neuropsychological deficits. Family 1 includes individuals presenting with exclusively 
ALS. Family 2 includes individuals presenting with a spectrum of neurodegenerative 
phenotypes including ALS, frontotemporal dementia (FTD), myelopathy, Alzheimer’s 
disease (AD), and Parkinson’s disease (PD). Family 3 includes individuals presenting 
with ALS and a behavioural variant of FTD (bvFTD). 
Interestingly, all three families harbour a hexanucleotide repeat expansion in the 
C9orf72 gene. The expansion size among the three families did not differ yet the inter- 
and intrafamilial clinical presentation varied significantly. We sought to determine 
whether individuals with atypical disease presentation carried additional genetic 
variation. Specifically, I hypothesized that the variation in clinical presentation among 
the patients can be explained by additional genetic variants that are modifying the 
neurodegenerative syndrome. In addition to performing C9orf72 expansion testing, we 
also processed DNA of affected individuals on the ONDRISeq to potentially identify 
additional genetic variation using protocols described in Chapter 6. 
In this Chapter, I describe our approach of identifying the genetic variation that 
may in part explain the variability in phenotypes across the three families. We performed 
genetic analysis consisting of C9orf72 expansion, ATXN2 expansion, and ONDRISeq to 
identify whether there was any coding variation in neurodegeneration genes. 
Chapter 7 was prepared as an independent study: “Oligogenic inheritance in 
families with amyotrophic lateral sclerosis and frontotemporal dementia” and is currently 
submitted for publication (Farhan et al., 2016). 
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7.1 Overview 
We have ascertained three families affected with familial amyotrophic lateral sclerosis 
(ALS) in which the same hexanucleotide repeat expansion in the C9orf72 gene has been 
identified, but in which the clinical manifestations vary significantly. The inter- and 
intrafamilial disparity in clinical phenotype ranged from a much earlier age of onset, ALS 
combined with a frontotemporal dementia (FTD), or ALS with no additional features. 
Given this marked phenotypic heterogeneity, we screened for additional genetic 
variation. We performed genetic testing consisting of C9orf72 expansion, ATXN2 
expansion, and targeted next generation sequencing of 80 genes known to be associated 
with neurodegenerative diseases namely, ALS, FTD, Alzheimer’s disease, Parkinson’s 
disease, or vascular cognitive impairment. We observed the presence of an ATXN2 
expansion, ARHGEF28 p.Lys280Met>fs40Ter, or an OPTN p.Met468Arg in patients 
with a C9orf72 expansion and who exhibit an atypical disease course. These genetic 
profiles segregated with distinct clinical presentations in all three families and are likely 
modifying the ALS phenotype. We suggest that the variability in the clinical expression 
of C9orf72 expansion carriers is driven by the presence of these additional genetic 
mutations and provide further evidence for biologically relevant oligogenic inheritance in 
ALS. 
 
7.2 Introduction 
Based on both clinical and genetic studies, it has been proposed that amyotrophic lateral 
sclerosis (ALS) and frontotemporal dementia (FTD) are part of the same 
neurodegenerative disease continuum (Hardiman et al., 2011; Woolley and Strong, 2015). 
ALS is a progressive adult-onset neurodegenerative disorder in which the loss of both 
upper and lower motor neurons leads to a relentless weakening of limb, bulbar, and 
respiratory muscles. Death usually ensues within 3–5 years of onset (Renton et al., 2014). 
In contrast, FTD is characterized by progressive neuropsychological deficits, including 
cognitive and behavioural dysfunction. Survival is generally on the order of five to ten 
years (Rohrer et al., 2015).  
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There is increasing recognition that ALS and FTD can occur in the same 
individual and that both disorders are syndromic with multiple potential etiologies, many 
of which are genetic in origin (Hardy and Rogaeva, 2014; Ittner et al., 2015). In general, 
approximately 15% of ALS or FTD cases will progress to develop both phenotypes 
(Hardy and Rogaeva, 2014; Ittner et al., 2015). This observation underlies the current 
conceptualization that ALS and FTD are two points on a continuum of a single disorder. 
The discovery that a large proportion of ALS and FTD cases harbour a pathogenic 
hexanucleotide expansion in C9orf72 provides some support for this hypothesis 
(DeJesus-Hernandez et al., 2011; Renton et al., 2011). However, this does not explain the 
significant clinical heterogeneity among patients with similar C9orf72 expansion profiles 
(Rohrer et al., 2015). Families in which similar C9orf72 expansions are present, but in 
whom there is clinical heterogeneity both within families and between pedigrees, can 
provide insight into this question. However, until recently the finding of a single genetic 
variant led to a cessation of the search for additional genetic variants. This reductionist 
approach has generally constrained the ascertainment of the full extent of genetic 
mutations in ALS and FTD. However, when such an approach has been used, it has 
supported the concept of digenic (hereafter termed oligogenic) mutation inheritance 
leading to atypical disease presentation (summarized in Table 7.5) (Bury et al., 2015; 
Chio et al., 2012; Kaivorinne et al., 2014; King et al., 2013; Lashley et al., 2014; Pottier 
et al., 2015; Tarlarini et al., 2015; van Blitterswijk et al., 2012a; van Blitterswijk et al., 
2012b). 
 In this report, we describe three families that lie along this spectrum of ALS and 
FTD. While each family harbours a similar C9orf72 expansion, each family varies 
significantly with respect to their mutation load. We used an agnostic approach by 
determining the families’ C9orf72 expansion profiles in addition to sequencing all known 
ALS-associated disease genes. We found that all three harbour additional genetic variants 
and postulate that the presence of oligogenic inheritance accounts for phenotypic 
variability. 
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7.3 Materials and methods 
7.3.1 Ethics 
All study subjects provided written and informed consent to participate in our study. All 
clinical, cognitive, and molecular testing were conducted in accordance with protocols 
approved by the Research Ethics Board (105522) at Western University, London, 
Ontario, Canada. 
 
7.3.2 Sample collection clinical assessment 
We have ~25 years of clinical documentation on the history of the families and their 
affected relatives. All study participants and their affected relatives, were independently 
evaluated by multiple neurologists including Dr. Strong. In our study, Dr. Strong 
conducted a neurological evaluation including the Montreal Cognitive Assessment 
(MoCA) on all individuals. 
 
7.3.3 DNA isolation 
DNA was isolated from 34 participants using methods described in Chapter 2, subsection 
2.3.3. 
 
7.3.4 C9orf72 testing 
Study participants were tested for the C9orf72 expansion using: i) amplicon length 
analysis and ii) repeat-primed PCR. Additionally, post-autopsy brain sections were 
collected from deceased individuals and immunohistochemistry on brain sections was 
performed to verify the presence of the C9orf72 dipeptide repeat proteins. Our results 
were validated by three independent research laboratories, and some samples were 
validated using laboratories with clinical laboratory improvement amendments (CLIA) 
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certification. DNA from positive and negative control samples as well as deceased 
individuals were also tested for the C9orf72 expansion via Southern immunoblotting. 
 
7.3.4.1 Amplicon length analysis 
The G4C2 hexanucleotide repeat in C9orf72 was PCR amplified using one fluorescently 
labeled primer: 5’-FAM-CAAGGAGGGAAACAACCGCAGCC-3’ and a regular RVS 
primer: 5’-GCAGGCACCGCAACCGCAG-3’. The PCR reaction was performed using a 
mixture containing 1M betaine solution, 1% dimethylsulfoxide (DMSO) and 7-deaza-2-
deoxy GTP in substitution for dGTP in accordance with previously tested protocols with 
slight modifications (DeJesus-Hernandez et al., 2011; Renton et al., 2011). PCR 
conditions were as follows: (1) initial denaturation: 98°C for 5 min; (2) denaturation: 
97°C for 30 sec; annealing: 65-56°C for 30 sec; extension: 68°C for 1.5 min. This entire 
cycle was repeated 10x and with every cycle, the annealing temperature was decreased by 
1°C. Another set of cycles are programmed: (3) denaturation: 97°C for 30 sec; annealing: 
55°C for 30 sec; extension: 68°C for 1.5 min. This entire cycle was repeated 24x. A final 
extension for 68°C for 10 min was next. Samples were diluted 1:10 and analyzed using 
fragment length analysis on an ABI3730 DNA Analyzer. Allele identification and scoring 
was performed using GeneMapper v4.0 software. 
 
7.3.4.2 Repeat-primed PCR 
To assess the presence of an expanded (G4C2)n hexanucleotide repeat in C9orf72, we 
performed repeat primed PCR using three primers: (1) FAM-
TGTAAAACGACGGCCAGTCAAGGAGGGAAACAACCGCAGCC-3’; (2) 5’-
CAGGAAACAGCTATGACC-3’; and (3) 5’- 
CAGGAAACAGCTATGACCGGGCCCGCCCCGACCACGCCCCGGCCCCGGCCCC
GG-3’. Primer concentrations added were in a 2:1:2 ratio, respectively. The PCR reaction 
was performed in a mixture containing 1M betaine solution, 5% DMSO and 7-deaza-2-
deoxy GTP in substitution for dGTP. PCR conditions were as follows: (1) initial 
denaturation: 95°C for 5 min; (2) denaturation: 95°C for 30 sec; annealing: 70-56°C for 
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30 sec; extension: 72°C for 8 min. This entire cycle was repeated 8x with every cycle, the 
annealing temperature was decreased by 2°C. Another set of cycles are programmed: (3) 
denaturation: 95°C for 30 sec; annealing: 56°C for 30 sec; extension: 72°C for 8-16 min. 
This entire cycle was repeated 26x and with every cycle the extension time was increased 
by 20 sec. A final extension for 72°C for 7 min was next. PCR products were analyzed on 
an ABI3730 DNA Analyzer and visualized using GeneMapper software. 
 
7.3.4.3 Immunohistochemistry 
Dr. Tania Gendron and Dr. Leonard Petrucelli at the Mayo Clinic, Jacksonville, Florida, 
performed these procedures. 
To confirm that the hexanucleotide expansion of C9orf72 was pathogenic in the 
affected individuals, we immunostained cerebellar tissue from each case for poly(GP), 
poly(GA) or poly(GR) proteins. Five-micron thick cerebellar slices were cut from 
formalin-fixed, paraffin-embedded blocks and mounted on glass slides. After drying, 
slides were deparaffinized and rehydrated in xylene and alcohol washes before being 
steamed for 30 min in deionized water for antigen retrieval. All slides were processed on 
a Dako Autostainer with the Dako EnVision™ system and 3’3-diaminobenzidine 
chromogen. After staining with anti-GP (Rb5823; 1:5,000), anti-GA (Rb9880, 1:50,000) 
or anti-GR (Rb7810, 1:2,500), slides were counterstained with Lerner hematoxylin and 
coverslipped with Cytoseal permanent mounting media. Cerebellar sections were 
examined using an Olympus BX41 microscope and images captured with cellSens 
Standard 1.5 software.  
 
7.3.4.4 Southern immunoblotting 
In addition to verifying the results of fluorescent fragmental length analysis using 
protocols prepared by other research and clinical laboratories, we performed Southern 
immunoblotting on positive and negative control samples. We also performed Southern 
immunoblotting using DNA from frozen brain tissue of deceased individuals. 
Unfortunately, we did not have sufficient quantities of DNA from study subjects to 
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perform Southern immunoblotting. A 241 base pair digoxigenin (DIG)-labeled probe was 
made from genomic DNA (gDNA) of a healthy control by PCR using FWD primer: 5’-
AGAACAGGACAAGTTGCC-3’ and RVS primer: 5’-AACACACACCTCCTAAACC-
3’. The PCR DIG probe synthesis kit was used in accordance with manufacturer’s 
instructions (Sigma-Aldrich, St.Louis, MO, USA). A total of 10 μg of gDNA was 
digested with XbaI at 37 °C for ~20 hours and electrophoresed. DNA was transferred to a 
positively charged nylon membrane by capillary blotting and cross-linked by UV 
irradiation. Post prehybridization in DIG EasyHyb solution (Sigma-Aldrich) at 47°C for 
3h, hybridization was at 47°C overnight. The membranes were then washed in 2X 
standard sodium citrate (SSC), 0.1% sodium dodecyl sulfate (SDS) at room temperature 
for 5 min and in 0.1x SSC, 0.1% SDS at 68°C for 15 min each. An anti-DIG antibody 
(1:10,000; Sigma-Aldrich) in blocking solution was added for 30 mins at room 
temperature. Membranes were then washed using standard wash buffer. Detection of the 
hybridized probe DNA was achieved using the CDP-star chemiluminescent substrate and 
signals were visualized on LI-COR. 
 
7.3.5 ATXN2 expansion testing 
Study participants were screened for the ATXN2 CAG expansion using fluorescent 
fragment length analysis similar to the C9orf72 amplicon length analysis protocol. 
Initially, a laboratory with CLIA certification detected an ATXN2 expansion in gDNA of 
patient II-3 from family 2. We tested the other members of family 2: II-2, II-5, and III-5, 
using protocols developed at the Rogaeva lab. Dr. Ming Zhang performed these analyses 
at the Rogaeva lab. 
 
7.3.6 Next generation sequencing 
DNA of family 1, III-2 and III-5; family 2, II-3; and family 3, III-5 and III-7 were 
subjected to a next generation sequencing. All family members were screened for genetic 
variants identified in the index patients, using standard PCR and Sanger sequencing 
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protocols as described in subsequent sections. Samples were sequenced at the London 
Regional Genomics Centre on the Illumina MiSeq Personal Genome Sequencer 
(Illumina, San Diego, CA, USA) using the MiSeq Reagent Kit v3 in accordance with 
manufacturer’s instructions as described in Chapter 6, subsection 6.3.4. 
 
7.3.7 Sequence alignment 
Sequence alignment was performed as described in Chapter 6, subsection 6.3.5. 
 
7.3.8 Variant calling 
Variant calling was performed as described in Chapter 6, subsection 6.3.6. 
 
7.3.9 Variant annotation 
Variant annotation was performed as described in Chapter 6, subsection 6.3.7. 
 
7.3.10 Variant classification and prioritization 
Variant classification and prioritization were performed as described in Chapter 6, 
subsection 6.3.8. We previously identified ARHGEF28 p.Lys280Met>fs40Ter in patient 
III-5 in family 1. In addition, we identified OPTN p.Met468Arg in patient II-3 in family 2 
and patients III-5 and III-7 in family 3. 
 
7.3.11 Variant validation 
To determine whether ARHGEF28 p.Lys280Met>fs40Ter and OPTN p.Met468Arg 
segregated with disease status in the respective pedigree, we genotyped family members 
using standard Sanger sequencing methods as described in Chapter 2, subsection 2.3.12.1 
and 2.3.12.2. 
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7.3.11.1 PCR 
Forward and reverse primers for ARHGEF28 p.Lys280Met>fs40Ter are: 5’-
GGATCATTTTGCCAGTTGGA-3’ and 5’-TGATGCCTGCATTCTCTGAA-3’, 
respectively. Forward and reverse primers for OPTN p.Met468Arg are 5’-
CTGCTATCGGAATGTACCTGG-3’ and 5’-ATGCTGATGTGAGCTCTGGG-3’, 
respectively. The PCR conditions for both primer sets were as follows: initial 
denaturation at 95˚C for 5 minutes; 30 cycles of denaturation at 95˚C for 30 seconds; 
annealing at 60˚C for 30 seconds; extension 72˚C for 30 seconds and a final extension at 
72˚C for 7 minutes. 
 
7.3.11.2 Imaging, purifying, and sequencing of PCR products 
Imaging, purifying, and sequencing of PCR products were performed using the same 
procedures described in Chapter 2, subsection 2.3.12.2. 
 
7.4 Results 
7.4.1 Clinical description 
The content in this section was compiled and transcribed by me and extensively reviewed 
by Dr. Strong and Dr. Hegele. The table containing all genetic and clinical information 
on all individuals within the study can be found in Appendix C. 
In family 1, patient III-2 initially presented with left upper extremity weakness at 
age 60 and later developed features of bulbar dysfunction, diffuse limb wasting and 
weakness, and pathologically brisk reflexes. Given the multigenerational history of ALS 
in the family (I-1, II-2, and II-4), the clinical diagnosis was definite familial ALS using 
the El Escorial criteria (Brooks, 1994). The patient survived 4 years from the time of 
symptom onset. The post mortem neuropathology confirmed the diagnosis of ALS in the 
absence of frontotemporal lobar degeneration.   
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Her brothers, III-3 and III-5, were also diagnosed with definite ALS but initially 
presented at a much younger age of 47 and 49, respectively. On examination, III-3 
presented with bilateral upper extremity weakness as well as limb wasting. His total 
disease duration was 65.2 months). An autopsy was not conducted on III-3. Similar to III-
2, the first symptoms observed in III-5 were left upper extremity weakness. He later 
developed symptoms of bulbar dysfunction, limb wasting, and pyramidal weakness. The 
total disease duration was >86 months. We conducted neurological and cognitive 
examinations on the two remaining siblings, III-7 and III-9. Neither had any features 
suggesting motor neuron degeneration or dementia. Both individuals are much older (70 
and 63 years) than the average age for disease onset in their family, which may suggest 
that they are unlikely to develop ALS. To our knowledge, there is currently no single 
individual affected with ALS in the subsequent generation; however, all are younger than 
the age of onset of their affected parent. We have examined all members of generation IV 
and found no evidence of motor neuron disease or dementia (all members received 
MoCA scores within the normal range).  
Family 2 consists of individuals with multiple, distinct neurodegenerative 
phenotypes. Patient II-3 initially presented at age 53 with bulbar dysfunction and 
subsequently developed limb wasting, pyramidal weakness, and cognitive impairment 
(previously described in Strong et al, 1999). The total disease duration was 22.3 months. 
His brother, II-5 presents with a perplexing clinical syndrome. While some of his 
symptoms overlap with those of II-3, he does not meet the diagnostic criteria for ALS and 
has a communicating hydrocephalus, significant cervical spondolytic pathology and a 
previous history of head injury from a motor vehicle accident resulting in a loss of 
consciousness. He is currently 70 years of age and displays progressive cognitive decline 
with both short and long-term memory impairment. He is unable to recall people’s names 
and gets lost in familiar environments. He scored 10/30 on MoCA testing. He is currently 
wheelchair bound with significant spasticity. Their sister, II-7, was diagnosed during life 
with behavioral variant FTD (bvFTD) and at autopsy was found to also have motor 
neuron disease (MND). Their eldest sister, II-2, has no deficit on either neurological 
examination or on MoCA testing.   
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Family 3 is characterized by ALS (I-2, II-3, II-8, II-13), bvFTD and historical 
reports of dementia described as Alzheimer’s disease (II-4 and II-17), although there are 
no records that would allow differentiation of Alzheimer’s from FTD in these latter cases. 
At the age of 56, III-3 began displaying inappropriate behaviour consisting of apathy, 
agitation, reduced verbal output, poor financial judgement, sexual indiscretion, obsessive-
compulsive behaviour, and repetitive movements. Within two years, she also developed 
impairment in executive function with deficits in attention and concentration, language, 
visuospatial construction, memory and facial recognition. Dysarthria and dysphagia had 
become prominent. Her examination demonstrated ocular impersistence with preserved 
optokinetic nystagmus, prominent primitive reflexes, and a generalized loss of muscle 
bulk with diffuse, severe spasticity. Electrophysiological studies were unremarkable with 
the exception of an incidental median entrapment neuropathy. Within two years, she had 
become preservative, inattentive, whispered when speaking and, in addition to diffuse 
motor neuron dysfunction, had mild cogwheeling. She did not consent to further 
electrophysiological studies, and died at age 56 years. An autopsy was not performed.  
Her siblings, III-5 and III-7 had a very similar disease course. III-5, a 53 year old 
accountant, first developed difficulty with organizational skills, word finding difficulties, 
an inability to do the daily household banking, an increased appetite, and an obsessive 
behaviour with increasing stubbornness. Within 4 months, he had developed choking 
episodes, dysarthria and reduced speech volume. His clinical and electrophysiological 
examinations at that point were consistent with definite ALS. This was confirmed by 
neuropathological examination at the time of his death 16 months following initial 
symptom onset, as was evidence of a frontotemporal lobar degeneration. Case III-7 
presented with first episode psychosis at age 56. He began incessant smoking and became 
homeless. One year later he developed aspiration pneumonia and was placed on full 
ventilator support. His course thereafter was typical of ALS with complete anarthria, 
diffuse muscle wasting with fasciculations, pathologically brisk reflexes, and 
electrophysiological evidence of multisegmental acute and chronic motor unit 
remodelling. Neuropathological examination confirmed the presence of frontotemporal 
lobar degeneration with ALS including TDP-43 immunoreactive inclusions within 
cortical and spinal motor neurons.
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Figure 7.4.1. Pedigrees of three families affected with ALS or ALS-FTD. 
Family 1 is affected primarily with ALS without features of cognitive impairment. Family 2 is affected with mixed neurodegenerative 
phenotypes. Family 3 is affected with bvFTD and ALS. Small dashes above family members in the pedigrees indicate those 
individuals who were available for DNA analysis. Squares and circles denote male and female family members, respectively. 
Coloured symbols represent affected family members as described on the legend, and open symbols represent unaffected family 
members. Diagonal lines indicate deceased family members, and arrows indicate the proband(s) in each family. Coloured small circles 
within individuals represent their carrier status of genetic variants identified on the legend.
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7.4.2 Variants identified in patients with ALS 
Patients and participating family members were screened for a hexanucleotide (G4C2) 
expansion in C9orf72 using amplicon length analysis coupled with repeat-primed PCR as 
previously described (DeJesus-Hernandez et al., 2011; Xi et al., 2012). Positive and 
negative control samples as well as affected individuals with a C9orf72 expansion were 
also independently validated via Southern immunoblotting using a DIG labelled probe. 
C9orf72 genotypes are provided in supplementary table 1 as well as figures 3 and 4. In 
families 1, 2, and 3, we identified eight, three, and four C9orf72 expansion carriers, 
respectively. However, all expansions were less than 100 repeats and are within the 
‘uncertain clinical significance’ classification (Figure 7.4.1, Table 7.4.4). Of the carriers 
identified in family 1, two (III-2 and III-5) died with a diagnosis of ALS. It is unclear 
whether the other six carriers in family 1 (IV-2, IV-3, IV-16, IV-17, V-2 and V-3) are 
disease free or are currently pre-symptomatic as no neurologic abnormalities were 
observed when examined by a neurologist with expertise in ALS (Dr. Strong). Similarly 
in family 2, we identified three carriers (II-3, II-7, and III-6) who are also neurologically 
intact. II-3 and II-7 were diagnosed with ALS-FTD and are deceased. The third carrier, 
III-6 is the son of an ALS-FTD affected individual. In family 3, we identified four 
C9orf72 expansion carriers (III-3, III-5, III-7, and IV-5); three carriers were diagnosed 
initially with bvFTD, which manifested into bvFTD-ALS. The living carrier, IV-5, is 
currently unaffected or presymptomatic. 
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Figure 7.4.2.1 Genetic analyses of C9orf72 genotypes of representative individuals 
from each family. 
Results from fluorescent fragment length analyses. The presence of two individual peaks 
corresponds to non-C9orf72 expansion carriers. Repeat numbers are beside each peak and 
are calculated by subtracting 117 from the number determined using the horizontal axis. 
Single peaks represent either homozygosity or heterozygosity for the corresponding peak. 
Single peak profiles can also be indicative of a C9orf72 expansion that cannot be detected 
using this technique. Here, positive and negative controls are a C9orf72 expansion carrier 
and a non-C9orf72 expansion carrier, respectively. The other panels show a positive and 
negative C9orf72 expansion carrier in each family. All participants were evaluated and 
all results were repeated three times with the same findings across all three experiments. 
The vertical and horizontal axes represent fluorescent intensity and product size, 
respectively. 
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Figure 7.4.2.2 Genetic analyses of C9orf72 expansion profiles of representative 
individuals from each family. 
Results from fluorescent fragment analysis traces show the C9orf72 expansion profiles. 
The ‘saw-tooth’ slopping pattern is indicative of a C9orf72 expansion. Here, positive and 
negative controls are a C9orf72 expansion carrier and a non-C9orf72 expansion carrier, 
respectively. The other panels show a positive and negative C9orf72 expansion carrier in 
each family. All participants were evaluated and all results were repeated three times with 
the same findings across all three experiments. The vertical and horizontal axes represent 
fluorescent intensity and product size, respectively. 
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We also screened participants for CAG expansions within ATXN2. In family 2, II-
3, II-5, and III-6 are heterozygous carriers of ~30 repeats (Figure 7.4.1, Fig 7.4.2.3, Table 
7.4.4). Interestingly, the ATXN2 variation seems to segregate with spasticity as non-
carriers are unaffected and are older than the typical age of onset with the exception of 
III-6, who may possibly be presymptomatic as he possesses both C9orf72 and ATXN2 
expansions. 
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Figure 7.4.2.3 Genetic analysis of ATXN2 genotyping profiles of family 2. 
Results from fluorescent fragment length analyses. Repeat numbers are beside each peak 
and are calculated by subtracting 54 from the number determined using the horizontal 
axis. A negative control shows homozygosity for repeat length <30. The other panels 
show ATXN2 expansion carrier status in family 2. The vertical and horizontal axes 
represent fluorescent intensity and product size, respectively.
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Concurrently, we used a targeted neurodegeneration sequencing panel to identify 
any additional genetic variation in the three families. Previously, members of the Strong 
lab have identified ARHGEF28 p.Lys280Met>fs40Ter (Droppelmann et al., 2013) in III-
5. As a result, we subsequently genotyped additional family members to determine if they 
are carriers of ARHGEF28 p.Lys280Met>fs40Ter. In doing so, we identified an 
additional eight ARHGEF28 p.Lys280Met>fs40Ter heterozygous carriers (II-9, IV-4, IV-
7, IV-13, IV-16, IV-17, V-2, and V-4) (Figure 7.4.1, Figure 7.4.2.4, Table 7.4.4). We also 
identified ARHGEF28 p.Lys280Met>fs40Ter in two unrelated spouses (IV-4 and IV-7), 
which may be explained by common ancestral origins as both individuals are from the 
same Northern Netherlands region as other members of the family. Based on family 
history, there are no known consanguineous unions in family 1.  
In family 2 and family 3, we identified a novel OPTN mutation (p.Met468Arg) 
(Figure 7.4.2.2). Variants in OPTN have been previously reported to be associated with 
ALS and FTD (Cirulli et al., 2015; Maruyama et al., 2010; Pottier et al., 2015). We 
subsequently genotyped other members of the families and in total, observed OPTN 
p.Met468Arg in four individuals (family 2, II-3; family 3, III-3, III-5, and III-7) with 
ALS-FTD who are also C9orf72 carriers and one who is also an ATXN expansion carrier 
(family 2, II-3) (Figure 7.4.1, Table 7.4.4). We also observed the variant in an individual 
(IV-4) who is not a C9orf72 carrier and is currently free of any disease symptoms.  
ARHGEF28 p.Lys280Met>fs40Ter and OPTN p.Met468Arg are both very rare 
variants based on their absence from public databases archiving genetic information on 
individuals free of neurodegenerative disease ExAC as well as diseased individuals, 
including  Human Gene Mutation Database (HGMD), ClinVar, and ALS Online genetics 
Database (ALSoD). Based on the location of the mutation (amino acid 280 of 1731) 
leading to the eventual termination of the RGNEF polypeptide, it is likely to disrupt 
protein function. OPTN p.Met468Arg is harboured within a highly conserved ubiquitin-
binding domain and is predicted to exert a damaging effect on OPTN function based on a 
compilation of in silico software. 
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Figure 7.4.2.4 Validation of variants in OPTN and ARHGEF28. 
Sanger sequencing electropherograms of OPTN p.Met468Arg and ARHGEF28 
p.Lys280Met>fs40Ter in wild type and heterozygous carriers as observed in the families. 
 
 
 
 
 
 
 
 
 
 
  
236 
 
7.4.3 C9orf72 dipeptide immunostaining 
Cerebellar sections from each case were obtained from archived neuropathological 
specimens and immunostained for dipeptide repeat proteins [poly(GP), poly(GA), and 
poly(GR)] produced from C9orf72 G4C2 expansions through repeat associated non-ATG 
(RAN) translation. In each instance, dipeptide repeat proteins were observed (Figure 
7.4.3). 
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Figure 7.4.3 Cerebellar dipeptide repeat protein pathology.  
Characteristic neuropathological lesions immunopositive for poly(GP), poly(GA) or poly(GR) proteins in Purkinje cells (PC), the 
granule cell layer (GL) or the molecular layer (ML) of the cerebellum. Scale bar 10 µm. Case 1 is family 2, II-3; cases 2 and 3 are 
family 1, III-2 and III-5, respectively; and cases 4 and 5 are family 3, III-5 and III-7, respectively.
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7.4.4 Oligogenic inheritance in patients 
While the relationship between C9orf72 expansion length and phenotype remains 
unclear, the expansions observed are unlikely to explain the inter- and intrafamilial 
clinical heterogeneity as all three families possessed expansions of similar size (Hardy 
and Rogaeva, 2014; Rohrer et al., 2015). It is more likely that the C9orf72 expansion 
carriers within this range are at a greater risk and the burden of additional variants in 
other ALS causing genes further modulates the expression of C9orf72 or disrupts the 
same pathway. 
In family 1, the index patient (III-5) carried a C9orf72 expansion as well as 
ARHGEF28 p.Lys280Met>fs40Ter and presented with ALS 12 years earlier than his 
sister (III-2) who carried only a C9orf72 expansion. Their brother presented with ALS at 
age 47, two years earlier than the index patient and 14 years earlier than his sister. 
However, it is uncertain whether he carried any genetic variation, as his DNA was 
unavailable. All members of the subsequent generation are currently unaffected and are 
younger than the typical age of onset. However, it is likely that C9orf72 expansion 
carriers are currently presymptomatic and may develop ALS related symptoms when they 
become ~60 years of age. Carriers of C9orf72 expansions as well as ARHGEF28 
p.Lys280Met>fs40Ter may develop ALS much earlier than individuals who only carry a 
C9orf72 expansion. 
In family 2, the index patient (II-3) carried a C9orf72 expansion, ATXN2 
expansion, and OPTN p.Met468Arg. He presented with ALS at age 53 and was found to 
have frontotemporal dysfunction on neuropsychological testing. His disease duration was 
less than 2 years. His sister’s death was also due to FTD with ALS being found at 
autopsy. While she was documented as harbouring a C9orf72 expansion, this was done 
elsewhere and we were unable to obtain DNA for further analysis. II-5 carries an ATXN2 
expansion and has myelopathy, spasticity, and progressive cognitive decline. The 
proband’s son (III-6) carries both a C9orf72 expansion and an ATXN2 expansion and is 
likely presymptomatic as he is currently younger than the typical age of onset within this 
pedigree. 
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The clinical presentation was consistent in all affected individuals in family 3 in 
that all three patients initially presented with features of bvFTD and then progressed to 
either ALS or a diffuse motor neuron disease marked by prominent spasticity.  Death 
occurred within 1 to 4 years following symptom onset. All affected individuals were 
carriers of a C9orf72 expansion as well as OPTN p.Met468Arg. Members of the 
subsequent generation currently do not display features suggestive of ALS and were 
screened for both variations. We observed two individuals who each carried one variant, 
but no individual carried both variants. Based on the effect of the C9orf72 expansion, it is 
likely that the individual with this variant is at risk for developing ALS or FTD. 
However, whether the individual carrying only OPTN p.Met468Arg will develop ALS or 
bvFTD remains uncertain.
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Table 7.4.4 Summary of clinical and genetic information. 
 
ID Family 1 Family 2 Family 3 
N, affected 6 2 8 
N, relatives affected with other 
phenotypes 
1, cerebral palsy 1, myelopathy; 1 Parkinson’s 
disease 
2, Alzheimer’s disease 
Primary diagnosis ALS ALS bvFTD 
Diagnosis subcategory  FTD ALS 
Site of onset limb bulbar mixed, primarily behavioural 
changes 
Female:male 3:3 1:1 3:5 
Mean age of onset (years±SD) 52 (±6) 54.4 (±2) 55 (±8) 
Minimum age of onset (years) 47  35 
Maximum age of onset (years) 60  64 
Average disease duration (months±SD) 66 (±16) 29 (±7) 25 (±8) 
No. of C9orf72 expansion carriers 8 4 3 
No. of ATXN2 expansion carriers 0 3 0 
No. of OPTN p.Met468Arg carriers 0 1 4 
No. of ARHGEF28 p.Lys280Met>fs40Ter 
carriers 
9 0 0 
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7.5 Discussion 
We have identified three families with multiple generations affected with ALS or ALS-
FTD. All three families are carriers of a C9orf72 expansion of similar repeat size but 
present with distinct clinical features. Although the length of the pathological expansion 
falls within the equivocal range with respect to predicting disease occurrence, 
neuropathological examination confirmed the presence of inclusions formed of dipeptide 
repeat proteins within cerebellar tissue. Thus, the C9orf72 expansions reported here are 
pathogenic.  
 Given the remarkable phenotypic heterogeneity observed here, we next explored 
whether additional genetic variations contributed to this heterogeneity. We used a 
neurodegeneration targeted next generation sequencing gene panel to sequence affected 
individuals and their families. We identified two additional mutations that may confer 
additional disease risk. In family one, the index patient carried both a C9orf72 expansion 
and an ARHGEF28 variant, and developed ALS 12 years younger than his sister who 
possessed only the C9orf72 expansion. In family two, the proband carried C9orf72 and 
ATXN2 expansions and a variant in OPTN, which collectively may have contributed to 
his earlier onset of ALS and FTD. Finally, in family three, the disease course in 
individuals III-3, III-5, and III-7 was very similar and all carried a C9orf72 expansion in 
addition to an OPTN variant. Therefore, the genetic variants are segregating with distinct 
clinical presentations in all three families and a greater mutation burden is likely 
mediating an atypical ALS or ALS-FTD disease course.  
In addition to our small sample size, one clear limitation of validating our findings 
is the inherent complexity involved in quantifying qualitative traits such as abnormal 
behaviour or progressive cognitive decline. However, our findings highlight the 
importance of agnostically screening all at risk patients for all known neurodegenerative 
disease genes. Although today this approach remains relatively costly, recent targeted 
next generation sequencing approaches like the ONDRISeq neurodegeneration gene 
panel facilitates these approaches on a rapid, efficient, and economical basis. Clinicians 
faced with patients who have atypical disease presentation are encouraged to consider 
additional mutations in related genes to identify possible oligogenic interactions. Table 
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7.5 summarizes findings of studies that conducted additional genetic testing in patients 
(Bury et al., 2015; Chio et al., 2012; Kaivorinne et al., 2014; King et al., 2013; Lashley et 
al., 2014; Pottier et al., 2015; Tarlarini et al., 2015; van Blitterswijk et al., 2012a; van 
Blitterswijk et al., 2012b). By identifying additional genetic variation, complex 
phenotypes can be explained by the additive effect of variants with large or small, yet 
significant effects that converge on the same disease pathway.
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Table 7.5 ALS and/or FTD patients with multiple genetic variants. 
 
Study Diagnosis Other symptoms Site of onset Sex Age at onset 
(years) 
Disease duration 
(months) 
Ethnic origin C9orf72 
expansion 
Other variation 
Chio et al., 2012 ALS FTD Bulbar M 43  Sardinia Yes TARDBP p.A382T 
 ALS Mild FTD Spinal F 69 43 Sardinia Yes TARDBP p.A382T 
 ALS Flail arm variant Upper limb M 35  Sardinia Yes TARDBP p.A382T 
van Blitterswijk 
et al., 2012 
ALS      NL Yes VAPB p.V234I 
van Blitterswijk 
et al., 2012 
ALS  Cervical M 42 >91 NL Yes TARDBP p.N352S 
 ALS  Cervical F 47 >15 NL Yes TARDBP p.N352S 
 ALS  Cervical M 61 8 NL No (1) TARDBP p.N352S; 
(2) ANG p.K17I 
 ALS  Lumbosacral F 73 47 NL No (1) TARDBP p.N352S; 
(2) ANG p.K17I 
 ALS  Cervical M 54 52 NL No (1) TARDBP p.N352S; 
(2) ANG p.K17I 
 ALS  Cervical F 51 77 NL Yes SOD1 p.D90A 
 ALS  Lumbosacral F 53 >24 NL Yes (1) FUS p.R521C;  
(2) ANG p.K17I 
 ALS  Lumbosacral M 58 25 NL  FUS p.Q210H 
King et al., 2013 FTD  Behavioural F 57 ~144  Yes MAPT p.A239T 
 ALS FTD Lower limb M 60 ~24  Yes MAPT p.A239T 
 ALS FTD Lower limb M 51 ~24  Yes MAPT p.A239T 
Kaivorinne et 
al., 2014 
FTD  Behavioural M 54 >120 Finland Yes TARDBP p.S292del 
 FTD  Behavioural F 47 >36 Finland Yes TARDBP p.S292del 
Lashley et al., 
2014 
ALS FTD  F 59 ~84 UK Yes GRN p.C31fs 
 ALS FTD  F 46 ~36 UK Yes GRN p.C31fs 
Bury et al., 2015 ALS FTD     UK Yes OPTN p.E322K 
Tarlarini et al., 
2015 
ALS FTD Bulbar F 68 38 Italian Yes FUS p.R491C 
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Pottier et al., 
2015 
FTD agPPA  M 68 ~48  No (1) OPTN 
p.Gly538Glufs*27;  
(2) TBK1 p.Arg117* 
 
Abbreviations are as follows: M, male; F, female; NL, Netherlands; UK, United Kingdom; agPPA, progressive non fluent/agrammatic 
variant of primary progressive aphasia.
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7.6 Conclusion 
In this Chapter, we describe three families affected with ALS with or without FTD 
among other neurodegenerative symptoms.  While each family harbours a similar 
C9orf72 expansion, each family varies significantly with respect to their mutation load. 
We used an agnostic approach by determining the families’ C9orf72 and ATXN2 
expansion profiles in addition to sequencing all known ALS-associated disease genes. 
We found that all three families carry additional genetic variation and attribute the 
phenotypic variability to oligogenic inheritance. It is likely that across all three families, 
the C9orf72 expansion is the main driver of disease expression as all affected individuals 
carry the expansion. However, there are presymptomatic C9orf72 expansion carriers and 
we intend to follow these study participants as they age and continue to visit Dr. Strong’s 
clinic. If they never go on to develop ALS and/or FTD, it is likely that the presence of a 
C9orf72 expansion is not sufficient to cause disease in these pedigrees. From our results, 
we would expect all C9orf72 expansion carriers to develop ALS however, we also expect 
that individuals who carry additional genetic variants, which are likely acting as genetic 
modifiers, will develop ALS and/or FTD earlier or will likely present with an atypical 
disease course. 
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Chapter 8 - Discussion 
8 Summary 
The studies presented in this PhD Thesis have identified genetic variants underlying 
Mendelian diseases and genetic variation that may predispose individuals ascertained in 
these studies, to complex diseases, primarily neurodegenerative disorders. The context of 
each study findings, the strengths, implications, as well as limitations of my dissertation, 
and future goals, will be discussed in subsequent sections. 
 
8.1 Context of study findings 
In this section, I will highlight the conclusions and limitations from each chapter. 
 
8.1.1 Chapter 2: NFS1, a novel disease gene underlying a novel 
metabolic disease 
The findings of Chapter 2 include the discovery of a novel disease gene, NFS1 as the 
underlying genetic basis of a novel mitochondrial disease, infantile mitochondrial 
complex II/III deficiency (IMC23D) (Farhan et al., 2014b). Variants in genes encoding 
Fe-S proteins can disrupt Fe-S cluster assembly, which may result in various disorders 
such as Friedreich’s ataxia (Koeppen, 2011) or ISCU myopathy (Kollberg et al., 2009). 
In Chapter 2, I describe for the first time, the clinical presentation of patients affected by 
IMC23D. The application of a classic method, autozygosity mapping, and a more modern 
sequencing approach, exome sequencing, accelerated gene discovery. Using these 
experiments, I observed p.Arg72Gln in NFS1, in a candidate homozygous region on 
chromosome 20. NFS1 encodes a cysteine desulfurase, which is a Fe-S protein involved 
in Fe-S cluster biogenesis, iron maintenance, and DNA repair (Schmucker et al., 2011). 
Collectively, the results of Chapter 2 describe the first case of NFS1 deficiency in 
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humans and further demonstrate the importance of sufficient NFS1 expression in human 
physiology. 
While I conducted ex vivo experiments using patient cells to determine the effect 
exerted by NFS1 p.Arg72Gln, I did not recapitulate the results in an in vitro or an in vivo 
model. I leveraged previous experiments that consistently demonstrated Nfs1 deficiency 
leads to abnormal mitochondria morphology and function (Biederbick et al., 2006; Fosset 
et al., 2006). In patient cells, NFS1 p.Arg72Gln led to loss of function of the NFS1 
protein. Accordingly, I inferred that the same molecular defects were likely also 
occurring in patients with NFS1 deficiency. However, these experiments would have 
provided further evidence in support of an NFS1-mediated mitochondrial disease. The 
clinical features observed in the patients were consistent with the features of other 
patients diagnosed with mitochondrial diseases caused by Fe-S protein deficiency, which 
converge on the same pathway as NFS1. Taken together, the genetic data, the 
overlapping clinical features in other patients affected with Fe-S protein diseases, and the 
known role of NFS1 in mitochondrial function, suggest that NFS1 deficiency is the 
underlying mechanism of IMC23D. 
 
8.1.2 Chapter 3: Expanding the biological function of EXT2, a 
known disease gene in a novel neurodevelopmental disease 
Previous to the findings from this Chapter, heterozygous variants in EXT2 had been 
recurrently implicated only in autosomal dominant multiple exostoses (Busse-Wicher et 
al., 2014). In Chapter 3, I described the first instance of an autosomal recessive EXT2-
mediated neurodevelopmental disorder classified as seizures-scoliosis-macrocephaly 
(SSM) syndrome (Farhan et al., 2015). Similar to the methods discussed in Chapter 2, 
given the known consanguineous union between the parents, I used autozygosity 
mapping to identify homozygous regions in the genome, which I subsequently applied 
exome sequencing, to expedite variant discovery. Because of the known association of 
EXT2 in another Mendelian disorder, I studied the effect of EXT2 variants on protein 
expression and function in patient cells, and also using an in vitro system to ensure I did 
not merely identify rare, benign variants in a disease gene. These experiments yielded 
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results consistent with EXT2 loss of function as the probable mechanism leading to SSM 
syndrome. Thus, I have implicated EXT2 in a novel disorder (now available on OMIM 
#616682) and have further illustrated the importance of heparan sulfate biosynthesis 
enzymes in neurodevelopment. 
 Despite performing functional assays to validate the impact of the EXT2 variants 
on protein expression and function, I did not test whether there were other EXT2 
interactions that were also comprised. I also did not investigate whether integration of 
wild type EXT2 variants are able to rescue these interactions. Finally, while I reviewed 
the literature for EXT2 model organisms and discussed these in the manuscript, I did not 
perform any in vivo replication studies. These experiments would have strengthened the 
evidence of gene-based causality. 
 
8.1.3 Chapter 4: Confirming the association of KCTD7 in 
progressive myoclonus epilepsy 
Several independent studies have implicated KCTD7 variants in progressive myoclonus 
epilepsy (Azizieh et al., 2011; Blumkin et al., 2012; Kousi et al., 2012; Krabichler et al., 
2012; Staropoli et al., 2012). In this study, I also used autozygosity mapping and exome 
sequencing to identify a novel homozygous variant, p.Tyr276Cys in KCTD7 in three 
affected females (Farhan et al., 2014a). The results confirm previous reports describing 
the role of KCTD7 in epilepsy. As I discussed in Chapter 4, KCTD7 p.Tyr276Cys is now 
a genetic marker and can be used in genetic counseling for the siblings and their 
prospective mates and for other members of the same Mennonite community. 
Interestingly, following the publication of our manuscript, a local medical geneticist, Dr. 
Sharan Goobie, identified another family from the same Mennonite community with 
progressive myoclonus epilepsy. Affected individuals were immediately screened for the 
same variant, p.Tyr276Cys in KCTD7 and were also homozygous carriers. Our initial 
observation and report allowed for the prioritization of the variant, which is likely also 
causing the epilepsy phenotype in her patients. In addition, as discussed in Chapter 4, 
prior to identification of the genetic variant, the patients received a different diagnosis. 
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Our findings helped guide clinicians to correctly diagnose the patients with progressive 
myoclonus epilepsy in keeping with previous reports. 
 Because KCTD7 is a previously known epilepsy gene, I did not pursue any 
functional validation steps. This was also due to the specific brain expression of KCTD7, 
which limited us from obtaining any relevant tissues from the patients. However, future 
steps may include genetic engineering of KCTD7 p.Tyr276Cys in neural specific cell 
lines to examine whether the variant exerts a loss of gain of protein function therefore, 
determining the mechanism of epileptogenesis. 
 
8.1.4 Chapter 5: The application of a model organism to 
understand the function of a novel disease gene TMTC3, in 
neurodevelopment 
While the results of Chapter 5 are not yet finalized, we have identified several key 
features of the disease. Firstly, I observed two compound heterozygous variants in 
TMTC3, which encodes transmembrane and tetratricopeptide repeat containing 3 protein, 
in all four affected individuals. When measuring TMTC3 protein expression, we 
observed abolished expression in patient cells compared to the unaffected parents and a 
healthy, homozygous wild type control. Therefore, TMTC3 loss of function is the most 
probable disease mechanism. We are also currently studying the effect of TMTC3 
deficiency in Drosophila melanogaster and TMTC3 localization in collaboration with Dr. 
Jamie Kramer and Dr. Michael Poulter. Preliminary results from the Kramer lab suggest 
that neuronal knockdown of Drosophila melanogaster Tmtc3 causes increased 
susceptibility to mechanically induced seizures. In addition, preliminary results from the 
Poulter lab suggest TMTC3 is specifically localized at synapses in the rat brain. While 
TMTC3 is a poorly characterized gene, loss of function in patients with nocturnal seizures 
with developmental delay emphasizes an important role for TMTC3 in 
neurodevelopment. 
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8.1.5 Chapter 6: Developing a custom sequencing based method 
to study neurodegeneration 
In Chapter 6, I discuss our implementation of a next generation sequencing based 
neurodegeneration gene panel that is currently being used by a large, multidisciplinary 
study: The Ontario Neurodegenerative Disease Research Initiative (ONDRI). The 
approach of selecting the 80 genes within ONDRISeq was based on their known 
association with neurodegeneration. In this study, we processed DNA from 216 patients 
diagnosed with one of the five diseases: 1) Alzheimer’s disease/mild cognitive 
impairment; 2) amyotrophic lateral sclerosis; 3) frontotemporal dementia; 4) Parkinson’s 
disease; or 5) vascular cognitive impairment. We also independently validated a subset of 
the variant calls using multiple, independent genomic approaches including: NeuroX, 
TaqMan allelic discrimination assay, or Sanger sequencing. We observed 100% 
concordance for the variants identified via ONDRISeq and screened by other genomic 
technologies. We were successful in detecting known as well as novel rare variants in a 
large fraction of cases. Importantly, not all the variants observed are causal, and many 
need further validation. 
There are several important limitations in this Chapter. While I did not discuss 
any environmental factors, the ONDRI study coordinators documented all potential 
environmental influences that may have induced neurodegeneration in the study 
participants. Upon further evaluation of genetic variants, we intend on including any 
potential environmental influences in addition to the data from the other ONDRI 
platforms to further characterize the neurodegenerative diseases. In addition, we omitted 
the majority of human variation. Specifically, we did not investigate any variation outside 
of the 80 genes, which would have enabled us to identify novel neurodegeneration loci. 
We also did not assess the role of structural variation, copy number variation, non-coding 
variation, or epigenetic variation on disease. Examination of these omitted classes of 
variation may explain the genetically unsolved cases in the study cohort. However, we 
are in the early stages of implementing an algorithm to detect copy number variation 
using ONDRISeq. We are investigating whether we can use the uniformity of the targeted 
gene panel and normalize across the target regions to obtain baseline expression. This 
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way, we can determine whether a sample has copy number variation at certain regions by 
detecting any statistically significant deviation from baseline. These techniques have 
proven to be useful when assessing copy number variation in patients with hereditary 
hearing loss (Sommen et al., 2016). 
 
8.1.6 Chapter 7: The effect of multiple genetic variants on 
neurodegenerative disease risk 
In Chapter 7, I discuss the probable genetic basis of neurodegeneration in three families. 
The three families are affected with ALS and/or FTD and in which the same 
hexanucleotide repeat expansion in the C9orf72 gene has been identified, but their 
clinical manifestations vary significantly. The inter- and intrafamilial disparity in clinical 
phenotype ranged from a much earlier age of onset, ALS combined with FTD, or ALS 
with no additional features. Following genetic testing, I observed the presence of an 
ATXN2 expansion, ARHGEF28 p.Lys280Met>fs40Ter, or an OPTN p.Met468Arg in 
patients with a C9orf72 expansion and who exhibit an atypical disease course. These 
genetic profiles segregated with distinct clinical presentations in all three families and are 
likely modifying the ALS phenotype. Perhaps the variability in the clinical expression of 
C9orf72 expansion carriers is driven by the presence of these additional genetic variants 
further supporting the observation of oligogenic inheritance in ALS. 
Within this Chapter, there were several limitations that must be considered. First, 
I did not perform any experiments demonstrating an additive or synergistic deleterious 
effect on cell viability. In the literature, additional ALS genetic variants that may act as 
modifiers of C9orf72, have been previously reported, strengthening the oligogenic 
inheritance hypothesis (Bury et al., 2015; Chio et al., 2012; Kaivorinne et al., 2014; King 
et al., 2013; Lashley et al., 2014; Pottier et al., 2015; Tarlarini et al., 2015; van 
Blitterswijk et al., 2012a; van Blitterswijk et al., 2012b). Indeed, variation in all four 
genes (C9orf72, ATXN2, ARHGEF28, and OPTN) has been previously implicated in ALS 
or FTD however, the observation of multiple variants in genes implicated in the same 
disease is still not sufficient to establish that the presence of multiple genetic variants 
leads to an atypical disease course. 
  
254 
In addition, while we had access to clinical history and DNA from three large 
families, I was not able to genotype all affected and unaffected members of the family 
(past and present), which would have strengthened or countered the observation that 
multiple variants clustered in individuals with an atypical disease course. I also postulate 
that the genetic variants observed in the subsequent generation would likely manifest into 
the neurodegenerative phenotype. This assumption is based on the genetic profiles of 
deceased individuals. 
Another limitation of this study is the absence of knowledge regarding each 
family’s overall neurodegeneration risk. I assumed that the presence and accumulation of 
these genetic variants was inducing disease however, it is unclear whether these families 
already possess a heightened neurodegeneration risk (i.e. reside at the tale of distribution) 
and the presence of these additional variants further increases risk of neurodegenerative 
disease. Knowledge of the baseline neurodegeneration risk conferred by common genetic 
variation would allow for the investigation of all neurodegeneration genetic risk factors. 
Finally, in this study, I did not fully account for other confounding factors 
originating from each individual’s or family’s environment. We documented each 
participant’s educational attainment, whether they have ever experienced a head or neck 
injury, any potential toxin exposure, and their general lifestyle, however we did not 
measure the effect of genetic variants coupled with these insults, on cell viability. These 
variables are intrinsically difficult to quantify however, knowledge of their presence can 
aid in understanding why individuals who do not possess any genetic risk factors can 
nevertheless develop neurodegenerative phenotypes. In this study, all affected individuals 
carried at least one of the genetic variants discussed in our study. 
 
8.2 Methodological considerations 
There were several strengths and implications as well as general limitations in my 
studies, which I will discuss in depth here. I will also outline potential solutions to 
overcome these limitations in the future. 
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8.2.1 Study strengths and implications 
The results of this PhD thesis have helped further annotate the human genome, provided 
guidance for effective analytical approaches for gene discovery, and also provided 
genetic diagnoses for the affected families. In this PhD thesis, I characterized genes not 
previously associated with a disease; or associated with a well-characterized disease but 
now also underlie a novel phenotype; or implicated in the same phenotype and is now 
associated with additional clinical features. By defining the role of genetic variation in 
this subset of genes using conservative causality criteria, we are able to understand their 
normal biological function in the human genome more clearly. 
In addition, by applying next generation sequencing, I was able to rapidly and 
efficiently provide a genetic diagnosis for the patients and their families. In this context, a 
genetic diagnosis is defined as the observation of DNA variation in patients and in which 
the variation detected, are in accordance with conservative causality criteria. Knowledge 
of the DNA variation penetrance and each individual’s carrier status can help during 
genetic counseling and reproductive planning. In Chapters 2-5, the variants observed 
likely have a large effect on gene function and when transmitted in an autosomal 
recessive inheritance pattern, will cause the disease. In contrast, the late-onset 
neurodegenerative diseases described in Chapters 6 and 7, do not necessarily follow 
classical Mendelian disease inheritance patterns. It is likely that a burden of genetic 
variation within genes increases predisposition to disease. Therefore, the presence of a 
genetic variant in a disease gene does not always result in a disease phenotype. This 
discrepancy in simple, monogenic diseases and complex, oligogenic or polygenic 
diseases, may in part, be explained by incomplete penetrance, which makes the 
interpretation of DNA variation and genetic counseling immensely challenging. 
Furthermore, by deeply phenotyping the patients and performing gene-specific 
assays, we are able to guide during drug development. Based on my work, industry or 
translational scientists who are interested in the genes described here, will have a greater 
understanding of how loss or gain of function in this subset of genes, can affect patients. 
Also, we can provide information as to whether inhibition or activation of these genes 
will be the most applicable therapeutic intervention. Finally, knowledge of the patients’ 
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genetic information can make them eligible for clinical trials. For example, if industry or 
translational scientists have developed a therapeutic agent targeting LRRK2, a known 
Parkinson’s disease gene, they may be interested in recruiting patients with LRRK2 
variants in addition to non-LRRK2 carriers, to assess the efficacy of the drug. 
 
8.2.2 Additional study caveats 
There are additional study limitations that must be considered during the interpretation of 
the results generated in this PhD Thesis. First, in Chapters 2-5, given the rarity of each 
disease, the sample sizes were small and additional pedigrees were not available. To 
overcome the lack of replication in human samples especially for novel disease genes, I 
implemented objective metrics including identifying regions with high LOD scores 
during autozygosity mapping, and multiple functional assays to recapitulate the disease 
phenotype. Unfortunately, these limitations are common in rare disease research. 
Accordingly, many researchers have come together to form the Matchmaker Exchange, a 
rare disease global alliance that facilitates gene discovery among researchers by data 
sharing (Philippakis et al., 2015). This initiative allows researchers to connect and 
collaborate on novel or unexplained phenotypes by increasing their sample sizes. 
 Second, during these studies I derived genetic information by targeting the 
exome, which contains protein-coding variation only. There are valid biological reasons 
to prioritize variation within the exome, which are in parallel with the study design. For 
example, the overwhelming majority of Mendelian phenotypes are caused by DNA 
variants harbored within the exome, making exome sequencing the preferred sequencing 
approach (Chong et al., 2015; Ng et al., 2009). However, the selection of exome 
sequencing was also motivated by practical considerations. When we initially planned the 
experiments in 2012, the cost of sequencing one exome or genome were ~$4,000 and 
~$10,000, respectively. In addition to these expenses, the computational requirements to 
store the data, manipulate, and analyze the data, were extremely resource intensive. 
Because of these limitations, I implemented strategic approaches in selecting only a few 
samples, which were often the most severely affected patients, for exome sequencing. 
Without these barriers, which are beginning to be resolved as sequencing costs decrease 
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and computational approaches become less rigorous, I would have preferred to be 
unbiased and investigate the entire genome. Moreover, whole genome sequencing can 
detect indels, structural variation, non-coding variation, copy number variation, or 
multinucleotide expansions, which are often missed by exome sequencing (Belkadi et al., 
2015; Singleton, 2011). 
 Third, one of the greatest limitations of working with human samples is the 
inaccessibility to all affected tissues. These challenges are unlikely to be resolved until 
we develop less invasive extraction methods. Using these theoretical methods, we may 
obtain single cells or tissues and perform sequencing assays to identify any variation in 
expression. This approach is in part, already in place within the Genotype-Tissue 
Expression (GTEx) project, a control dataset of multiple human tissues from donors who 
are densely genotyped, to assess genetic variation within their genomes (Consortium, 
2013). 
 Finally, I did not systematically control for most environmental effects. A key 
assumption underlying the approach taken in Chapters 2-5 was that the disorders were 
more likely caused by monogenic variants, which are highly penetrant and are typically 
independent of the environment. Thus, the strong genetic effects in these instances made 
it less critical to account for environmental influences. Conversely, while the 
neurodegenerative disorders described in Chapters 6 and 7, can be modified or even 
caused by environmental factors such as traumatic brain injury or toxin exposure, I did 
not adequately measure these possibly confounding variables. 
 
8.3 Future directions 
While there is much advancement achieved through my PhD Thesis, there are still many 
future directions applicable to my own work, and some priorities that can be outlined for 
gene discovery research in general, which I will summarize here. 
 
(1) Open access to control datasets 
As sequencing costs decrease, more large-scale sequencing projects are pursued, which 
allows for a larger control dataset to develop. These control dataset act as reference 
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samples and are extremely beneficial in extracting allele frequencies for variants of 
interest. The database of Genotypes and Phenotypes (dbGaP) is one example of a 
repository to archive genetic information from a collection of studies with ethics approval 
(Mailman et al., 2007; Tryka et al., 2014). These studies range from array-based 
association studies or large-scale next generation sequencing studies, which investigated 
the relationship of genotypes and phenotypes in cases and controls. Another example is 
the United Kingdom Biobank, however this can be a costly endeavor and the genetic data 
are based on only 820,967 genetic markers on the Axion Array (Sudlow et al., 2015). 
While there are other publically available resources to determine variant allele 
frequencies such as 1000 Genomes (Genomes Project et al., 2015), NHLBI Exome 
Sequencing Project (Fu et al., 2013), or ExAC (Lek et al., 2015), individual level genetic 
data are not easily accessible. Furthermore, the phenotypes associated with each sample 
are not provided, which makes case-control studies difficult to conduct and interpret. 
Finally, in general these reference databases do not have adequate representation of all 
ancestries, especially African and Middle Eastern populations. 
 
(2) Interpretation of genetic variants 
Our ability to sequence human genomes has exceeded our ability to adequately interpret 
the wealth of genetic variation in a single genome. We are limited by our ignorance 
regarding the underlying mechanism of disease. How do we interpret variants that are 
observed in patients but are also observed in controls? How do we interpret variants that 
exert their effects later in life? These questions fall into the hands of members of the 
American College of Medical Genetics and Genomics (ACMG). ACMG members have 
the burden of developing standards and guidelines, which are forced to progress at the 
same rate as technological advancements to prevent any false interpretations in clinical 
genetic testing (Green et al., 2013; Hampel et al., 2015; Rehm et al., 2013; Richards et 
al., 2015). These initiatives serve the entire scientific community by developing and 
upholding standards in the interpretation of genetic variation. Despite the committee’s 
best efforts, many challenges lay ahead. One such challenge is determining the effect size 
of a genetic variant and whether its presence in a disease-free individual renders it benign 
or incompletely penetrant. 
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(3) Standardization of in silico predictive programs 
One of the most common approaches to interpreting the potential effect of genetic 
variation is the implementation of a series of computational (in silico) predictive 
programs. In silico tools use algorithms to assess the effect of non-synonymous 
nucleotide changes on genes and proteins. In general, in silico tools that assess the effect 
of missense changes rely on amino acid structural changes and conservation across 
species lineages. Alternatively, in silico tools that predict the effect of nucleotide 
variation on splicing depend on the proximity of nucleotides changes to the exon/intron 
boundaries and implement mathematical models to quantify the resulting entropy change. 
While many predictive programs implement multiple variables to assess the 
impact of nucleotide variation on the protein function, they are not always consistent 
among each other and perform poorly when evaluating insertions or deletions. Evidently, 
the most common predictive tools in clinical laboratories are PolyPhen2 (Adzhubei et al., 
2013), SIFT (Sim et al., 2012), and MutationTaster (Schwarz et al., 2010). Some of these 
tools use the same underlying criteria and are likely to yield similar results; therefore, 
they should be used in combination rather than as independent lines of evidence, as 
recommended by ACMG (Richards et al., 2015). In addition, the underlying assumption 
is that deviation from the conserved amino acid is predictive of deleteriousness. While 
this assumption is perhaps valid when evaluating metabolic traits, it may not be useful 
when studying neurodevelopmental or cognitive traits unique to humans. Finally, to the 
best of my knowledge, most in silico tools do not incorporate variant zygosity. Refining 
these tools to match the biological state of disease will likely resolve some of these 
matters although more research is needed to develop the exact criteria that should be 
implemented. 
 
(4) Technological advancements will allow us to be unbiased in variant detection 
As the cost of sequencing decreases, researchers are better equipped to study genetic 
diseases. Here, I focused primarily on the exome, which is a major limitation throughout 
my dissertation. Having access to the entire genome will allow researchers to conduct 
their studies comprehensively and investigate whether there are copy number variation or 
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non-coding variation that are modifying the human phenotype. Furthermore, researchers 
can implement multiple levels of evidence when evaluating the functional effects of 
genetic variation by performing tissue specific sequencing to identify any somatic 
variation. 
 
8.4 Final conclusions 
In this thesis, I have furthered our understanding of several human diseases and their 
genetic basis. Specifically, in Chapters 2-5, by extracting rare, non-synonymous variants 
within the exome, I was able to delineate the signals, which in this context are large 
effect, monogenic variants, from the noise generated by the voluminous amount of 
benign variation. Additionally, I used a smaller-scale genomic approach, which allowed 
for the detection of genetic variation within a preselected list of genes, for the 
neurodegenerative disease studies in Chapters 6 and 7. While I implemented multiple 
objective metrics to prevent false discoveries, and to directly link the newly discovered 
DNA variation to the human phenotypes, much remains to be learned about the altered 
protein function or dosage leading to disease pathogenesis. Nevertheless, the genetic and 
genomic discoveries made using next generation sequencing methods in this PhD Thesis 
as well as in other studies, have tremendously improved the diagnostic yield while 
minimizing time and cost. 
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Appendix B - Chapter 6: Primer list 
 
Primer ID Sequence (5'-->3') Tm (°C) 
LRRK2_FWD GTGTGCTCTTGTATATGCTTTCC 58 
LRRK2_RVS CACTTTCAGCCACTTCAGGAG 59 
MAPT_FWD ATCTCAGCAATGTCTCCTCCACC 62 
MAPT_RVS TAACCGAACTGCGAGGAGCA 61 
CD2AP_FWD AGCTAGATTCTGAACAGCTGCC 60 
CD2AP_RVS TAAATGCACCACCGCTGTCCA 63 
NEFH_FWD GAAGAAACAAAGTCTCCCCC 56 
NEFH_RVS TCCTTTGCTGGAGACTTGGCCT 64 
DNAJC13_FWD GCATTGGCCTTGAAAACCTGG 61 
DNAJC13_RVS AAGTGGAACTTGAACACAGG 56 
APP_FWD GTCAAGTTTACCTACCTCCACC 58 
APP_RVS CTCATCCAAATGTCCCCTGCA 60 
HTRA2_FWD TGCTGACGTCAGGAACTTCTG 60 
HTRA2_RVS AGGATCTCGATATAGACCACGG 58 
MC1R_FWD ATCCCAGAGAAGACTTCTGGG 59 
MC1R_RVS AGCAGATGAAGCAGTACATGG 58 
EIF4G1_FWD GACATGAAAGTAGGCAGTGGGA 60 
EIF4G1_RVS AGTAGACAGATGCCCAGCACA 61 
TREM2_FWD AATCTGGGGCTACAAAGGCC 60 
TREM2_RVS TGGCTAAGGGAGTTCACTGCC 62 
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Appendix C - Chapter 7: Expanded genetic and clinical information on all individuals within the study 
 
Patient 
ID 
Family relationship Disease status Age at onset 
(years) 
Current age 
(years) 
Age at death 
(years) 
Sex MoCA 
(30) 
C9orf72 
genotype 
Other variants(s) 
Family 1, amyotrophic lateral sclerosis 
III-1 Unrelated spouse Unaffected  78  M 27 2,5  
III-2 Related, patient ALS 61  64 F  2, exp.  
III-3 Related, patient ALS 47  52 M    
III-4 Unrelated spouse AD  80*  F    
III-5 Related, patient ALS 49  58 M  2, exp.  
III-6 Unrelated spouse Unaffected  70  F 28 2,5  
III-7 Related, brother of 3 affected 
individuals 
Unaffected  70  M 28 2,18  
III-8 Unrelated spouse Unaffected    F    
III-9 Related, brother of 3 affected 
individuals 
Unaffected  63  M 29 2,18 ARHGEF28 
p.Lys280Met>fs40Ter 
III-10 Unrelated spouse Unaffected  61  F 28 2,5  
IV-1 Unrelated spouse Unaffected    M    
IV-2 Related, daughter of an affected 
individual 
Unaffected or 
presymptomatic 
 50  F 26 2, exp.  
IV-3 Related, son of an affected individual Unaffected or 
presymptomatic 
 48  M 28 2, exp.  
IV-4 Unrelated spouse Unaffected  46  F 29 2,5 ARHGEF28 
p.Lys280Met>fs40Ter 
IV-5 Related, daughter of an affected 
individual 
Unaffected  43  F 28 5,5  
IV-6 Related, daughter of an affected 
individual 
Unaffected  46  F 28 5,5  
IV-7 Unrelated spouse Unaffected  45  M 30 2,2 ARHGEF28 
p.Lys280Met>fs40Ter 
IV-8 Related, daughter of an affected 
individual 
Unaffected    F    
IV-9 Related, son of an affected individual Unaffected   20* M    
IV-10 Related, son of an affected individual Unaffected  49  M 30 5,5  
IV-11 Unrelated spouse Unaffected  48  F 30 5,5  
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IV-12 Related, son of an affected individual Unaffected  48  M 30 2,5  
IV-13 Related, son of an affected individual Unaffected  46  M 27 5,5 ARHGEF28 
p.Lys280Met>fs40Ter 
IV-14 Unrelated spouse Unaffected    F    
IV-15 Unrelated spouse MS    F    
IV-16 Related, son of an affected individual Unaffected or 
presymptomatic 
 44  M 30 5, exp. ARHGEF28 
p.Lys280Met>fs40Ter 
IV-17 Related, son of an affected individual Unaffected or 
presymptomatic 
with ALS. 
Affected with 
CP. 
 44  M  5, exp. ARHGEF28 
p.Lys280Met>fs40Ter 
IV-18 Related, son of an unaffected 
individual 
Unaffected    M    
IV-19 Related, daughter of an unaffected 
individual 
Unaffected    F    
IV-20 Related, daughter of an unaffected 
individual 
Unaffected    F    
IV-21 Related, daughter of an unaffected 
individual 
Unaffected    F    
IV-22 Related, son of an unaffected 
individual 
Unaffected  36  M 28 5,18  
IV-23 Related, son of an unaffected 
individual 
Unaffected    M    
IV-24 Related, daughter of an unaffected 
individual 
Unaffected  29  F 28 2,2  
IV-25 Related, son of an unaffected 
individual 
Unaffected    M    
V-1 Related, granddaughter of an affected 
individual 
Unaffected    F    
V-2 Related, granddaughter of an affected 
individual 
Unaffected or 
presymptomatic 
 21  F 29 5, exp. ARHGEF28 
p.Lys280Met>fs40Ter 
V-3 Related, grandson of an affected 
individual 
Unaffected or 
presymptomatic 
   M  5, exp.  
V-4 Related, granddaughter of an affected 
individual 
Unaffected  19  F 28 2,5 ARHGEF28 
p.Lys280Met>fs40Ter 
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V-5 Related, granddaughter of an affected 
individual 
Unaffected  <18  F    
V-6 Related, granddaughter of an affected 
individual 
Unaffected  19  F 30 5,5  
V-7 Related, granddaughter of an affected 
individual 
Unaffected  <18  F    
V-8 Related, granddaughter of an affected 
individual 
Unaffected  <18  F    
V-9 Related, granddaughter of an affected 
individual 
Unaffected  <18  F    
V-10 Related, granddaughter of an affected 
individual 
Unaffected  <18  F    
V-11 
 
 
Related, granddaughter of an affected 
individual 
Unaffected  <18  F    
Family 2, mixed neurodegeneration 
1-1 Unrelated AD   Deceased M    
1-2 Unrelated AD   Deceased F    
1-3 Related Unaffected   Deceased M    
1-4 Related Unaffected   Deceased F    
II-1 Unrelated spouse, son of parents 
affected with AD 
Unaffected  80  M    
II-2 Related, sister of 3 affected 
individuals 
Unaffected  77  F  5,5  
II-3 Related, patient ALS and FTD 53  55 M  2, exp ATXN2 exp (22,30), 
OPTN p.Met468Arg 
II-4 Unrelated spouse Unaffected    F    
II-5 Related, patient Myelopathy and 
CI 
 70  M 10 2,2 ATXN2 exp (22,30) 
II-6 Unrelated spouse Unaffected by 
ALS. Affected 
by cancer. 
   F    
II-7 Related, patient FTD and ALS 56  59 F  exp#  
II-8 Unrelated spouse Unaffected    M    
III-1 Unrelated spouse Unaffected    F    
III-2 Related, son of an unaffected PD 49 52  M    
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individual 
III-3 Related, daughter of an unaffected 
individual 
Unaffected  55  F    
III-4 Related, daughter of an unaffected 
individual 
Unaffected  50  F    
III-5 Unrelated spouse Unaffected    F    
III-6 Related, son of an affected individual Unaffected or 
presymptomatic 
 41  M 29 2, exp ATXN2 exp (22,30) 
III-7 Related, son of an unaffected 
individual 
Unaffected    M    
III-8 Related, son of an unaffected 
individual 
Unaffected    M    
III-9 Biologically unrelated, adopted 
daughter of an affected individual 
Unaffected    F    
III-10 
 
Related, son of an affected individual 
 
Unaffected    M    
Family 3, amyotrophic lateral sclerosis and behavioural variant frontotemporal dementia 
I-1 Related ALS   64 F    
I-2 Unrelated spouse Unaffected   71 M    
II-1 Unrelated spouse Unaffected   Deceased F    
II-2 Related, son of an affected individual ALS   59 M    
II-3 Related, daughter of an affected 
individual 
ALS   35 F    
II-4 Related, son of an affected individual AD   77 M    
II-5 Unrelated spouse Unaffected        
II-6 Related, daughter of an affected 
individual 
CVA   86 F    
II-7 Unrelated spouse Unaffected   Deceased M    
II-8 Related, son of an affected individual ALS   60 M    
II-9 Unrelated spouse Unaffected    F    
II-10 Related, son of an affected individual Bone cancer   60 M    
II-11 Unrelated spouse Unaffected    F    
II-12 Related, daughter of an affected 
individual 
Pancreatic 
cancer 
  78 F    
II-13 Related, son of an affected individual ALS   60 M    
II-14 Related, son of an affected individual Unaffected   Deceased M    
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II-15 Related, daughter of an affected 
individual 
Unaffected    F    
II-16 Related, daughter of an affected 
individual 
Unaffected   Deceased F    
II-17 Related, son of an affected individual Senility/AD   74 M    
II-18 Unrelated spouse Unaffected    F    
III-1 Related, daughter of an affected 
individual 
Unaffected   Deceased F    
III-2 Unrelated spouse Unaffected   Deceased M    
III-3 Related, patient bvFTD, later 
developed ALS 
56  59 F  exp OPTN p.Met468Arg 
III-4 Unrelated spouse Unaffected  73  M    
III-5 Related, patient bvFTD, later 
developed ALS 
and 
parkinsonism 
53  54 M  8,exp OPTN p.Met468Arg 
III-6 Unrelated spouse Unaffected   Deceased     
III-7 Related, patient bvFTD, later 
developed ALS 
54  56 M  5,exp OPTN p.Met468Arg 
III-8 Unrelated spouse Unaffected        
IV-4 Related, daughter of an affected 
individual 
Unaffected  44  F 30 2,5 OPTN p.Met468Arg 
IV-5 Related, son of an affected individual Unaffected  40  M 28 2,exp  
IV-6 
 
 
Related, daughter of an affected 
individual 
Unaffected  39  F 24 2,5  
*Information based on family recall, not confirmed through birth or death records. Some individuals were not genetically tested as 
they were not age of consent, were deceased, or declined to participate. Their clinical and family history was provided to us and was 
included in experimental planning. #Unfortunately, we did not have access to clinical records or tissue samples to conduct genetic 
analysis but through personal communication with her neurologist, we know she is a carrier of a C9orf72 expansion. 
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Appendix D - Journal copyright approval 
 
Note: All other publications included in this PhD thesis are open 
access publications that are reproducible with attribution to the 
original source. 
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